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Abstract 
Type 1 diabetes is an autoimmune disorder caused by the destruction of insulin 
secreting ß cells in the pancreas.  The aim of this project is to explore the 
potential of using solid-coated microneedles to target skin dendritic cells with an 
auto-antigen to induce tolerance for the treatment of type 1 diabetes.   
 
A novel coating formulation has been developed to accommodate peptides with 
different lipophilicities.  The optimised coating formulation and electro-polishing of 
the microneedle surface were key factors which enhance the efficiency of peptide 
delivery.  Optimised coating formulation did not show adverse effects on peptide 
bioactivity or trigger a pro-inflammatory response.  
 
The delivery route (microneedle vs. intradermal injection) was shown to be the 
main factor that influenced the clearance of peptide from murine skin in vivo. 
Other factors such as temperature, skin hydration state and peptide solubility 
were also shown to have effects on peptide clearance. 
 
Two autoantigens were used to induce tolerance in non-obese diabetic mice – a 
potent mimotope m31 and endogenous antigen WE14.  The proliferation profile 
of transferred carboxyfluorescein succinimidyl ester labelled BDC2.5 T cells in 
pancreatic lymph nodes in non-obese diabetic mice was used as a readout for 
the development of immunological tolerance. The results herein provide the first 
demonstration that WE14-coated microneedles were able to induce tolerance in 
vivo, showing reduced proliferation of BDC2.5 T cells.  
 
Additionally, this project examined the potential of short-term topical application 
of betamethasone to enhance peptide-induced tolerance.  Both human and 
mouse dendritic cells showed a pro-tolerogenic state after treatment with topical 
application of betamethasone in vitro.  However, full dose betamethasone was 
shown to have systemic toxicity in vivo, resulting in depletion of CD11c+ dendritic 
cells and CD4+ T cells.  Diluted topical betamethasone facilitated a small effect 
on BDC2.5 proliferation; however no advantage on enhancing antigen specific 
immunotherapy was observed. 
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Chapter 1 General Introduction 
1.1 A brief introduction to type one diabetes 
Type one diabetes (T1D) is an autoimmune disorder which is caused by the 
destruction of insulin secreting beta-cells in the islets of Langerhans in the 
pancreas (van Belle et al., 2011).  The first primary pathology of the pancreas in 
human T1D was documented by Gepts (Gepts, 1965).  His work demonstrated 
that the loss of pancreatic beta cell mass occurs prior to the clinical presentation 
of the disease.  
 
Insulin, an endocrine hormone, is responsible for regulating the uptake of blood 
glucose by cells, which is broken down within cells to produce energy.  In 
response to elevated blood glucose levels beta cells secrete insulin, which is 
stored in granules in the beta cells.  In order to compensate for the consumption 
of insulin, proinsulin is converted into insulin and C-peptide (Uchizono et al., 
2007).  Hyperglycaemia, caused by dysregulation of glucose in the system, can 
cause damage to several organs and can lead to complications such as 
retinopathy (eye disease), nephropathy (nerve disease), and cardiovascular 
disease (Forbes and Cooper, 2013).   
 
Classified as a metabolic disease, T1D can be diagnosed clinically by a raised 
blood glucose level.  This is associated with reduced C-peptide concentration, 
the presence of beta cell-reactive T cells, and the presence of antibodies against 
insulin, IA-2 and GAD65 (American Diabetes, 2010).  T1D has also been referred 
to, in the past, as juvenile diabetes, as many patients are diagnosed with T1D at 
a young age.  Approximately 10% of the diabetic population have T1D with a 
~4% increase in incidence every year (Harjutsalo et al., 2008, Taplin et al., 2005).   
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With the development of scientific techniques and an improved understanding of 
autoimmunity, it was in the 1970s that T1D was classified as an autoimmune 
disease (Cudworth and Woodrow, 1977, Irvine, 1977).  The understanding of the 
immunological pathogenesis of the disease rapidly improved with the 
development of animal models, such as the biobreeding rat and the non-obese 
diabetic (NOD) mouse.  The development of the NOD mouse in 1980 (Makino et 
al., 1980) was particularly important due to its ability to develop T1D which is 
comparable to human disease. 
 
Currently, the most common treatment for T1D is the subcutaneous injection of 
insulin.  Although this approach reduces the risk of microvascular complications, 
patients are required to constantly monitor the blood glucose level, which can 
fluctuate, in order to avoid hypoglycaemia.  The use of insulin can help reduce 
acute complications and prolong patient life span, however, it does not provide a 
cure for T1D.  Patients, especially those diagnosed at a young age, need to rely 
on insulin treatment for the rest of their life span.  The need for daily insulin 
injections (the current delivery method of choice for patients) coupled with the 
need to be extremely vigilant with diet and lifestyle adjustments reduces patients’ 
life quality and may make tasks which are relatively simple for non-diabetic 
individuals.  Despite careful management, patients are often still susceptible to 
glucose level fluctuations and are therefore vulnerable to the acute effects of 
hypoglycaemia, which can cause damage to the heart and brain and can be life 
threatening, even in well-controlled diabetes.  This possibility may also place an 
emotional burden on the family and loved ones of patients, as they can have no 
control over such events.  The desire to improve life expectancy and reduce 
impediment to the life style of patients has led to forty years of T1D research 
undertaken mainly to elucidate the mechanisms of cellular immunology and 
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genetic susceptibility factors.  Despite this work, there currently remains no cure 
for this chronic disease.  (Pettus and von Herrath, 2013).    
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1.2 Basic concepts of the immune system as relating to T1D 
As a defence system, the immune system consists of the innate immune system 
and the adaptive immune system.  Apart from physical barriers, cells of the 
innate immune system are the first to respond to pathogens.  The innate immune 
response is quick and non-specific, and typically involves mast cells, 
macrophages, leukocytes, dendritic cells, natural killer cells, basophils and 
eosinophils (Storey and Jordan, 2008).  The adaptive immune system provides a 
second layer of immune protection and is an antigen-specific process, which 
involves T cells and B-lymphocytes.  T1D is an autoimmune disease caused 
mainly by the dysregulation of immune tolerance which involves an imbalance of 
pathogenic T cells and regulatory T cells (Tregs).  One of the cellular 
mechanisms of T1D is that under proinflammatory conditions DCs take up beta 
cell antigens, which are released due to the damage of beta cells, and become 
fully mature.  These mature DCs differentiate naïve CD4+ T cells into antigen 
specific pathogenic CD4+ effector T cells (Teff).  These CD4+ Teffs then help the 
activation of CD8+ cytotoxic T cells, which infiltrate the pancreas and induce 
apoptosis in beta cells.  Without the paired (accompanying) tolerogenic 
mechanism, such as CD4+ Tregs, this diabetogenic process progresses 
unhindered and eventually causes tissue damage.  On the other hand, together 
with appropriate regulatory signals, DCs can differentiate naïve CD4+ T cells into 
Tregs, which prevent the development of Teffs and thereby protect beta cells 
from damage by cytotoxic CD8+ T cells (Figure 1.1).  One potential therapy for 
T1D is to use the regulatory properties of DCs and Tregs in a beta-cell-antigen-
specific manner, i.e. antigen specific immunotherapy (ASI).  Therefore, it is 
important to understand the role of DCs and T cells, especially CD4+ T cells, in 
T1D.  By directing DCs and T cells toward different developmental pathways, it is 
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possible to provide a therapy, which works by re-inducing balance using 
tolerogenic dendritic cells and regulatory T cells.   
 
 
Figure 1.1 Schematic view of cellular mechanisms of T1D and antigen specific 
immunotherapy (ASI).  Naïve CD4+ T cells can be differentiated into either Teff or Treg 
under different immune signals.  Autoimmunity can occur when the regulatory mechanism 
is out of balance.  An organ specific immunotherapy (ASI) can be used to re-induce 
tolerance, which can prevent or delay the development of T1D.  Teff=Effector T cell, 
Treg=Regulatory T cell, CTL=cytotoxic T cell, ASI= antigen specific immunotherapy, 
T1D=type one diabetes. 
 
1.3 Dendritic Cells (DCs) and T cell cross-talk 
DCs are a special type of antigen presenting cell (APC).  DCs provide an 
important bridge between the innate immune system and adaptive immune 
system by capturing, processing and presenting antigens to T lymphocytes 
(Inaba et al., 1993, Moll et al., 1993, Reis e Sousa et al., 1993).  
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DCs were first identified in secondary lymphoid organs (spleen (SP) and lymph 
nodes (LNs)) in 1973 and named ‘Dendritic Cells’ due to their branched 
morphology (Steinman and Cohn, 1973).  There are two major DC subsets: 
conventional or classical DCs (cDC) and plasmacytoid DCs (pDC).  pDCs 
represent a small proportion of the total DC population, whose main function it is 
to respond to viral infection.  pDCs can be identified by their secretion of type one 
interferons and low expression of major histocompatibility complex II (MHC II) 
and CD80/CD86 co-stimulators (Reizis et al., 2011).  Unlike pDCs, cDCs express 
high levels of CD11c and MHCII and can be identified using these two surface 
markers (Miloud et al., 2010).  Resident in both lymphoid and non-lymphoid 
tissues, cDCs constantly sample their surroundings for foreign antigens or self-
antigens (Merad and Manz, 2009).  Therefore, cDCs play an important role in 
priming T cells to induce immune responses to foreign antigens or inducing 
tolerance to self-antigens.   
 
DCs are a highly heterogeneous group of cells that are able to perform different 
functions.  They can either prime T cells to induce immunity or educate T cells to 
have a tolerogenic function.  DCs are able to communicate with T cells using a 
number of different signals as illustrated in Figure 1.2. 
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Figure 1.2 Interaction between DCs and CD4+ T cells.  Three signals are involved in 
DC and naïve T cell interaction, which helps the differentiation of naïve CD4+ T cells into 
different subsets.  The first signal is through MHCII-peptide complex to TCR in an antigen 
specific manner.  The second signal from DC is through costimulators (CD80/CD86) to 
CD28, which is expressed by T cells and up-regulates activation signals in T cells.  When 
lacking co-stimulatory signals, naïve T cells become anergic.  CTLA4 expressed by T 
cells can also interact with CD80/CD86 and compete with CD28 binding.  CTLA4 is not 
able to induce activation signals but can induce a regulatory signal.  The third signal 
involved in DC/T cell interaction is via cytokines.  Proinflammatory cytokines, such as 
IFNγ, IL4 and IL6 differentiate naïve T cells into effector T cell subsets: Th1, Th2 and 
Th17.  Regulatory cytokines, such as IL10 and TGF-β help with Treg differentiation.  
Furthermore, the binding of CD40 and CD40 ligand (CD40L) gives positive feedback to 
DCs and promotes the activation of DCs (Merad et al., 2013). 
 
In the steady state, immature DCs are constantly sampling the surrounding 
environment for pathogens.  After phagocytosis, DCs digest pathogens into small 
protein or peptide fragments.  These fragments then bind with MHC molecules 
creating MHC-peptide complexes, which can then be translocated to the cell 
surface.  Intracellular pathogens, such as viruses, are processed in the 
cytoplasm and loaded on MHC I, which presents to CD8+ T cells.  On the other 
hand, extracellular pathogens, processed in endosome/lysosome, are loaded 
onto MHC II and presented to CD4+ T cells (Savina and Amigorena, 2007).   
 
DCs are activated and become fully matured once they encounter a pathogen, 
which is recognised through pattern recognition receptors, such as toll like 
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receptors (TLRs) (Hoarau et al., 2006).  Fully mature DCs undergo a phenotypic 
change (expressing high MHCII and CD80/CD86) and migrate to the draining 
lymph node where they are able to activate T cells through signals from MHCII, 
CD80/CD86 and pro-inflammatory cytokines, such as TNFα and IL12 (Romani et 
al., 2001, Kurita et al., 2006).   
 
In the steady state, DCs are resident in tissues and remain immature, with low 
expression of MHCII and costimulators (CD80, CD86) on the cell surface 
(Mommaas et al., 1995).  In the absence of costimulators (CD80, CD86), DCs 
stimulate T cells in a tolerogenic manner, inducing anergy (Appleman and 
Boussiotis, 2003).  It was suggested that by injection of a soluble antigen, DCs 
can avoid activation and thus induce T cell anergy (Miller et al., 2007).  DCs also 
play an important role in the maintenance of the T cell repertoire.  In the steady 
state, DCs constantly monitor T cells through self-peptide MHCII/TCR interaction.  
If a TCR has high affinity for self-peptide MHCII, T cells will be programmed to 
undergo apoptosis.  T cells with a low or intermediate affinity will survive, 
enabling successful antigen recognition (Garbi et al., 2010).   
 
DCs play an important role in maintaining peripheral tolerance.  DCs carrying 
self-antigen migrate to LNs without activation, showing a semi-mature state with 
high expression of MHCII and CD80/CD86 but low pro-inflammatory cytokine 
expression (Lutz and Schuler, 2002).  Instead of activating T cells, these semi-
mature DCs express IL10 and induce Tregs (Akbari et al., 2001).  These semi-
mature DCs have therefore been referred to as tolerogenic DCs (tol-DC), 
indicating their function in inducing tolerance.  Several factors have been 
investigated to determine their influence in educating DCs into tol-DCs.  Vitamin 
D3 can differentiate DCs into tol-DCs, which then promote the secretion of IL10 
and the apoptosis of mature DCs (Szeles et al., 2009, Penna and Adorini, 2000).  
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TNFα plays a critical role in inducing tol-DCs by vitamin D3.  Vitamin D3 treated 
DCs failed to induce Tregs when membrane bound TNFα (insoluble) was blocked 
(Kleijwegt et al., 2010).  Dexamethasone is another immune regulator that was 
used to induce tol-DCs.  Like vitamin D3, dexamethasone can modulate DCs into 
a semi-mature phenotype and these tol-DCs have been shown to induce IL10 
secreting Tregs (Unger et al., 2009).   
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1.4 T cells and autoimmunity 
1.4.1 CD4 T cell subsets and their functions 
T cells are derived from bone marrow and undergo maturation in the thymus, 
whereby they become single positive CD4 or CD8 T cells.  CD8+ T cells are 
cytotoxic T cells, which eliminate cells infected with intracellular pathogens, such 
as viruses (Zhang and Bevan, 2011).  CD8 T cell receptors recognise major 
histocompatibility complex class I (MHCI) and cytosolic pathogen fragments.  
CD4+ T cells are responsible for the elimination of intracellular pathogens, which 
can recognise MHCII / antigen complexes.  CD4+ T cells can be subdivided into 
effector T cells (helper T cell type (Th) 1, Th2, Th9, Th13 and Th17) and 
regulatory T cells (Tregs) (iTreg, Tr1, and Th3) according to their cytokine 
production and their function (Luckheeram et al., 2012) (Figure 1.3).   
 
Figure 1.3 CD4+ T cell subsets. After encountering antigen presenting DCs, naïve CD4+ 
T cells can differentiate into effector T cells and regulatory T cells. Differentiation factors 
(cytokines in the surrounding micro-environment) play a key role in the differentiation of T 
cells subtypes in response to different immune stimuli.  Transcription factors can then 
further promote and regulate the differentiation process. CD4+ T cell subsets then exert 
their effect through secretion of cytokines which mediate the function of other immune 
cells (Zhu and Paul, 2008, Gerlach et al., 2014, Geginat et al., 2014, Palucka et al., 2009, 
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1.4.1.1 Effector T cells 
It was in 1986 that activated CD4+ T cells were subdivided into two groups, Th1 
and Th2 (Mosmann et al., 1986).  The Th1 T cell subset differentiates from naïve 
T cells due to the presence of IL12 (which is released by APCs), and can be 
identified by the release of cytokines such as IFNγ (Romagnani, 1999).  IFNγ is a 
proinflammatory cytokine, which is predominantly secreted by Th1 CD4+ and 
CD8+ T lymphocytes and natural killer T cells (NKTs).  It is an important factor for 
activation of macrophages (Dinarello, 2000).  Other cytokines are released by 
Th1 T cells, including IL2, which is a growth factor required for T cell proliferation.  
Th1 cells are effector CD4+ T cells, which respond to intracellular pathogens (Del 
Prete, 1992).  Th1 cells elicit activation of macrophages and proliferation of CD8 
T cells.  It was shown that Th1 cells play an important role in the development of 
T1D and can induce diabetes in NOD-SCID mice following adoptive transfer 
(Bradley et al., 1999).   
 
Naïve CD4 T cells differentiate into Th2 cells in the presence of IL2 and IL4.  IL4 
is also a major cytokine released by Th2 cells.  Th2 cells respond to extracellular 
parasites and help B cells to secrete antibodies, especially IgE (Del Prete, 1992).  
Allergies and asthma are shown to be closely related to Th2 reactivity (Azar et 
al., 1999).  It is widely accepted that Th1 and Th2 cells are able to counter 
balance each other with the cytokines they release.  IFNγ released by Th1 cells 
inhibits the proliferation of Th2 cells, while Th1 cell proliferation can be inhibited 
by IL4 and IL10, which are released by Th2 cells (Luckheeram et al., 2012).  
 
Many cytokines contribute to the differentiation of Th17 cells, such as IL6, IL21, 
IL23, and TGFβ, among which TGFβ is critical for development of Th17 cells 
(Zhu and Paul, 2008).  Interestingly, TGFβ was also shown to be an important 
cytokine for differentiation of Tregs.  When naïve T cells are stimulated with a low 
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concentration of TGFβ and other cytokines such as IL6, naïve T cells 
differentiated to IL17-secreting Th17 effector cells (Luckheeram et al., 2012, 
Hatton, 2011).  On the other hand, when TGFβ is present at high concentration, it 
induces Foxp3, which differentiates naïve T cells into Tregs (Hatton, 2011).  Th17 
cells mediate immune function against extracellular bacteria and fungi as well as 
inducing autoimmunity.  In NOD mice, which can develop T1D spontaneously, a 
high concentration of IL17 was observed in the pancreas and islet antigen 
specific CD4 T cells were shown to be Th17 cells, which are known to induce 
diabetes in NOD-SCID mice (Shao et al., 2012). 
 
After activation, CD4+ Teffs go through different immune phases, including clonal 
expansion, contraction due to apoptosis and the memory phase.  These memory 
CD4+ T cells survive apoptosis after activation and preserve the antigen 
specificity and can be activated more quickly than naïve T cell when re-
challenged with the same antigen (MacLeod et al., 2009, MacLeod et al., 2010, 
Ammirati et al., 2012, Correia et al., 2014).  CD4+ memory T cells can be divided 
into two subsets: effector memory T cells and central memory T cells, as listed in 
Table 1.1 .   
 
Table 1.1 CD4+ memory T cell function and homing. Tcm=central memory T cells, 
Tem=effector memory T cells.  (MacLeod et al., 2009, MacLeod et al., 2010, Ammirati et 
al., 2012, Correia et al., 2014). 
 Tcm Tem 
Function Absence of immediate 
effector function 
Immediate effector function 
Anatomic 
location 
Lymph nodes, Blood Lung, liver and gut 
Migration  Secondary lymphoid 
organs 
Peripheral site of inflammation, 
non-lymphoid tissues 
Proliferation High Low 
Cytokine 
production 
IL2 IL4, IL17, IFNγ 
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1.4.1.2 Regulatory T cells (Tregs) 
Regulatory T cells (Tregs) play an important role in controlling ongoing immune 
response and silencing self-reactive T cells in peripheral tolerance.  There are 
two main Treg subsets: naturally occurring thymic-derived Tregs (nTregs) and 
antigen induced Tregs (iTregs) (Shevach and Thornton, 2014). These Treg 
subsets are identified based on their expression of cell surface markers, 
production of cytokines, and mechanisms of action (Jonuleit and Schmitt, 2003).   
 
Differentiated in the thymus, nTregs are a group of polyclonal Tregs with a TCR 
repertoire which can effectively bind MHC/self-antigen complex (Hsieh et al., 
2004).  Naturally occurring thymic-derived CD4+CD25+ Tregs (nTreg) are 
characterized by their constitutive expression of the transcription factor forkhead 
box P3 (Foxp3) and inhibitory cytokines such as IL10 and TGFβ.  Foxp3 plays a 
very important role in both the development and function of nTreg (Hori and 
Sakaguchi, 2004).  Foxp3 expressed by mTEC (medullary thymic epithelial cells) 
in the thymus plays a key role in Treg development in the thymus (Liu et al., 
2008, Aschenbrenner et al., 2007).  The importance of Foxp3 in Treg function 
was demonstrated by depletion of Foxp3+ T cells to induce autoimmune disease 
and disease was prevented when antigen specific Tregs were introduced (Kim et 
al., 2009a, Brode et al., 2006).  Two mechanisms are thought to be involved in 
nTreg suppression: Firstly, Tregs inhibit the differentiation of Naïve T cells into 
Teff and therefore prevent the expansion of Teff population.  Secondly, nTregs 
exert their tolerogenic effect on DCs through CTLA4, IL10 and TGFβ and 
indirectly inhibit fully differentiated Teffs through tolerogenic DCs (Shevach and 
Thornton, 2014). 
 
As well as deriving from the thymus, Tregs can also be generated by tolerogenic 
cytokines, IL10, TGFβ, or tol-DCs in the periphery (Matsumura et al., 2007, 
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Kushwah and Hu, 2011).  These antigen/cell specific T cells are referred to as 
induced Tregs (iTreg).  It was thought that iTregs retain similar functionality to 
nTregs.  In an in vitro experiment, TGF-beta, retinoic acid, and IL-2 were used to 
generate iTregs, which showed a suppressive effect on antigen-specific effector 
T cells in an experimental autoimmune encephalomyelitis (EAE) model (Zhang et 
al., 2010).   
 
It is thought that there are four basic mechanisms in the regulation of immune 
response which involve Tregs (Vignali et al., 2008, Schmetterer et al., 2012).  
These are demonstrated in Figure 1.4 as follows:  1, Suppression of Teff 
proliferation by inhibitory cytokines, such as IL10 and TGF, which control the 
inflammatory response and inhibit Teff function.  2, Induction of Teff apoptosis by 
metabolic disruption due to competitive deprivation of the growth factor IL2.  3, 
Induced apoptosis through secretion of granzyme A or B, which causes cytolysis 
of Teff cells.  4, Indirect inhibition mediated through DC and Treg amplification 
loop.  Cytotoxic T-lymphocyte antigen 4 (CTLA4) is expressed on Tregs and 
interacts with CD80/CD86 on DC, up-regulating the expression of indoleamine 
2,3-dioxygenase (IDO); an enzyme that degrades tryptophan.  IDO was 
demonstrated to inhibit Teff functions as well as help naïve T cells to differentiate 
into Tregs (Mellor and Munn, 2004).   
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Figure 1.4 Four basic mechanisms that Treg utilise to regulate immune responses.  
Tregs regulate immune response by the direct prevention of proliferation or by inducing 
apoptosis.  Tregs also can prevent Teff function indirectly through DCs (Vignali et al., 
2008, Schmetterer et al., 2012).   
 
As described above, Tregs are important in maintaining peripheral tolerance. 
Both antigen-specific and polyclonal Tregs have a role in regulating the immune 
system in the prevention of autoimmune disease.  In a model of EAE, using a 
transgenic mouse model, Hori et al. demonstrated that both antigen-specific 
Tregs and polyclonal Tregs prevented EAE development with equivalent efficacy 
(Hori et al., 2002).  Thus, Tregs can be a useful tool in the therapy of 
autoimmune disease.  Young patients with T1D who received in vitro expanded 
Tregs in a clinical trial showed a reduced blood glucose level and an increased 
Treg population in the blood for two weeks following treatment.  No adverse 
effect was demonstrated over a year following treatment (Marek-Trzonkowska et 
al., 2012).  However, these fundamental insights are not yet ready to be utilized 
as an effective clinical therapeutic intervention, due to factors such as Treg 
purity, dosage, specificity and dynamics (Tang and Bluestone, 2013). 
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1.4.1.3 Markers of CD4+ T cells 
 
Apart from their functions, CD4+ T cell subsets also can be recognised by their 
phenotypic characteristics such as surface and intracellular markers.  Some of 
these markers are listed in Table 1.2.   
 
Table 1.2 CD4+ T cell markers. Tn=Naïve T cell, Teff=Effector T cell, Treg=Regulatory T 
cell, Tem=Effector memory T cell, Tcm=Central memory T cell, N/K=not known. 
Name Expression Function Tn Teff Treg Tem Tcm 




- +++ - - - 
CD44 Surface Cell 
adhesion 
+ +++ - +++ +++ 
CD62L Surface Homing +++ - +++ +/- +++ 
CD25 Surface IL2 receptor  - ++ +++ - - 
GITR Surface Activation  + +++ +++ N/K N/K 
Foxp3 Intracellular Suppressive 
function 
marker 
- + +++ N/K N/K 
 
CD62L is L-selectin which is expressed on T cells and controls T cell migration to 
secondary lymphoid organs.  Upon activation, T cells in circulation migrate to 
both lymphoid and non-lymphoid organs and down-regulate CD62L.  A high 
expression of CD62L was found on naïve T cells and less on activated effector T 
cells (Klinger et al., 2009). CD62L-expressing CD4 T cells prevented 
development of T1D and restored normal glycaemia in a mouse model, thus 
demonstrating a regulatory function (You et al., 2004, Ermann et al., 2005, 
Tarbell et al., 2007). 
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CD44 is a surface molecule expressed on a wide range of cells.  In T 
lymphocytes, it is responsible for adhesion, activation, migration and proliferation 
(Graham et al., 2007).  CD44 is upregulated when T cells are activated and a 
high expression on memory T lymphocytes is retained.  It has been shown that 
CD44 plays an important role in Th1 cell survival (Baaten et al., 2010) 
 
CD69 is a type II integral membrane protein belonging to the C-type lectin 
superfamily (Natarajan et al., 2000).  It is an early T cell activation marker, and is 
shown to be upregulated rapidly approximately 3-4 hours after activation.  
Expression of CD69 declines after 24 hours if the stimulus is removed (Testi et 
al., 1994).  The level of CD69 expression was shown to be correlated with T cell 
activation and proliferation, and has been analysed quantitatively using flow 
cytometery (Lindsey et al., 2007, Caruso et al., 1997).  It was shown that CD69 
influence the differentiation of Th17 cells through the Jak3/Stat5 signalling 
pathway (Martin et al., 2010).  CD69 was also shown to alter the Th2 cell 
migration to the asthmatic lung by altering the expression of VCAM-1 (Miki-
Hosokawa et al., 2009).  This indicated that CD69 is related to CD4 T cell 
differentiation and migration which further influence the inflammatory response. 
 
GITR (glucocorticoid-induced TNFR family related gene) is a member of the 
TNFR (tumour necrosis factor receptor) super family.  GITR is upregulated when 
T cells become activated and it was shown to be involved in the control of 
glucocorticoid-induced T cell apoptosis (Zhan et al., 2004). GITR also plays an 
important role in CD4+CD25+ regulatory T cell expansion and suppressive 
functions.  CD4+CD25+ T cells were shown to lose their regulatory function when 
GITR was knocked out (Ronchetti et al., 2004).  However, it was found that GITR 
has effects on both Teffs and Treg and promotes function in both types of T cell 
(Shevach and Stephens, 2006). 
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CD25 is a transmembrane protein, which acts as an alpha chain of receptor for 
the cytokine IL2, a T cell growth factor.  CD25 was shown to have a low affinity 
with IL2.  However, when combined with IL2 receptor gamma chain CD122, 
CD25 has a high affinity for IL2 (Letourneau et al., 2009).  Treg cells were shown 
to express a high level of CD25, which was thought to compete with effector T 
cells for IL2, when IL2 is in low concentration.  IL2 starvation caused by Treg with 
high expression of CD25 was thought to be one of the mechanism by which Treg 
suppresses Teff functions (for detail see section 1.4.1.2, and Figure 1.4).  CD25 
is not expressed on resting T cells but is upregulated when T cells become 
activated (Nelson and Willerford, 1998).  T cells also express a high level of 
CD25 during the early development stages in the thymus (Godfrey and Zlotnik, 
1993).  CD25 In the periphery, nTregs can be identified by high expression of 
CD25 on CD4+ T cells (Letourneau et al., 2009).  
 
Foxp3 is a protein belonging to the forkhead family of transcription factors.  
Foxp3 plays a key role in Treg development and function (Hori et al., 2003).  
Expression of Foxp3 is associated with the upregulation of other Treg markers 
such as CD25, CTLA4 (Cytotoxic T-lymphocyte-associated protein 4) and GITR 
(Hori and Sakaguchi, 2004).  In T1D, Foxp3+ Tregs were able to protect against 
the destruction of pancreas in NOD mice by adoptive transfer and depletion of 
Foxp3+ Treg could lead to fatal autoimmunity in mice at 3-4 weeks of age 
(Petzold et al., 2013). 
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1.5 Central tolerance, peripheral tolerance and autoimmunity 
Another mechanism used by the immune system to distinguish between self and 
non-self is by self-tolerance, a mechanism that protects self-tissue against 
immune response.  There are two stages of tolerance: central tolerance and 
peripheral tolerance.  During these tolerance processes, self-reactive cells are 
depleted, become anergic or are regulated.   
 
1.5.1 Central tolerance 
T cells are first selected in the thymus by positive and negative selection, in a 
process called central tolerance.  T cells are selected in central tolerance 
depending on the affinity between their TCR and self-peptide/MHC complex. 
 
Derived from bone marrow progenitors, T thymocytes initially lack T cell 
receptors (TCR) or CD4 and CD8 markers; at this stage they are termed “double 
negative”.  Double negative T thymocytes then undergo proliferation when TCR 
are rearranged and they become CD4+CD8+ double positive thymocytes.  At this 
stage TCRs have random specificity with a broad TCR repertoire (Hogquist et al., 
2005).  In the cortex, double positive T cells interact through TCRs with cortex 
epithelial cells, which express MHCI, MHCII and self-peptide.  T thymocytes with 
TCR which do not bind self-peptide/MHC complex is undergo apoptosis due to 
neglect (Xing and Hogquist, 2012).  T thymocytes with TCR that weakly bind with 
self-peptide/MHC complex survive and migrate to medulla where they become 
single CD4 or CD8 positive.  This selection process is called positive selection, 
during which the TCR is selected to recognize self-peptide/MHC complex.   
 
In the medulla, an inner region of the thymus, single positive CD4 and CD8 T 
cells are further selected during the negative selection process.  During negative 
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selection, T cells with TCR that can recognize self-antigen/MHC complexes with 
high affinity will be deleted from the T cell repertoire (McCaughtry and Hogquist, 
2008).  This process is also referred to as clonal deletion.  The fine threshold of 
affinity between TCR and self-peptide/MHC distinguishes between positive 
selection and negative selection (Palmer and Naeher, 2009).  It is thought that 
polyclonal T cell progenitors are deleted during positive selection in the cortex 
and tissue specific progenitors are deleted during negative selection in the 
medulla (Xing and Hogquist, 2012).  Two types of cells in the thymus are 
involved in clonal deletion: mTEC and DCs.  mTECs express a protein called 
autoimmune regulator (AIRE), which is involved in regulating the expression of 
tissue specific antigens.  It has been demonstrated that tissue specific self-
antigen in the thymus is controlled by the AIRE gene (Liston et al., 2003).  A 
mutation in this gene can lead to autoimmune disease. 
 
In addition to clonal deletion, T thymocytes can also be diverted down a different 
developmental route during the negative selection period in a process called 
clonal diversion.  During this stage, tissue-antigen specific Tregs are 
differentiated from T thymocytes.  Several factors can determine the fate of T 
thymocytes, including TCR signal, signal through CD28 and cytokines: It was 
suggested that the generation of foxp3+ Treg is correlated with a weaker TCR 
signal compared to the negative selection process.  The reduced expression of 
MHCII on mTEC was shown to prevent T thymocytes from being deleted (Klein et 
al., 2009).  Apart from the TCR signal, signal from costimulator CD28 is also 
important in the generation of Tregs in the thymus.  The intrinsic signal induced 
by CD28 was shown to be involved in generation of Foxp3- Treg precursors (Lio 
et al., 2010).  Signals from cytokines, such as IL2 and TGFβ, can help the 
survival of Tregs; IL2 was shown to promote the expression of Foxp3 on T 
thymocytes (Lio and Hsieh, 2008), whilst TGFβ was shown to be able to protect 
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Tregs from clonal deletion (Ouyang et al., 2010).  The generation of Tregs in the 
thymus, i.e. nTreg, also plays a vital role on peripheral tolerance, which will be 
discussed in the next section, 1.5.2. 
 
1.5.2 Peripheral tolerance 
The processes that enable central tolerance are not able to eliminate all 
autoreactive T cells.  This is because some T lymphocytes have a low affinity for 
MHC/self antigen and can escape central tolerance.  Additionally, not all self-
antigens are expressed in the thymus. T cells that escape the central tolerance 
mechanism can be further regulated by peripheral tolerance via inactivation or 
elimination.   
 
TolDCs are important in the induction and maintenance of peripheral tolerance 
(details see Section 1.3).  Inactivation is achieved by absence of activation 
signals from DCs (such as costimulators CD80/CD86), which induces T cell 
anergy.  To be activated, T cells require signals from TCR, CD28 and 
inflammatory cytokines and therefore lack of a signal from CD80/CD86 to CD28 
results in T cell anergy (Thompson et al., 1989, Sharpe and Freeman, 2002).  
Another important co-stimulator in T cell anergy is CTLA-4.  CTLA-4 can down 
regulate the T cell activation process and block growth cytokine IL2 receptor 
expression, even when T cells are activated (Walunas et al., 1996).  A lack of 
CTLA-4 has been shown to cause severe autoimmune disease in mice (Tivol et 
al., 1995).   
 
Immune homeostasis can also be achieved with Tregs by cell-cell contact in the 
periphery (Takahashi et al., 1998).  Both nTreg and iTreg (see section 1.4.1.2) 
are able to maintain peripheral tolerance.  Tregs can directly induce Teff 
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apoptosis by metabolic disruption or enzyme cytolysis.  Additionally, Tregs can 
secrete anti-inflammatory cytokines, such as TGFß and interleukin-10 (IL10), 
which have been shown to inhibit immune response in vivo (Hawrylowicz and 
O'Garra, 2005).  The details of Treg regulatory mechanisms were introduced in 
the previous section 1.4.1.2.   
 
A process, which causes an imbalance during any of these regulatory processes, 
may lead to the development of an autoimmune disorder, and such is the case 
for T1D.  A detailed pathology of T1D in animal model will be introduced in the 
next section, 1.6.1. 
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1.6 The NOD (Non Obese Diabetic) mouse 
The causes of T1D are complex.  Therefore, models are needed to help 
understand the mechanisms behind this chronic disease.  The use of efficient, 
convenient, cost effective and appropriate animal models is important in assisting 
the development of a potential prevention or intervention for the treatment of 
T1D.  Two animal models, which spontaneously develop diabetes, have been 
widely used for study of T1D: the Biobreeding rat and the NOD mouse (King, 
2012).  The most commonly used of these two models is the NOD mouse.  The 
Biobreeding rat is most useful for studying environmental influences on T1D and 
pancreatic transplant intervention studies (Mordes et al., 2004, King, 2012).  One 
disadvantage of the Biobreeding rat is that it can develop T cell lymphopenia, 
which is not found in the NOD mouse or in human patients with T1D (Mordes et 
al., 2004).   
 
1.6.1 Pathology of T1D in NOD mouse 
The NOD murine subline was originally developed in order to study cataract 
disease (Leiter et al., 1987).  NOD mice were also shown to develop T1D 
spontaneously in a manner similar to human T1D, via genetic and cellular 
mechanisms (Serreze and Leiter, 1994, Atkinson and Leiter, 1999, Leiter, 2001).  
There are differences in rates of disease incidence between males and females.  
Approximately 60-80% of female NOD mice develop disease between 12-14 
weeks old, while only 10-20% of male mice become diabetic at a comparable 
ages. (Markle et al., 2013, Bao et al., 2002, Baxter et al., 1991).   
 
Insulitis in the NOD mouse is initiated by APCs, together with the death of beta 
cells.  A wave of beta cell death occurring at 1-2 weeks of age was observed in a 
rat model (Scaglia et al., 1997).  This was thought to be part of a process called 
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“tissue remodelling”, a renovation process which occurs during the neonatal 
stage of development, in order to maintain the mass of beta cells.  This process 
has also been observed in the Biobreeding rat and NOD mouse models.  Rapid 
beta cell apoptosis was observed at 13 days of age in both models (Trudeau et 
al., 2000).  The increased number of dead cells and/or dead cell fragments 
during tissue remodelling in these developing neonatal tissues can potentially 
provide both an activation signal and self-antigenic fragments to APCs.  APCs 
can engulf beta cell antigens in the pancreas and prime T cells in PLNs 
(pancreatic lymph nodes).   
 
Enhanced APC ability of DCs was found in NOD mice.  It was suggested that 
elevated expression of NF-κB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) on mDCs (myeloid DCs) was associated with the increased 
expression of TNFα and also increased ability to prime T cells (Poligone et al., 
2002).  Following depletion of mDCs from NOD mice, reduced T cell activation 
was observed (Saxena et al., 2007).  Interestingly, a DC subtype, pDC 
(plasmacytoid DC), was able to counter-regulate the activation process.  
Absence of pDCs can accelerate diabetes progression in NOD-SCID mice and 
local regulation was restored when pDCs were re-introduced (Saxena et al., 
2007).  
 
During maturation, DCs migrate to the pancreatic lymph nodes (PLN) where they 
prime naïve T cells.  T cells play a key role in insulitis during the development of 
T1D.  It was shown that T cells infiltrate the pancreas of NOD mice at the age of 
3-4 weeks and cause onset of diabetes by the age of 12 weeks (Leiter, 2001).  
T1D can be induced by transferring T cells (CD4+ and CD8+) from diabetic NOD 
mice to NOD-SCID mice; this can be prevented by depletion of T cells, which can 
be achieved by using anti-CD3 antibody to treat NOD mice (Christianson et al., 
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1993, Chatenoud et al., 1994).  This evidence indicates that T1D in NOD mouse 
is a T cell-mediated disease.  Loss of central and peripheral tolerance in the NOD 
mouse enables the escape and activation of diabetogenic T cells.  Abnormal 
migration of thymocytes in the NOD mouse was shown to be due to the reduced 
expression of integrin-type fibronectin receptors, VLA-4 and VLA-5 (Cotta-de-
Almeida et al., 2004).  Although research has shown that the total T cell migration 
from the NOD mouse thymus was not different from a control strain, a greater 
proportion of Foxp3+ T cells were shown to remain in the thymus in NOD mice 
(Mendes-da-Cruz et al., 2008).  Failure of depletion is also related to the 
insufficient expression of self-antigens in the thymus.  AIRE (autoimmune 
regulator) is a transcription factor that regulates expression of self-antigen in the 
thymus, and was shown to down-regulate ICA69 (islet cell autogantigen 69 KDa) 
in NOD thymus, which may explain the inefficient depletion of autoreactive T cells 
in the NOD thymus (Bonner et al., 2012). 
 
Activation of naïve diabetogenic T cells by DCs occurs in the PLN.  Removing 
PLNs before the age of 3 weeks protected NOD mice from developing T1D 
(Gagnerault et al., 2002).  However, further insulitis could not be prevented by 
the removal of PLN alone in mice that were more than 10 weeks old (Gagnerault 
et al., 2002).  Several factors influence the activation of the autoreactive T cells in 
the NOD mouse.  I-Ag7, an MHCII molecule expressed on the surface of DCs, 
was found to have an unusual β chain, which is associated with diabetes 
susceptibility (Acha-Orbea and McDevitt, 1987).  I-Ag7 lacks an aspartic acid 
residue at position β-57 and has a larger pocket at P9 compared with another 
MHCII molecule I-Ad (Corper et al., 2000, Stratmann et al., 2000).  These 
features enable enhanced binding between the autoantigen (originating from 
GAD65 protein) and the MHCII molecule, which further provides a strong 
activation signal to T cells.  Another activation signal is through co-stimulators, 
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CD80/CD86 on DCs.  CTLA4 expressed on CD4 T cells can compete with CD28 
by binding with CD80/CD86 and providing a negative signal to T cells, which 
inhibits T cell activation (Walunas et al., 1996).  Loss of CTLA4 can result in 
unregulated T cell activation, which could contribute to the development of 
autoimmune disease (Tivol et al., 1995).  In NOD mice the susceptibility to T1D 
could also be associated with a lack of the CD80/CD86 ligand-binding domain on 
CTLA4 (Ueda et al., 2003) 
 
After activation, T cells homing back to the pancreas showed up-regulation of 
CD44 and down-regulation of CD62L.  These activated T cells kill beta cells by 
Fas/FasL, release of perforin and granzymes, and release of cytokines to create 
an inflammatory environment (Pirot et al., 2008).   
 
1.6.2 The BDC2.5-TCR (T cell receptor)-Tg (transgenic) mouse 
It has been widely accepted that T1D is a T cell mediated autoimmune disease 
both in humans and in the NOD mouse (van Belle et al., 2011, Phillips et al., 
2009, Roep, 2003, Sakumai et al., 2007).  Interestingly, diabetic T cells have 
been isolated in order to understand the molecular and cellular mechanisms of 
T1D disease progression.  The first islet antigen-specific T cell clone isolated 
from the NOD mouse (BDC2.5) was a CD4 T cell clone (Haskins et al., 1988).  
This BDC2.5 T cell was shown to be highly reactive to islet antigens and was 
shown to be pathogenic and able to infiltrate the pancreas in vivo (Haskins et al., 
1989).  The TCR was subsequently cloned and a BDC2.5-TCR-Tg-mouse was 
first reported by Katz and colleagues (Katz et al., 1993).  CD4+ T cells from these 
mice express the TCR genes Vα1 and Vβ4.  It has been suggested that BDC2.5 
T cells are positively selected in the thymus and comprise over 95% of CD4+ T 
cells in the Tg-mouse.  The BDC2.5 T cells from the Tg mouse shows a naïve 
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phenotype compared with the cloned T cells, which display an effector/memory 
phenotype (Dobbs and Haskins, 2001).  Both types of BDC2.5 T cell appear to 
be biochemically similar, which suggests that BDC2.5 T cells from the TCR-Tg-
mouse are present in their activated state.  BDC2.5 TCR-Tg-mice with the NOD 
genetic background had a lower diabetes incidence compared with those on the 
B6g/7 congenic background (Gonzalez et al., 1997).  This could be due to an 
inhibitory effect on disease progression by CD4+DX5+ T cells (Gonzalez et al., 
2001).  NOD-SCID recipients, adoptively transferred with BDC2.5 T cells isolated 
from a TCR-Tg-mouse, were shown to develop diabetes rapidly (Peterson and 
Haskins, 1996).  These studies demonstrate that the BDC2.5-TCR-Tg mouse is a 
useful tool for the study of T1D pathology and these mice provide a valuable 
model for use in studies designed to improve understanding of tolerance in this 
autoimmune model.   
 
It was not until recently that Chromogranin A (ChgA) was identified as an 
autoantigen for the BDC2.5 T cell and WE14 (WSRMDQLAKELTAE), derived 
from ChgA, is the natural antigenic epitope that stimulates the BDC2.5 T cell 
receptor (Stadinski et al., 2010).  However, WE14 has a low affinity for the 
BDC2.5 TCR and thus has a low potency for BDC2.5 T cell stimulation.  A further 
study suggested that transglutamination is a key post-translational modification 
required to generate pathogenic peptides.  After transglutaminase (TGase) 
modification, WE14 becomes 10 times more potent in stimulating BDC2.5 T cells 
in vitro.  NOD-SCID mice developed T1D quicker when transferred with BDC2.5 
T cells and stimulated with TGase modified WE14 than when transferred with 
cells stimulated with untreated WE14 (Delong et al., 2012).  The BDC2.5 
mimotope 1040-31 (m31) (YVRPLWVRME) is a synthesized peptide, which 
mimics the sequence of the autoantigen (GAD65 fragments) but has a greater 
affinity for the TCR (Judkowski et al., 2001).  BDC2.5 T cells can respond to m31 
  28 
at a concentration of less than 10ng/ml (Montero-Hadjadje et al., 2002, Curry et 
al., 2002), whereas WE14 has a low potency and requires a 1000 fold greater 
dose than the m31 in order to activate BDC2.5 T cell clones in vitro (Stadinski et 
al., 2010, Delong et al., 2013). 
 
1.6.3 Auto-antigens in the NOD mouse 
As T1D is mainly mediated by T cells, it is important to identify their auto-
antigenic targets.  Depletion of CD4+ and CD8+ T cells using antibodies, 
conferred prolonged protection of T1D in NOD mice and resulted in an increased 
population of CD4+CD25+ Treg in PLN but not in the SP (Yi et al., 2012).  
Following the isolation of BDC2.5, several diabetogenic T cell clones have been 
isolated from NOD mice indicating that more than one autoantigen contributes to 
the destruction of beta cells (Babad et al., 2010).  A summary of the autoantigens 
isolated to date is listed in Table 1.3. 
 
As described in the previous section, 1.6.2, ChgA (Chromogranin A) is a newly 
discovered autoantigen of T1D, which can be isolated from secretory granules of 
a beta cell (Stadinski et al., 2010).  WE14, a natural cleavage product of ChgA, 
binds weakly to the MHCII I-Ag7 molecule (Curry et al., 2002, Stadinski et al., 
2010).  As ChgA is not exclusively expressed in beta cells, this has raised 
questions as to why there are no other organs targeted and therefore no 
pathology related to ChgA has been demonstrated outside of the pancreas in 
T1D.  One potential explanation was that organ specific post-translational 
modification of ChgA had occurred in the pancreas, which could contribute to its 
inflammatory state.  It was suggested that WE14 could have been modified using 
transglutaminase, resulting in a modified molecule capable of stimulating BDC2.5 
T cells more potently than original WE14 peptide (Haskins and Cooke, 2011, 
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Delong et al., 2012).  NOD-SCID mice transferred with BDC2.5 T cells pre-
cultured with transglutaminase-treated WE14 developed disease more rapidly 
than using WE14 pre-treated BDC2.5 T cells (Delong et al., 2012).  Although the 
BDC2.5 T cell clone derived from the NOD mouse can respond to ChgA and 
WE14, it was necessary to confirm that ChgA and WE14 are also human 
autoantigens, due to species differences.  In a recent study, CD4 T cells from a 
newly diagnosed T1D patient (<1 year) were shown to respond to WE14 at a 
concentration of 40µM while transglutaminase-treated WE14 stimulated the CD4 
T cells at both 20µM and 40µM.  Average IFNγ ELISPOT counts of PBMCs in 
response to TGase-treated WE14 were elevated in the T1D patient group 
compared to a healthy control group (Gottlieb et al., 2014).  These data indicated 
that ChgA and WE14 are autoantigens in the NOD mouse model as well as in 
human patients newly diagnosed with T1D.   
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Table 1.3 Auto-antigens found in the NOD mouse, which have a role in T1D 
development.  (Roep and Peakman, 2012) 
Autoantigen Tissue distribution Mice 
Auto Abs T cells 
Pre-proinsulin β cells, thymus Yes CD4 
Glutamic decarboxylase 65 
(GAD65) 
Islet cells, adrenal 
gland, CNS, neurons, 
testis, ovary 
No CD4 
GAD67 Islet cells, neurons No CD4 
Tyrosine phosphatase like 
autoantigen or insulinoma 
antigen-2 (IA-2; ICA512, PTPRN) 
Islets Yes CD4 
IA-2β (Phogrin, PTPRN2) Islets No CD4 
Islet cell antigen-69 (ICA69) Pancreas, heart, and 
brain 
No No 
Zinc transporter-8 (ZnT8) β cells   
Chromogranin A Neuroendocrine cells No CD4 
38 kDa granule antigen Neuroendocrine cells No ? 
Peripherin Neurons No CD4 
Islet amyloid polypeptide 
(ppIAPP) 
Islets No CD4 
Carboxypeptidase H/E Neuroendocrine cells; 
adrenals 
No No 






Islets No CD8 
Sulfatide Ubiquitous No No 
Ganglioside Ubiquitous No No 
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1.7 Antigen specific immunotherapy (ASI) 
1.7.1 Antigen Specific Immunotherapy (ASI) 
ASI is a type of immunotherapy targeting specific immune cells in an antigen-
specific manner (Sabatos-Peyton et al., 2010).  One approach to ASI is to target 
immature DCs using an endogenous antigen (Anderson and Jabri, 2013).  During 
this process, DCs are maintained in an immature or semi-mature state, thus 
boosting antigen-specific Treg population in vivo (Lutz and Schuler, 2002) 
(section 1.3 and 1.4.1.2. ).  As the mechanism of Treg suppression requires cell-
cell contact and it is required at the site of inflammation (Vignali et al., 2008, 
Schmetterer et al., 2012), an autoantigen which was involved in the inflammatory 
autoimmune response, should be used in order to home back to the disease 
organ and target the source from which antigens originated, in the case of T1D, 
beta cells in the pancreas.  More than one autoantigen has been shown to 
contribute to the development of T1D (Table 1.3).  Whether one or several 
antigens should be targeted in therapy remains unanswered.  The growing 
number of antigens with a role in T1D necessitates a selective approach to the 
discussion of antigen therapy, as presented here.  Therefore one of the main 
autoantigens, insulin, is discussed in further detail to demonstrate the efficacy of 
the ASI approach.  A recently discovered auto-antigen, WE14, which is used in 
this project, is also discussed.  
 
Single antigen therapy has been used for ASI in animal and clinical studies.  In 
the early 90’s, insulin was shown to protect NOD mice when delivered either 
subcutaneously or orally (Atkinson et al., 1990).  Following these observations 
proinsulin B9-23 was identified as an autoantigen for T1D, stimulating several 
islet reactive T cell clones.  Proinsulin B9-23 has been delivered via. 
subcutaneous or intranasal routes to induce tolerance in NOD mice (Daniel et al., 
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1995, Daniel and Wegmann, 1996).  This promising pre-clinical data led to the 
use of insulin and its peptides in clinical trials.   
 
The administration of insulin or insulin-peptide by different routes has resulted in 
different clinical outcomes.  When insulin autoantibody levels were used as the 
end point, an oral insulin clinical trial showed no effect on prevention or 
intervention of T1D (Skyler et al., 2005, Chaillous et al., 2000).  However, when 
using plasma C-peptide as readout, a positive result was achieved.  Newly 
diagnosed T1D patients were either treated with 1mg/day or 10mg/day oral 
insulin.  Follow-up results showed that patients in different age groups responded 
to varying insulin doses differently.  A high dose was more effective in reducing 
the loss of C-peptide in patients younger than 20 years old, while a low dose was 
more effective in reducing the loss of C-peptide in patients more than 20 years 
old (Ergun-Longmire et al., 2004).   
 
Relatives of patients with T1D who were positive for IA-2 antibodies; an indicator 
of T1D susceptibility, were recruited for another clinical study.  Insulin was 
administered subcutaneously twice daily for 36 months, and no differences in 
T1D prevention were observed (Vandemeulebroucke et al., 2009).  Rather than 
using subcutaneous delivery, a phase I trial used pro-insulin C19-A3 peptide, 
administered intradermally, which can target the DC-rich skin region.  Long-
standing T1D patients with human leukocyte antigen (HLA)-DRB1*0401 
genotype were selected and split into two groups, injected with C19-A3 either at 
a low dose (10µg) or at a high dose (100µg) repeated monthly for 3 months.  
Both dose regimes were well tolerated.  Interestingly, the low dose (10µg) 
treatment group showed increased levels of C19-A3-specific T cells (which 
secrete IL10) at the 3 month time point in 4 out of 18 cases.  This may suggest 
that such an immunotherapeutic approach to T1D treatment is promising, 
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however; this conclusion can only be speculative as the study was not designed 
to elucidate the immunological mechanism of the patients’ response (Thrower et 
al., 2009).   
 
Another approach to target mucosal DCs is to administer antigen intranasally.  
The early nasal administration of insulin was performed on infants and their 
siblings with two positive T1D antibodies and HLA-DQB1 susceptibility.  No 
prevention of T1D was observed; however, this approach changed the insulin 
autoantibody level (Nanto-Salonen et al., 2008).  A recent study suggested that 
targeting mucosal DCs with insulin could induce tolerance.  Patients diagnosed 
with recent-onset T1D but with no dependence on exogenous insulin were 
recruited and nasal insulin was administered for 12 months.  With 24 months 
follow-up, the insulin antibody level was retarded and IFNγ released by T cells in 
response to pro-insulin was reduced in patients treated with nasal insulin; 
however, no preservation of beta cell function was observed using this approach, 
(Fourlanos et al., 2011).  This tolerogenic effect can be enhanced by combination 
with an adjuvant.  IFA (incomplete Freund’s adjuvant), together with proinsulin 
B9-23 has been injected intramuscularly.  After 2 years follow up, it was shown 
that insulin B-chain-specific CD4+ T cells isolated from the proinsulin-B9-23 
treated group showed a tolerogenic phenotype and function (Orban et al., 2010).  
These studies suggested that by carefully choosing the targeting autoantigen, the 
ASI approach did not cause any adverse effect in patients and was well tolerated.  
Peripheral tolerance could be enhanced, which is demonstrated by reduced 
insulin autoantibody levels, reduced proinflammatory cytokine (IFNγ) levels and 
increased regulatory cytokine (IL10) levels.  Importantly to this study, the 
aforementioned studies suggested that delivery route, i.e. oral, subcutaneous, 
intranasal or intradermal, may also influence the ASI outcome.   
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Chromogranin A (ChgA) has been shown to be an autoantigen for pathogenic 
BDC2.5 T cell clones in vitro and in vivo and these cells also respond weakly to 
its naturally occurring proteolytic cleavage peptide, WE14 (Curry et al., 2002, 
Stadinski et al., 2010) (for detailed introduction see section 1.6.3).  This weak 
affinity peptide has been shown to be able to induce tolerance in vivo.  Using an 
adoptive transfer model, a subcutaneous injection of WE14 was shown to delay 
the progress of transferred T1D in NOD-SCID mice (Haskins et al., 2012).  A 
more recent study suggested that ChgA is an antigen in human patients (Gottlieb 
et al., 2014).  These promising findings suggested that ChgA and its peptides 
could be used in future intervention trials.   
 
ASI has been shown to be efficient in prevention of T1D in animal models.  
However, there are still hurdles to overcome when translating these findings into 
effective human therapy.  Parameters such as the timing of treatment, dose 
regime and frequency still need to be optimised.  One clinical risk of using 
autoantigen for ASI is the potential for boosting effector T cells; therefore control 
of the DC signal is of key importance.  This can be controlled by delivery route 
(intranasal, oral, subcutaneous or intradermally), or using a tolerogenic adjuvant 
(Incomplete Freund’s Adjuvant or an alum-formulation) (Ludvigsson et al., 2008, 
Ludvigsson et al., 2014, Fousteri et al., 2010).  
 
1.7.2 Non-antigen based therapy 
One immunotherapeutic approach is to suppress the systemic immune response 
by utilising a general suppressive drug, such as cyclosporin A and anti-CD3 to 
down- regulate the immune response systemically.  Both approaches achieved a 
degree of success in animal models, however, no obvious benefits were 
observed in clinical T1D prevention trials (Herold et al., 2002, Daifotis et al., 
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2013, Herold et al., 2013, Lernmark and Larsson, 2013, De Filippo et al., 1996).  
Furthermore, immunosuppressive drugs do not specifically target diabetogenic 
cells; rather they suppress the entire immune system.  Therefore, when treated 
with therapies, which involve systemically immunosuppressive drugs, the ability 
of the body to defend against pathogens is reduced and patients may become 
more susceptible to infection.   
 
In this study, in order to avoid the problems associated with general suppression, 
antigen/organ specific therapy was utilised.  In order to maximise the opportunity 
for antigen to be taken up by DCs, we chose the skin as the target organ for 
delivery.  Skin is not only an easy to access organ but it is also densely packed 
with DCs, especially Langerhans cells.  Therefore, the next section will introduce 
the structure and immunology of the skin.  
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1.8 Skin structure and skin immunity 
The skin is the largest organ in the human body and functions as the first line of 
the body’s defence system.  It consists of three main layers, the epidermis, 
dermis and hypodermis (Widelitz et al., 1997).  The hypodermis is a fatty tissue 
where nutrients are stored and body temperature is regulated (Kanitakis, 2002).  
The dermis is a supportive layer between the hypodermis and epidermis, 
containing sweat glands, blood vessels and lymphatic vessels.  The epidermis is 
the outermost layer; which functions as a barrier for maintaining hydration and 
excluding pathogens.  As a protective organ, the skin protects the body from 
pathogens not only by providing a physical barrier (i.e. the stratum corneum) but 
a fully functional immune network.   
 
Keratinocytes are the major cell type in the epidermis, which exhibit the full range 
of innate immune functions.  Keratinocytes can express toll like receptors (TLC) 
and CD1d, which can recognise microbes, kill invaders and release pro-
inflammatory cytokines and chemokines (Pivarcsi et al., 2004).  Transplantation 
experiments have revealed that keratinocytes have a non-professional antigen 
presentation function with the expression of MHC II (Nickoloff and Turka, 1994).  
Hapten-modified Ia+ keratinocytes were shown able to help generate Treg in vitro 
and reduce the contact allergy in vivo (Gaspari and Katz, 1991).  Keratinocytes 
were also demonstrated to play an important role in skin DC maturation.  Type 
one IFNs and IL18 secreted by keratinocytes could assist the DCs to polarise into 
a matured state, which can further induce Th1 response (Lebre et al., 2003). 
 
Human skin DCs can be categorised into two main groups according to their 
location: epidermal DCs and dermal DCs (Figure 1.5).   
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Figure 1.5 Skin anatomy and skin DCs.  LCs are resident in the epidermis (most 
prominently in the stratum spinosum) and form a network within a layer of densely 
packed keratinocytes.  Dermal DCs are mainly located in the same level as capillaries 
and the upper dermis. Figure copied from Nature Reviews Immunology 9, 679-691, 
doi:10.1038/nri2622 (Nestle et al., 2009) 
 
Langerhans cells (LCs) are a type of DC located in the epidermis, within which 
they form a network to defend the body from intruders.  LCs were first described 
by Paul Langerhans in 1869 (Jolles, 2002).  It was thought LCs can be 
recognised by the expression of a surface marker CD1a, CD207 (langerin) and 
MHCII and are characterised by a distinctive intracytoplasmic marker, the Birbeck 
granule (Nestle et al., 2009, Kashihara et al., 1986, Valladeau et al., 1999).  LCs 
are capable of engulfing and processing pathogens they encounter which triggers 
the maturation of the LCs.  The matured LCs then migrate across the basal 
membrane and migrate into the lymphatic vessels resident in the dermis.  During 
this migration process, LCs firstly detach from adjacent keratinocytes by down 
regulation of E-cadherin expression and become mobile (Kissenpfennig et al., 
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2005, Konradi et al., 2014).  LCs and other epidermal cells then secrete 
collagenase IV to enable LCs to cross the connective tissue matrix in the dermis 
(Kobayashi, 1997).  It was suggested that LCs can cross-prime naïve CD8+ T 
cells (Nestle et al., 2009).  However, another research suggested that it was 
Langerin+ dermal DCs cross present to CD8+ T cells (Seneschal et al., 2014).  
Under certain conditions, such as treatment with glucocorticoid or vitamin D3, 
human LCs can be educated to induce a tolerance effect.  For example, after 
treatment with vitamin D3, LCs can express TGF-ß cytokine and induce Foxp3+ T 
cells (Palomares et al., 2011).  Compared with dermal DCs, LCs were thought to 
be more tolerogenic (Shklovskaya et al., 2011).  Bacteria-primed LCs showed a 
relatively poor stimulation of memory T cells and Teffs, compared with dermal 
DCs; rather they induced bacteria specific Foxp3+ regulatory T cells (van der Aar 
et al., 2013).  Unlike LCs, which have been shown to have a regulatory function, 
dermal DCs were thought to be more immunogenic.  It was suggested that 
dermal DCs but not LCs isolated from draining LNs after initial challenge were 
able to activate T cells in vitro, which indicate the role of dermal DCs in immune 
response (Fukunaga et al., 2008) 
 
Apart from differences in biological function, LCs and dermal DCs also show 
different migration abilities, either during steady state or the migration stage.  It 
has been shown that dermal DCs begin to migrate to skin draining LNs 24 hours 
after skin was painted with a fluorescent dye and the number of DCs migrating to 
LNs peaks at 2 days (Kissenpfennig et al., 2005).  In the same study, LCs have 
been shown to achieve peak migration number in LNs 4 days after stimulation.  It 
was suggested that LCs and dermal DCs migrate to different compartment of 
LNs.  Dermal DCs were shown to migrate to the outer paracortex, which near the 
B cell follicles, while LCs migrate into the paracortex, a T cell rich region 
(Kissenpfennig et al., 2005).  
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These results indicated that by targeting different skin DC subtypes may result in 
a different outcome.  In this project, we would like to induce tolerance by utilizing 
tol-DCs, therefore, it is rational to target LCs rather than dermal DCs.  However, it 
is technically difficult to target only specific cell type without modifying the 
peptide, which is outside of the scope of this study.  In previous studies, 
glucocorticoid has been shown able to induce tol-DCs in vitro and in vivo (Moser 
et al., 1995).  Therefore, in this project a topical application of glucocorticoid, 
betamethasone, was used to ‘pre-educate’ skin DCs to a tolerogenic state 
(presented in Chapter 4).   
 
Other immune cells such as skin resident T cells (CD8+, CD4+ and NKT cells) 
and macrophages form an effective immune network by protecting the body from 
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1.9 Administration of drugs using Microneedles (MNs) 
1.9.1 Drug administration methods,  
Drug delivery is the method or process of administering a pharmaceutical 
compound to achieve a therapeutic effect in humans or animals.  Drugs can 
either be delivered through enteral routes (sublingual, oral and rectal) or 
parenteral routes (intravascular, intra/transdermal injection, intramuscular, 
subcutaneous and inhalation).  The route of administration is determined not only 
by the physical characteristics of the drug, but also the site of action, which may, 
in turn determine the speed at which the drug is absorbed and subsequently 
released.   
 
The oral route is the most commonly used, due to its many advantages such as 
the low cost, high patient compliance and large absorption area.  There are, 
however, limitations of the oral route, including the first-pass effect, local irritation 
to the gastric mucosa and degradation of certain drugs; such as peptides and 
proteins (Morishita and Peppas, 2006, Gupta et al., 2009a).  Intravascular 
delivery has the advantages that it is precise, accurate, high dosage and the drug 
can take effect almost instantly.  Some of the difficulties associated with 
intravascular delivery include the lack of controlled release and a relatively high 
risk of acute overdose, compared with other delivery methods. 
 
As a large and accessible organ, the skin is an interesting target for drug 
delivery.  The main obstacle for delivery drug through skin is the protective 
mechanisms of skin.  One such important mechanism is offered by the stratum 
corneum, which provides a significant physical barrier to drug ingress.  There are 
two types of skin delivery routes: transdermal and intradermal (ID).  Delivery by 
the transdermal route involves delivering active ingredients across the skin for 
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systemic distribution.  Drug can either pass through transcellular or intercellular 
pathways.  The aim of ID injection is to inject a small amount of the drug locally, 
i.e. ID injection is not useful for systemic administration.  This type of injection 
has several uses; including allergy tests and vaccinations.   
 
In this project, a delivery method was required for targeting skin DCs locally in a 
minimally invasive manner in order to deliver a ‘negative’ vaccination signal.  
Therefore, the ID delivery is the chosen method for this purpose.   
 
1.9.2 A brief introduction to MNs 
MNs are needle-like structures with diameters in the order of microns and lengths 
of up to 1mm.  These structures are used to penetrate the upper layer of the skin 
to enable dermal/transdermal drug delivery and for taking biological samples via 
the skin.  The major advantage of using MNs for drug delivery is their ability to 
pierce the skin in a relatively non-invasive and painless way.   The first MN was 
designed and patented in 1976 (Gerstel, 1976).  Since then, MNs have been 
produced in various geometries and using different materials such as silicon, 
metals and polymers (Chandrasekaran et al., 2003, Chu et al., 2010, Jing Ji, 
2006, Lee et al., 2008, Martin et al., 2012, N Wilke, 2007).  Drugs, including 
oligonucleotides, desmopressin, human growth hormone, insulin and DNA have 
been delivered using MNs.  There are, however some significant barriers, such 
as health and safety regulation and mass manufacture costs, which will need to 
be overcome before a MN based drug delivery or monitoring device is 
marketable.   
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MNs can be useful for systemic and local skin delivery.  This project focuses on 
the delivery of autoantigen to skin by locally targeting DCs with a minimally 
invasive approach.   
 
1.9.3 MN types 
There are four general approaches to dermal drug delivery by different types of 
MNs: ‘poke and flow’ (hollow type), ‘poke and patch’ (solid/patch type), ‘coat and 
poke’ (solid-coated type) and ‘poke and release’ (solid/dissolvable type) (Kim et 
al., 2012) (Figure 1.6).  
 
Hollow MNs function in a similar manner to hypodermic needles when used as a 
drug delivery device.  They deliver drugs via the ‘poke and flow’ approach, 
facilitating force-driven fluid flow, thereby allowing a faster rate of delivery and 
larger volume than solid MNs.  Another advantage of hollow MNs is that the dose 
of the desired drug in solution can currently be more easily controlled compared 
with other MN systems (Wang et al. 2006).  Hollow MNs have some intrinsic 
disadvantages.  Because of their hollow structure, there is risk of the hole 
clogging during insertion, causing a blockage.  Blocked needles can potentially 
lead to leakage or prevent drug from being released and thereby cause 
inaccurate dosage.  The hollow structure of this MN design also offers reduced 
mechanical strength, compared against solid MNs with the same geometry (Kim 
et al., 2012). 
 
Solid/patch MNs are applied to puncture the skin creating micropores, allowing 
drug incorporated in a patch or topical formulation to bypass the stratum corneum 
and diffuse into the skin, i.e. the ‘poke and patch’ approach Figure 1.6.  
Compared with intact skin, the permeability coefficient of calcein (MW  =  622.55) 
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was significantly increased by 104 to 105 times on skin pre-punched with 150um 
length MNs (Wu et al. 2008).  For the ‘poke and patch’ approach to be effective, it 
is very important that the micropores stay open during the drug application 
period.  Micropores are shown to close very rapidly in vivo, taking approximately 
15 minutes (Milewski et al. 2010).  Various approaches have been used to 
improve the lifetime of micropores.  Maintaining hydration and occlusion is 
important because water has been shown to influence signalling during the skin 
repair process.  Microchannels remained open for 24 hours (in some cases up to 
72 hours) after MN treatment coupled with treatment to ensure the maintenance 
of hydration (Kalluri et al. 2011; Li et al. 2010).  The ‘poke and patch’ approach is 
a simple way to achieve extended drug delivery via the skin.  It enables the 
potential for delivery of drugs with high molecular weight, which are difficult to 
deliver successfully by other methods whilst maintaining their function.  On the 
other hand, the lack of precise dosing and the low loading of drug, which can limit 
the effective dose delivered per treatment, has previously limited the usefulness 
of this method (Tuan-Mahmood et al., 2013).  
 
Another way of delivering drugs by the ‘poke and release’ approach utilises 
dissolvable or biodegradable MNs.  Polymer and sugar based MNs are able to 
encapsulate drugs in their needle matrix.  The hypothesis is that encapsulated 
drugs can be released as the MN dissolves or degrades in situ.  BSA 
encapsulated dissolving MNs made from carboxymethyl cellulose (CMC) and 
amylopectin have been produced, and were shown to dissolve completely in 
porcine skin within 1 hour (Park et al., 2006).  A similar release rate for protein 
was found using dextran MNs (Ito et al., 2011a).  Controlled release can be 
achieved by using dissolvable MNs.  Extended release was achieved applying 
Gantrez® AN13 (a type of poly(methylvinyl ether/maleic anhydride) to deliver 
encapsulated theophylline into porcine skin (Donnelly et al., 2011).  Dissolving 
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MNs can also be used for vaccination and delivery of peptides, such as human 
growth hormone (Lee et al., 2011).  There are obstacles which need to be 
resolved before this technology can be widely used:  These include low dosing, 
high fabrication temperature (during manufacture process) causing peptide to 
break down and low mechanical strength, which can be inadequate to reliably 
penetrate skin.  A sugar based MN array was reported recently which was 
fabricated under vacuum conditions at low temperature (Martin et al., 2012).  Due 
to the more amenable conditions used to produce these MNs, this approach 
could enable encapsulation of easily denatured or deactivated drugs, such as 
peptides and proteins.  
 
An alternative approach to the ‘solid/patch’ method is using the ‘solid-coated’ 
approach.  Solid MN arrays are coated with drug and deliver the drugs when 
inserted into the skin.  Compared with hollow and solid/patch MNs, solid-coated 
MNs do not require additional equipment such as a pump, syringe or patch.  
Furthermore, solid-state drugs coated on MNs have a longer shelf life and no 
need for special storage compared to drugs in solution.  One key benefit of solid-
coated MNs is therefore relatively low cold chain costs.   
 
A key step for the ‘solid-coated’ approach is the drug coating step.  Various 
coating procedures, formulations and coating devices have been developed.  The 
coating efficiency is influenced by the rate of solvent evaporation, wettability, 
viscosity and de-wetting (Gill and Prausnitz 2007a).  To create a near-optimal 
coating formulation, it is important to decrease the surface tension and increase 
the viscosity of the coating formulation.  Coating solutions have been developed 
for the ‘dip-coating’ method.  A coating solution comprising 1% CMC and 0.5% 
Lutrol F-68 was shown to form a uniform thin film on solid stainless steel MN 
surfaces (Gill and Prausnitz 2007a).  For hydrophobic drugs, 5% PVP in ethanol 
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has been used (Gill and Prausnitz 2007a).  The aqueous coating solution was 
applied to deliver influenza virus-like particles and whole attenuated virus using 
the coat and poke approach (Marc 2010; Zhu et al. 2009) (Figure 1.6).  It was 
thought that use of pre-coatings on the surface of MNs, such as PLGA or 
chitosan, could improve coating efficiency (Gill and Prausnitz 2007a).  The dip-
coating method has some drawbacks.  It requires an excess volume of coating 
solution, causing wastage during preparation.  The immersion and removal 
process must also be repeated several times in order to ensure sufficient coating.  
Other coating methods have been developed as an approach, which ensure 
uniform coating and may also be scalable.  In one example, silicon MNs were 
sprayed with hydroxypropylmethyl cellulose or CMC (McGrath et al. 2011).  A 
micron-scale thickness film was coated uniformly on MNs treated in this way 
(McGrath et al. 2011). 
 
 
Figure 1.6 Schematic view of delivery method using four types of MNs.  A. Drug 
deposition for four different types of MN before drug is released into skin.  B. Drug 
diffusion within skin after MN application.  Solid MNs can be used to create microconduits 
and drug can be delivered by applying a drug-encapsulated patch over the microconduits.  
Delivery of coated MN can be achieved by pre-coating solid MN with a layer of drug and 
drug can be released into skin during the MN penetration period.  Drug can also be 
encapsulated into a dissolvable material and moulded into a dissolvable MN.  Drug can 
be released into skin upon the dissolution of the needle within skin.  Hollow MNs deliver 
drug in a fashion similar to conventional hypodermic needle.  Drug solution can be pre-
loaded in a syringe and injected into the skin using back pressure (Kim et al., 2012). 
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1.9.4 MN safety 
1.9.4.1 Poration and microbial infection 
Effective skin penetration is directly related to the length of the MN that is used.  
Two lengths of stainless steel MNs (200µm and 400µm) were tested on human 
volunteers to assess skin irritation and pain sensation.  As predicted, the TEWL 
(transepidermal water loss) value increased when using 400µm long MNs 
compared with 200µm and started to drop back to baseline after two hours in 
both cases.  Interestingly, no difference in skin redness or blood flow was 
observed between the two lengths, which are used as indicators of skin irritation.  
It was suggested that use of 400µm long MNs will effectively penetrate skin 
without causing significantly increased skin irritation (Bal et al., 2008).  Both 
needle length and density were also shown to be linked to the degree of damage 
caused by MNs.  Short MNs (100µm or 200µm) were not able to induce sufficient 
drug flux even with low needle density (Yan et al., 2010).  Long MNs, greater 
than 600µm, effectively penetrated the skin when needle density was less than 
2000 needles/cm2 (Yan et al., 2010).  TEWL values have indicated that 400µm 
long MNs are able to penetrate skin but no drug flux was observed if the needle 
density was greater than 60000 needles/cm2 (Yan et al., 2010).   
 
The size of the skin microconduit has been shown to be related to the radius or 
base width of the needle.  MNs made of maltose with a 213±12µm base width 
created 60µm diameter open channels in hairless rat skin (Kalluri and Banga, 
2011).  A similar poration size was found using 770µm long metal MN with 
140µm base width; a pore with a 70µm open conduit was observed in hairless rat 
by using calcein imaging (Kalluri et al., 2011).  It has also been suggested that 
the ability of skin to regenerate its barrier function was not related to the needle 
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length used.  In the cases of 370µm and 770µm lengths of MN, TEWL recovered 
to baseline levels 4-5 hours post treatment (Kalluri et al., 2011).  
 
One concern is that microbes might travel through the conduits created by MN 
insertions; either transferred directly from the MN surface during insertion or 
transferred from the environment after MN removal (Donnelly et al., 2009b).  Two 
in vitro skin models have been used to demonstrate the movement of dry state 
microbes on the skin into the skin substructure during the application of MNs: a 
50µm thick Silescol® was used to mimic the intercellular liquid pathway and 
400µm thick neonatal porcine skin was used to represent human skin.  Three 
species of microbes, which are commonly found on human skin, were tested: 
Staphylococcus epidermidis, Candida albicans, and Pseudomonas aeruginosa.  
Results demonstrated that MNs caused less microbial penetration in both skin 
models than use of a 21G hypodermic needle.  Therefore it was suggested that 
MNs could be used clinically with low risk of local and/or systemic infection 
(Donnelly et al., 2009b).   
 
Another in vivo study was designed to investigate the flux of Staphylococcus 
aureus in solution through conduits after very short MN (70-80µm long) 
treatment.  It was demonstrated that the MN treatment did not cause an increase 
in white blood cell counts, leukocytes and neutrophils in blood, which was 
thought to be due to the minimal damage caused to the dermal layer.  On the 
other hand, damage caused by a 1500µm long needle on the skin enabled the 
transport of microbial load through the skin and showed an increased level of 
immune cells in the blood (Li et al., 2010).  Their study also assessed skin 
damage by testing fibronectin level.  Fibronectin–EIIIA and EIIIB were not found 
in undamaged rat skin as well as the short MN treated rat skin, indicating that 
damage caused by short MNs was minimised (Li et al., 2010).   
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The self-sealing ability of the skin is important in order to prevent unwanted 
infection after MN treatment.  It has been shown that skin-resealing time is 
related to MN density, base width and length.  Density played an important role 
on the rate of skin resealing.  Skin resealed almost 6 times quicker when using 
10 needles compared with 50 needles.  Thick and wide needles were shown to 
prolong the skin resealing time.  Furthermore, skin sealed 35% faster when using 
short (500µm) rather than long (750µm) needles (Gupta et al., 2011a).   
 
1.9.4.2 Pain sensation  
VAS (visual analogue scale) has been used to measure the pain sensation 
during MN application.  Silicon MNs with 180µm long and 400/9mm2 density were 
tested on volunteers compared with a smooth surface control and a 26G 
hypodermic needle.  It was reported that no significant difference was observed 
between smooth surface and MN treatment with mean scores as 0.42 and 0.67 
relatively, while hypodermic needles scored as high as 23.9 (Kaushik et al., 
2001).   
 
Pyramidal silicon MNs with 180µm and 280µm length were tested on human 
volunteers to investigate the pain sensation as compared with 25G hypodermic 
needles, using the McGill Pain Questionnaire Short Form and VAS.  Both lengths 
of MNs caused less pain than a hypodermic needle.  Furthermore, on average, 
the 280µm long MN was described as less painful than 180µm long MN (Haq et 
al., 2009).  This was reported to be due to the need for the clinician to push 
harder with the shorter length MN device to ensure sufficient skin penetration.   
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It has been demonstrated that the VAS pain score for application of MNs is 
related to the geometry of MNs used.  Stainless steel electro-polished MNs were 
fabricated with different length (l), thickness (t), base width (w) and density (n).  
The most painful type of MN was the longest, with dimensions of 1500(l) x75 (t) 
x200 (w) n=10, followed by the thick and dense MNs (750(l) x125 (t) x500 (w) 
n=50).  The least painful MNs were shown to be those with shorter needles 
(500(l) x125 (t) x500 (w) n=50) or those of lower needle density (750(l) x75 (t) 
x200 (w) n=10).  All MNs scored lower than the 26G hypodermic needle used in 
the same test (Gupta et al., 2011a).   
 
Pain sensation induced by hollow MNs has been thought to be attributed to the 
liquid infusion as well as MN puncture.  A small volume of methyl nicotinate (1µl) 
was injected in volunteers’ forearms using silicon hollow MNs and a sensation of 
pressure but not pain was reported (Sivamani et al., 2005).  Hollow MN delivery 
of insulin was reported to be less painful than catheter based devices but caused 
a tingling feeling when injection flow rate was at 1ml/minute.  This tingling 
sensation was not noticeable when injection flow rate was less than 0.5ml/minute 
(Gupta et al., 2009c).  A further study investigated the relationship between MN 
injection volume and pain sensation.  In accordance with the previous 
observations, flow rate was shown to be positively related with the degree of pain 
sensation.  Low flow rates (0.1ml/min) caused significantly less pain than high 
flow rates (1m/min), when the injection volume is high (1ml).  Injection volume 
itself, however, was suggested not to be the main contributory factor to the 
pressure and pain sensation.  Similarly, observations seen in solid MN 
penetration tests demonstrate that long hollow macro needles (1mm) caused 
more pain than short MNs (500µm) (Gupta et al., 2011b).   
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1.9.5 MNs used for drug delivery 
MNs have been used for delivery of different drugs, such as, DNA (Coulman et 
al., 2006, Pearton et al., 2012); nanoparticles (Coulman et al., 2009); influenza 
vaccine (Pearton et al., 2010b, Song et al., 2010); siRNA (Chong et al., 2013); 
proteins such as botulinum toxin A (Torrisi et al., 2013) and recombined human 
growth hormone (Ameri et al., 2014); and peptides such as exenatide (Zhu et al., 
2014), salmon calcitonin (Tas et al., 2012) and cosmetically relevant peptides 
(Mohammed et al., 2014).  As this project is related to inducing immune response 
using a peptide (autoantigen), two main applications of MNs are of particular 
relevance here: vaccines and peptides.   
1.9.5.1 Vaccine delivery using MN 
Use of a hollow MN (1mm long, 34G) was studied for delivery of vaccines 
intradermally compared with an intramuscular (IM) injection using a 30G 
hypodermic needle.  Three different vaccines were delivered: whole inactivated 
virus, trivalent human vaccine and DNA plasmid vaccine.  Delivery using hollow 
MNs was shown to be dose-sparing for all three types of vaccines compared with 
IM delivery (the dose required to elicit a specific immune response was shown to 
be much lower for MN delivery as compared to IM delivery) (Alarcon et al., 2007).  
It was shown that the delivery route and delivery depth are important factors in 
inducing immune response.  The dimensions of MNs used in this study were on 
the upper borderline of acceptable dimensions for a MN as defined earlier in this 
chapter (Alarcon et al., 2007).  A phase II clinical study was carried out using this 
microinjection device for delivery of influenza vaccine compared with a licensed 
IM vaccination.  ID (intradermal) injection of vaccine was shown to induce a 
similar immune response to IM injection, but using a smaller volume (0.1ml vs. 
0.5ml) at a lower dose (9µg vs. 15µg).  No adverse effects were observed using 
MNs in this 3-year follow up clinical study (Beran et al., 2009).  Another shorter 
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hollow MN, which comprised of four 450µm long silicon needles, was also used 
in a clinical trial for the delivery of influenza vaccine.  A low dose (3µg or 6µg) of 
hemagglutinin was delivered using MN, and a full dose (15µg) hemagglutinin was 
delivered using a 25G needle by IM injection.  Both low doses delivered by MN 
were shown to be able to elicit immunogenic responses similar to a full dose IM 
injection.  Furthermore, MN injection was demonstrated to be less painful than IM 
injection.  At the same time, MN injection did cause a mild response, resulting in 
localised redness and swelling, which may have been due to liquid diffusion as 
discussed above (Van Damme et al., 2009).   
 
Dissolvable MNs made of CMC (carboxymythylcellulose) have been tested in 
mice for inducing immune response.  After a 10 minute application on the ventral 
side of the ear, MNs were seen to have dissolved, and the vaccine was therefore 
assumed to have been delivered.  Both OVA and influenza vaccine were able to 
induce similar immune response when using dissolvable MNs compared to IM 
injection.  The MN, however, was shown to require almost 45 times less influenza 
vaccine than IM injection, which was thought to be due to the targeting of skin 
DCs with these short needles (80µm long on average) (Raphael et al., 2010).  
Similar observations were made with another dissolvable MN made of a water-
soluble polymer, PVP (polyvinylpyrrolidone).  Dissolvable MNs can induce a 
robust humoral and cellular response in mice with a single-dose immunisation 
compared to IM injection using the same dose (Sullivan et al., 2010).   
 
As previously mentioned, one important consideration using solid-coated MNs is 
the choice of coating formulation.  It was shown that by adding trehalose to the 
coating formulation, improved influenza vaccine stability was observed (Quan et 
al., 2009).  Using this coating formulation, 0.4µg of inactivated influenza vaccine 
was coated on 700µm long stainless steel MNs.  Compared with IM injection, 
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using the same dose regime, MN immunisation showed a similar humoral 
response and an improved cellular response (Kim et al., 2009b).  A long lasting 
humoral and cellular response was also observed using virus-like particles 
(VLPs).  Influenza H5 VLP coated MNs were shown to be able to elicit higher 
levels of antibodies, when compared with traditional IM injection in mice, even at 
8 months post-vaccination.  Both MN and IM injection were shown to protect 
mice against lethal challenge 16 weeks after vaccination (Song et al., 2010).   
 
As the skin DCs, especially LCs in the epidermis play an important role in both 
innate and adaptive immunity, it is important to understand the role of these DCs 
during the vaccination processes.  Pearton et al. demonstrated that LCs changed 
their morphology after the delivery of VLP vaccine using ID or MN injection.  
More LCs migrate from the epidermis 48 hours after treatment when using MN 
rather than using ID, indicating that MN delivery is more efficient to target 
epidermal LCs (Pearton et al., 2010a).  An in depth understanding of the 
immunological response to subunit influenza vaccine coated MN treatment has 
also been investigated.  It was suggested that IM vaccination increased IgG1 
antibody levels, while MN vaccination induces IgG2 antibodies, which indicates a 
Th1 response.  MN treatment has been shown to enhance protection by rapid 
virus clearance, which contributed to the activation of an adaptive immune 
response (Koutsonanos et al., 2012).  One interesting observation was that after 
lethal challenge, mice treated with MNs had higher IL10 levels in the lung than a 
comparable IM treated group, which consequently resulted in reduced lung 
inflammation (Koutsonanos et al., 2012).   
1.9.5.2 Peptide delivery using MN 
Peptides have been successfully delivered using a dissolvable MN system.  
Leuprolide acetate, a GnRH (gonadotropin-releasing hormone) agonist, was 
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encapsulated in a dissolvable MN, which was shown to be stable for 3 months 
when stored at ambient and low temperatures.  However, low bioavailability was 
observed when using MN delivery, which was thought to be due to the 
degradation of leuprolide acetate within the skin (Ito et al., 2011b).  Another 
peptide, exenatide, was also delivered using dissolvable MNs.  MNs made of 
low-molecular-weight sodium hyaluronate (HA) can quickly dissolve in rat skin 
within 2 minutes following insertion time.  Using these MNs, exenatide showed 
comparable pK compared with subcutaneous injection (Zhu et al., 2014).   
 
Several peptides have been delivered using solid-coated MNs, such as 
desmopressin, PTH-1-34, salmon calcitonin and group of cosmetic peptides 
(Cormier et al., 2004) (Daddona et al., 2011) (Tas et al., 2012, Mohammed et al., 
2014).  Desmopressin coated MN arrays have been administered to hairless 
guinea pigs.  High delivery efficiency (85%) can be achieved when using low 
drug loading and an application time of 15 minutes.  Approximately 10% of drug 
was found on the skin surface, regardless of drug loading.  This was thought to 
be due to the coating technique.  The non-homogenous coating and drug coated 
on the base of MNs caused insufficient and inconsistent delivery (Cormier et al., 
2004).   
 
Using an improved coating technique, PTH1-34 (parathyroid hormone 1-34) was 
administered for Phase I and II clinical studies.  The site of application was 
shown to have an impact on the bioavailability of PTH.  Using the same dose of 
peptide, the AUC (area under curve) of PTH was found to be highest when 
delivered to the skin of the abdomen (65.7 pg*h/mL), followed by the skin of the 
upper arm (46.5 pg*h/mL), and the lowest was on the skin of the thigh (29.9 
pg*h/mL).  MN delivery, however, showed lower bioavailability when using the 
same dose as the standard subcutaneous (SC) injection.  Thereafter PTH coated 
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on to MNs at double the dose (40µg) was compared with 20µg SC injection.  MN 
delivery of PTH not only increased spine bone mineral density, but also, 
increased bone mineral density in the hip bone, which was not shown in control 
patients, treated using standard SC injection (Daddona et al., 2011).   
 
Salmon calcitonin was also delivered using a solid-coated MN approach.  The 
coating formulation for salmon calcitonin was prepared with a mixture of CMC, 
trehalose and Lutrol F-68.  Coated MNs were applied on the dorsal side of rat ear 
for 20 minutes and the concentration of salmon calcitonin in serum was analysed 
for pK study.  MN delivery of salmon calcitonin was able to achieve Cmax quicker 
than subcutaneous injection, which was thought to be due to the quicker 
absorption from dermal capillaries when using MN delivery.  The choice of 
coating formulation is important.  It has been shown that the loss of bioactivity of 
salmon calcitonin during formulation preparation and coating process contribute 
to the low bioavailability when using MNs (250ng/mL*min), compared to 
subcutaneous injections (403ng/mL*min) (Tas et al., 2012).   
 
These studies have demonstrated that there is potential to successfully deliver 
peptides using MNs.  However, because each peptide has different physical and 
chemical properties, there is no universal solution to deliver peptides using MNs.  
Furthermore, improving the low bioavailability of peptide using MNs, which could 
due to the stability of the peptide within the coating formulation and the solubility 
of peptides, still remains a difficult challenge.  For this project, two auto-antigenic 
peptides were to be delivered using a solid-coated MN system.  However, the 
physical and chemical properties of these two peptides make them difficult to 
deliver using any previously published coating formulation.  The second obstacle 
is delivering the desired amount of peptide in vivo, due to a number of factors 
such as low solubility of peptide and hydration state of skin (as discussed in 
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section 2.4.2. and section 2.5.2. . As an added concern, the additives in 
published coating formulations may trigger an unwanted inflammatory immune 
response, which could counteract the desired effects of the ASI.  Therefore, 
newly designed coating formulation specific to the peptide to be delivered was 
required for this project.  The detailed aims and objectives for this project are 
listed in the next section.    
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1.10 Aims and objectives 
T1D is an autoimmune disease caused by self-destruction of insulin secreting 
beta cells.  One approach for potential treatment of this disease is ASI.  However, 
one potential problem with using an ASI approach is controlling T cell 
polarisation.  ASI treatment poses a risk of inducing Teff rather than Treg, which 
may cause further damage to the pancreas.  In this project, we believe using a 
minimally invasive delivery method (MN) and targeting skin DCs, could reduce 
the risk of side effects whilst enhancing the effect of ASI to induce peripheral 
tolerance.  We also investigated whether solid-coated MN delivery of autoantigen 
combined with use of a topical application of glucocorticoid could enhance the 
peripheral tolerance induced using a solid-coated MN approach.  The schematic 
in Figure 1.7 illustrates the intended mechanisms underlying the approach taken 
for this project. 
 
Therefore, the hypotheses for this project are: 
1. Solid-coated MN delivery of autoantigen can enhance peripheral 
tolerance. 
2. Topical application of glucocorticoid can enhance the effect of tolerance 
when combined with solid-coated MN delivery of autoantigen. 
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Figure 1.7 Schematic view of using solid-coated MN to induce tolerance in vivo.  
MNs were loaded with beta cell autoantigen and delivered to the skin.  Autoantigen was 
then engulfed and processed by skin DCs, which then migrate to draining LNs (axillary 
lymph nodes) and present antigen to naïve T cells.  Without full maturation, these skin 
DCs can induce antigen specific Tregs in skin draining LNs, axillary LNs (ALNs).  These 
antigen specific Tregs home back to the PLN, where antigen specific Tregs deplete or 
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The aim of this project is to investigate the potential of ASI for the treatment of 
T1D using solid-coated MNs with or without the assistance of pre-treatment with 
a glucocorticoid cream.   
Specific experimental objectives are as follows: 
• Design and manufacture a solid-coated MN system suitable for both 
human and mouse skin 
• Design a universal MN coating formulation system suitable for both 
hydrophobic and hydrophilic peptides 
• To investigate the clearance of peptide delivered using MNs vs ID 
injection in mouse skin 
• To investigate the potential of inducing tolerance in NOD mice in vivo 
using MN or ID injection of antigen 
• To investigate the effect of short term topical application of glucocorticoid 
(betamethasone dipropionate (BD)) pre-treatment on enhancing ASI in 
vivo  
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Chapter 2 MN design and coating formulation 
2.1. Introduction 
2.1.1. Choice of MNs for ASI 
As introduced in section 1.9.3, four approaches are commonly used for the 
intradermal or transdermal delivery of active pharmaceutical ingredients (APIs) 
by MN; solid/patch, solid-coated, dissolvable and hollow MNs (Figure 1.6).  
However, each MN type has its limitations as listed below. 
 
The solid/patch method involves two separate processes: firstly creating micron-
dimensioned pores in the skin using MNs and then delivering APIs through these 
pores using a topically applied carrier (e.g. patch, hydrogel, suspension or 
solution) (Bal et al., 2010, Wermeling et al., 2008, Pearton et al., 2008).  There 
are two major limitations to using this method. Firstly, it is difficult to control the 
dose of API which penetrates the skin, and secondly, any excipients contained in 
the carrier may trigger an unwanted immune response.  Therefore, solid/patch 
MN approach was not chosen for this project. 
 
Dissolvable (or degradable) MNs encapsulate APIs in the body of the needles 
allowing APIs to be released into the skin when the needle is inserted into a 
hydrated environment (i.e. the dermis).  One drawback to this approach is that 
APIs may lose their activity during the needle encapsulation process (Donnelly et 
al., 2009a).  For this project, a minimum excipient content is required to minimise 
the potential inflammatory effect of excipient.  This is also important to isolate the 
solo effect of antigen and delivery route on ASI output.  Therefore the dissolvable 
MNs are not suitable for this project due to their high excipient to drug ratio. 
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Hollow MNs can deliver APIs into skin in a similar fashion to hypodermic needles, 
but with less pain and a more precise delivery depth.  The advantage of hollow 
MNs is that they can deliver a large volume of drug solution with a precise dose 
(Norman et al., 2013, Gupta et al., 2009b).  One type of hollow MN, MicronJet® 
(NanoPass, Israel) has shown efficacy in clinical trials in inducing immune 
response following influenza vaccination.  Compared with full dose intramuscular 
injection, ID injection using MicronJet® showed a similar immunogenic response 
at a reduced dose, demonstrating the dose-sparing potential of a MN delivery 
system (Kenney et al., 2004, Van Damme et al., 2009).  Therefore Micronjet® 
was chosen to compare with solid-coated MNs in this project.                 
 
An alternative approach to the ‘solid/patch’ method is the ‘solid-coated’ approach.  
Solid MN arrays are coated with drug which is delivered when the MNs are 
inserted into the skin.  Compared with hollow and solid/patch MNs, solid-coated 
MNs do not require extra equipment such as a syringe or additional patch.  
Furthermore, solid-state drugs coated on MNs have a longer shelf life compared 
with drugs in solution.  Solid MNs can be manufactured in a desired shape and 
length for different purposes but without losing their mechanic strength like hollow 
MN and dissolvable MN.  Solid-coated MNs have been shown to target skin DCs 
and LCs effectively, which results in a dose-sparing effect on vaccination using 
solid-coated MN (for details see section 1.9.5).  By targeting DCs locally, a 
systemic response can be avoided.  This targeted delivery method provides a 
safe and efficient strategy for ASI without causing systemic suppression.  For 
these reasons, solid-coated MNs were chosen for this project.  
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2.1.2. Coating formulation for solid-coated MNs 
A fundamental step for the ‘solid-coated’ approach is the coating procedure.  
Various coating formulations and coating devices have been developed.  The 
coating is influenced by the rate of solvent evaporation, wettability, and viscosity.  
Therefore, for a coating solution, it is important to decrease the surface tension 
and increase the viscosity in order to form a film during the coating process.  
After drying, this film will solidify and deposit APIs on the surface of the needle.  
Coating solutions have been developed for the ‘dip-coating’ method, whereby 
MNs are repeatedly introduced into the drug formulation.  For example, a 
formulation comprising 1%w/v CMC and 0.5%w/v Lutrol F-68 was shown to form 
a uniform thin film on solid stainless steel MN surfaces (Gill and Prausnitz, 
2007c).  For the coating of hydrophobic drugs, 5%w/v PVP (Polyvinylpyrrolidone) 
in ethanol was employed as a solvent and inactive additive.  The aqueous 
coating solution was used to deliver influenza virus-like particles (VLPs) and 
whole attenuated virus using the solid-coated approach (Zhu et al., 2009, Marc, 
2010).  It has also been reported that pre-coatings on the surface of MNs, which 
alter MN surface properties, such as PLGA or chitosan, can improve coating 
efficiency (Gill and Prausnitz, 2007a).  However, the dip-coating method has 
some drawbacks.  The method requires an excess volume of coating solution, 
causing wastage during preparation.  The immersion and removal process needs 
to be repeated several times to ensure sufficient coating for an adequate dose.  
Other coating methods have been developed for uniform MN coating, which may 
also be scalable in the commercial context.  In one example, silicon MNs are 
sprayed with hydroxypropylmethylcellulose or CMC.  Using this approach a 
micron scale thickness film was coated uniformly on MNs (McGrath et al., 2011).   
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Compared with hydrophilic drugs, there are only few publications which discuss 
coating formulations for hydrophobic drugs.  Two strategies were used by Gill 
and Prausnitz to encapsulate hydrophobic drugs in a coating formulation; 1) the 
use of organic solvents and 2) the use of low melting point polymers (Gill and 
Prausnitz, 2007c).  Ethanol and acetonitrile were used as solvents for the 
preparation of the hydrophobic drugs, curcumin and sulforhodamine.  
Polyethylene glycol (MW1500) was melted and solid sulforhodamine was 
suspended in the liquid polymer, which was then coated on MNs.  Both methods 
have the disadvantage that they only provide low drug loading dose, 0.01-
0.1%(w/v).  In another study, ketoprofen gel was coated onto solid MNs and the 
pharmacokinetics were tested in vivo following delivery (So et al., 2009). In this 
study, ketoprofen was encapsulated in a hydrogel mixture with a loading 
efficiency of 24mg/kg.  The AUC (area under curve) of ketoprofen in the plasma 
of rats was shown to be higher when using coated MNs than using gel alone.  
However, the delivery efficiency of ketoprofen using coated MNs was not 
reported in this paper.  The difficulty in delivering hydrophobic drugs is not just 
related to the dosage.  In another study an aqueous coating formulation, salmon 
calcitonin (with a solubility of 1mg/ml in water) partially lost its activity during the 
dissolution and coating process (Tas et al., 2012).   
 
2.1.3. Solid MN geometry and drug transportation 
Several studies have been performed to determine the effect of MN geometry on 
skin puncture and drug transportation.  Dermaroller® MNs of different needle 
length have been analysed for their ability to penetrate skin to deliver insulin in 
vivo to diabetic rats (Badran et al., 2009, Zhou et al., 2010).  MNs with a needle 
length of 500µm were sufficient to increase drug flux without causing significant 
skin damage.  MN safety studies have also been undertaken on human 
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volunteers (Coulman et al., 2011).  Skin redness and dermal blood flow have 
been measured to indicate the degree of irritation caused by MN puncture.  It 
was postulated that increasing the length of needle would increase the likelihood 
of induced redness of the skin.  There was, however, no difference in blood flow 
or pain scoring with MNs between 200µm and 400µm long (Bal et al., 2008).   
 
Needle interspacing is also an important parameter to enable successful MN 
penetration of the skin.  In MN arrays, needle interspacing of less than 150µm 
requires an increased penetration force to enable successful penetration due to 
skin deformation and distribution of application force (Olatunji et al., 2013).  
Analytical models have been developed to study the combination of MN 
parameters such as dimensions and spacing on the skin damage and drug 
transportation.  In skin pre-treated with silicon MN arrays, acyclovir fluxes 
increased with the increment of needle length.  This effect, however, is reduced 
when needle density is greater than 2000/cm2 (Yan et al., 2010).  Sharpness of 
the needle also influences drug transportation.  Increased tip radius, i.e. blunt 
MNs, can increase the damage to the skin, which will increase drug flux through 
skin.  However, blunt MNs also need more application force to enable successful 
penetration (Olatunji et al., 2012), whereas sharper needles are able to penetrate 
the skin relatively easily.  Coated MNs of different shapes have been analysed 
for their effect on insulin delivery and subsequent insulin concentration in blood.  
One report suggested that ‘rocket’ shaped MNs can distribute insulin evenly 
across the skin whilst a conical shape results in the least even dispersal of 
delivered load (Al-Qallaf et al., 2009).  These studies provide some insight, which 
can guide MN design, and help prediction of drug transportation dynamics in the 
skin using these MNs.   
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2.2. Objectives 
• To develop a formulation system which is suitable for peptides with a wide 
spectrum of solubilities.   
• To determine the factors which influence the delivery efficiency of peptide 
via coated MNs  
• To design a coated MN system that is suitable for both human and murine 
studies for the efficient targeting of skin DCs 
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2.3. Methods 
2.3.1. Preparation of human skin explants 
All human skin samples were obtained from female patients undergoing 
mastectomy or breast reduction surgery under informed patient consent and local 
ethical committee approval (South East Wales Ethics Committee Ref. 
08/WSE03/55).  Excised skin was transported from surgery to the laboratory at 
4˚C in Dulbecco's Modified Eagle's Medium Base 5030 (DMEM 5030), 
supplemented with 1% penicillin/ streptomycin (100IU/ml), as described in a 
previous study (Ng et al., 2009).  The subcutaneous fat was trimmed off of the 
skin using blunt dissection.  The skin was then stretched to approximately its 
normal tension using pins on a cork dissection board.     
 
2.3.2. Imaging MNs using Scanning Electron Microscopy (SEM) 
SEM is an imaging technology that can be used to image the topology of an 
appropriately prepared sample.  A scanning electron microscope utilises an 
electron beam which scans the object (sample) surface, producing signals such 
as secondary electrons emitted from atoms of objective surface (which is the 
primary signal used for normal SEM imaging), as well as backscattered electron 
and X-rays, which also have some imaging and analytical utility.  The resolution 
of a modern SEM image can be better than 1nm, with a typical working resolution 
suitable for prepared samples in the micron range.  Samples prepared for SEM 
can be relatively large in three dimensions and sample preparation is usually 
relatively simple, particularly for metallic, mineral and dehydrated samples.  
Preparation typically involves sputter coating with a heavy metal such as gold, 
which provides a good source of secondary electrons as well as dispersing any 
localised surface charging from the incident electron beam.  Its resolution, 
analytical capabilities and ease of use make SEM, a relatively simple and useful 
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technique to examine surface morphology in great detail (Jensen, 2012).  For 
SEM observation, MNs were carefully mounted on 32 x 10 mm aluminium 
specimen stubs (Agar Scientific, G318). A small piece of a 12mm adhesive 
carbon tab (Agar Scientific, G3347N) was cut to shape and placed underneath 
the MN to provide an appropriate angle for observation in the SEM. Leit-C 
Conducting Carbon Cement (Agar Scientific, G3300) was then used to secure 
the specimen in place. Mounted samples were then placed in an EMscope 
sputter coater under a low pressure argon atmosphere and coated with gold 
(Agar Scientific, AGB7184) to improve surface conductivity and increase 
generation of secondary electrons, thereby improving the signal/noise ratio. 
Samples were observed in a JEOL JSM-840A scanning electron microscope 
(JEOL, Tokyo, Japan) operating at 5kV. Images were captured using a SIS 
ADDAII Image grabber with analysis software (Soft Imaging System GmbH, 
Munster, Germany). 
 
2.3.3. OCT (Optical Coherence Tomography) imaging 
OCT is a non-invasive medical imaging system, which is mainly used in the 
diagnosis of ocular and skin diseases (Chen and Lee, 2007).  OCT maps the 
biological tissues by collecting signals from backreflected and backscattered low 
frequency lights (i.e. infrared), using a principle similar to ultrasonography.  
Compared with other systems such as MRI (magnetic resonance imaging) or X-
ray, OCT has the advantage of providing higher resolution (<10µm/pixel) images 
(Huang et al., 1991).  In recent studies, OCT has proven to be a useful tool to 
examine the penetration of skin by MNs, both in vitro and in vivo (Donnelly et al., 
2010, Coulman et al., 2011).  In this study, an OCT system (VivoSight, Germany) 
with a quoted resolution of 4µm/pixel was used to image MN insertion depth in 
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situ, and poration in vivo.  Image processing was performed according to the 
manufacturers guidance.   
 
To image MN insertion depth in human skin explants, the majority of the dermal 
layer was first carefully trimmed off using a pair of fine scissors.  The resulting 
processed skin was approximately 2 mm thick, which matches the maximum 
imaging depth of the OCT device provided.  MNs were inserted into the skin 
explants from the epidermal side.  The MNs and skin were turned gently upside 
down, leaving the dermal side facing upward.  The light source used in OCT 
cannot penetrate optically opaque objects, such as the MN base; therefore, the in 
situ images were taken from dermal side of the skin.  In order to do so, the OCT 
scanning probe was carefully placed on the dermal side, and held still manually 
until one scan was completed.  
 
Ethical approval for measuring MN penetration in human volunteers was 
obtained from The Cardiff School of Pharmacy and Pharmaceutical Sciences 
Ethics Committee. Human volunteers were recruited and provided written 
consent to the procedures. All MNs used in this study were sterilised with 70% 
v/v ethanol and then air dried.  The skin area of interest was first cleaned with an 
isopropanol swab and then marked with a marker pen to ensure the scan area is 
consistent.  OCT scans were performed before MN treatment and immediately 
after MN treatment.   
 
All image data was analysed using ImageJ software to assess the degree of 
tissue damage. 
 
  68 
2.3.4. Skin delivery using hollow MNs 
To study the delivery depth and drug distribution using hollow MNs, an array of 
four 450µm long pyramid shaped silicon hollow MNs, MicroJet® (provided by 
NanoPass Technologies Ltd), was used.  A 1 ml syringe was filled with the 
delivery material and attached to the hollow MNs.  MNs were then inserted into 
the skin with an angle of approximately 60˚ with the bore-opening side facing the 
skin as illustrated in Figure 2.1 (Yeshurun et al., 2009). A successful injection 
should form a bleb on the skin surface, without rupturing or evidence of leakage 
of injectable from skin.   
 
 
Figure 2.1 Schematic view of MicronJet® MN application to human skin (Yeshurun 
et al., 2009).   
 
2.3.5. Coating procedure for solid MNs 
To coat MNs, 0.4µl of the required formulation (which theoretically equates to 
10µg peptide (25mg/ml)) was taken up using a pipette (range from 0.1µl-2.5µl) 
and 10µl ultra long tip.  The tip was then carefully removed from the pipette 
ensuring that there was no loss of liquid.  Peptide was then deposited onto 
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individual MNs by brushing the aperture of the pipette tip over the point of each 
needle (Figure 2.2).  Due to adhesion/cohesion effects, a small amount of liquid 
is left on the surface of each needle.  The needle can then be left to air dry, 
leaving peptide coated on the needle surface.  This is repeated for three MN 
arrays (i.e. 30 needles in total) until all of the coating formulation had been 
coated onto the MN surfaces.  
 
  
Figure 2.2 Schematic diagram showing the coating process using a tip coating 
method.  0.4µl (10µg peptide) coating formulation was taken for coating MNs (shown in 
green) and coated on MNs (black) surface by brushing liquid onto needle surface.  a. 
Oblique view of coating process to show that needles can be precisely coated without 
depositing peptide on the base of MNs.  b. Anterior view showing coating process. 
 
2.3.6. Imaging the MN after coating 
GeorgiaTech 750um MNs were coated, as described in section 2.3.5 with FITC-
conjugated proinsulin B9-23-FITC, MNs were then imaged using a fluorescent 
microscope (Leica DM IRB Microscope, UK), to ensure coating quality and 
uniformity.  The excitation and emission wavelengths of FITC are 490nm and 
517nm respectively; therefore a blue excitation filter was used to detect the 
distribution of FITC conjugated peptide.  During the imaging one MN array was 
placed on a glass slide and x4 and x10 magnification images were taken to 
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analyse the coating distribution and coating uniformity.  Images were then 
processed using ImageJ software.  
 
2.3.7.  Skin delivery using solid MNs  
Human skin explants were prepared using the method described in Section 2.3.1.  
MNs were firmly pressed into the skin by applying vertical pressure.  The MNs 
were then held in place for 10 minutes before removal. 
 
Three MN arrays were held together using a specially designed holder (Figure 
2.3a).  To apply MNs in vivo, a NOD mouse was shaved near the neck area 
using a clipper.  MN arrays were then pinched and held against skin for 10 
minutes with the mouse under general anaesthetic (Figure 2.3b).   
 
Figure 2.3 Solid MN assembly and application method on mouse. a. Three MN 
arrays (30 needles in total) assembled using a purpose built MN holder.  Arrays were 
separated using a spacer and held together using a mini screw.  b. In vivo MN 
application.  The MN array was delicately pinched against shaved skin at the base of the 
mouse neck area and held still in order to maintain a stable delivery position. 
 
2.3.8. Quantification of delivery efficiency of 5-TAMRA conjugated peptide 
using UV-vis absorbance 
5-TAMRA is a pH sensitive photostable fluorophore.  At pH7.0, Ex/Em (excitation 
and emission pair) is 553nm/576nm while in the solid state Ex/Em is 
549nm/577nm.  In 10%v/v acetic acid solution, its UV-vis peak absorbance 
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wavelength is 559nm.  Using 5-TAMRA, different peptides can be quantified 
using the same UV-vis absorption, which provides a quick and reliable analytical 
method for different peptides. 
 
The delivery efficiency of 5-TAMRA conjugated peptides was inferred by UV-vis 
spectrometry (NanoVue Plus Spectrophotometer, GE lifesciences) of the material 
remaining on the MNs after skin delivery.  After skin insertion MNs were 
immersed in 100µl 10%v/v acetic acid in a sealed container and kept in the fridge 
for 15 minutes to wash off any residual peptide from the MNs.  The absorbance 
of peptide-5TAMRA in the supernatant was then measured at 559nm using a 
NanoVue™ spectrophotometer and the concentration of residual peptide was 
then calculated using a calibration curve.  This was repeated with MNs that had 
not been inserted into skin to determine the peptide loading of MNs. The residual 
mass of peptide on MNs and delivery efficiency were calculated using the 
equations below: 
 
Equation 2.1 Calculating the mass of peptide that remained on solid MNs. 𝑀𝑎𝑠𝑠   µμ𝑔 = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛   µμ𝑔/𝑚𝑙 ∗ 0.1𝑚𝑙 
 
Equation 2.2 Calculating the delivery efficiency of peptide using solid MNs.  𝐷𝑒𝑙𝑖𝑣𝑒𝑟𝑦  𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦   𝐷𝐸 = 𝑀𝑎𝑠𝑠  𝑏𝑒𝑓𝑜𝑟𝑒  𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑦 −𝑀𝑎𝑠𝑠  𝑝𝑜𝑠𝑡  𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑦𝑀𝑎𝑠𝑠  𝑏𝑒𝑓𝑜𝑟𝑒  𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑦 𝑋100% 
 
2.3.9. Skin histology 
Skin tissue was immersed in optical cutting temperature embedding matrix at 
room temperature in a plastic mould with air carefully removed.  This was then 
snap frozen using a mixture of methanol and dry ice.  Sections (8µm thickness) 
were obtained using a Cryostat FSE (Thermo Scientific) with the chamber 
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temperature and the sample temperature set at -20˚C.  Sections were collected 
on glass slides and kept at -80˚C for further use. 
 
Haematoxylin and Eosin (H&E) staining is commonly used in the light 
microscopic study of histological specimens, and is a routine technique in 
diagnostic pathology.  Haematoxylin, in the presence of aluminium salt, is a 
positively charged basic blue dye, which readily binds with molecules with a 
negative charge, such as DNA.  For this reason nuclear material in an H&E 
histological section appears blue.  Eosin is a pink/red negatively charged acidic 
dye, which binds with positively charged molecules such as arginine and lysine 
rich cytoplasmic protein and peptides.  This is typically seen as pink connective, 
membranous and fibrous tissue in a prepared section (Fischer et al., 2008, Kuru, 
2014).   
 
Prior to H&E staining, cryosections were fixed in ice cold acetone for 10 minutes, 
then washed with PBS three times to remove OCT media.  Sections were then 
stained in filtered Haematoxylin for 5 minutes before rinsing in running water for 2 
minutes.  Sections were decolourised by immersing in 1%v/v acid alcohol (1%v/v 
HCl in 70%v/v ethanol/water) for 1 second.  Sections were then differentiated in 
eosin aqueous solution stain for 10 seconds before rinsing in running water until 
the water ran clear. Samples were dehydrated using an ethanol gradient; 10 
seconds in 50%, 70%, 80%, 95% and 100% v/v alcohol sequentially. Slides were 
left in 100% alcohol for another 1 minute, cleared with xylene and mounted with a 
cover slip using mounting media.  Once the mounting media was dry, the 
coverslip was sealed using clear nail varnish to improve the lifespan of the slide 
and prevent the section from becoming desiccated.  Slides were stored at room 
temperature, in a slide box, avoiding light. 
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2.3.10. Measurement of pH value of acetic acid solution 
Acetic acid was diluted in water to v/v dilutions of 20%, 12.5% and 10%.  The pH 
meter was calibrated against standards.  To test each solution, the pH probe was 
first washed in water, and then gently dried with a tissue paper. The probe tip 
was placed into the solution to be measured together with the temperature probe.  
The reading was allowed to stabilise and a recording was taken.  After each 
measurement, the probe was washed in water, dried with a paper towel and 
stored immersed in 3M KCl solution.   
 
2.3.11. Electro-polishing stainless steel MNs 
Electro-polishing is a surface finishing process, which is able to remove surface 
imperfections (burrs) from a cut metal surface.  As opposed to electroplating, 
metal on the anode side dissolves into electrolyte solution when a current is 
applied.  On the irregular shaped metal surface the charge is concentrated on the 
protruding point resulting a rapid removal of metal atoms, therefore deburring the 
surface of metals and providing a smooth surface (Lee, 2000).   
 
MNs were wire cut from stainless steel sheets using wire electrical discharge 
machining (wire-EDM) at the Cardiff School of Engineering.  The MNs were then 
electro-polished using a method adapted from that described previously (Gill and 
Prausnitz, 2007a).  An electrolyte bath was prepared containing glycerol, ortho-
phosphoric acid (85%) and water in a volume ratio of 6:3:1.  The cathode was 
connected to a copper plate and the anode was connected to a MN array.  The 
electrolyte bath was heated to 70˚C and a magnetic stirrer was used to distribute 
the heat evenly.  A current of 1.8 mA/mm2 was applied for each MN array 
accordingly for 15 minutes coupled with the agitation of the MNs, by an agitating 
device (made in-house), which was used to remove bubbles (oxygen from the 
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anode, hydrogen from the cathode), increasing the efficiency of the process.  
After electro-polishing, the MNs were washed for 30 seconds in de-ionised (DI) 
water followed by 25%v/v nitric acid solution; these washing steps were repeated 
three times.  MNs were then rinsed in hot running tap water before rinsing in DI 
water.  MNs were then air dried, wrapped in lens tissue and kept in an airtight 
container to await further use. 
 
Figure 2.4 Schematic view of the MN electro-polishing process.  The electro-
polishing step uses a temperature controlled viscous acid bath (electrolyte solution) to 
remove uneven surfaces.  Post treatment involves washing in nitric acid and water to give 
the desired finish.  
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2.4. Results 
2.4.1. Choice of MNs for targeting skin DCs 
2.4.1.1. Delivery depth, solid versus hollow MNs 
In order to optimally target LCs in the skin, the delivery depth of two commercially 
available MNs was compared: Nanopass® MicronJet and Dermaroller®.  
Nanopass® 450µm consists of an array of hollow silicon MNs comprising four 
angled 450µm MNs in a row (Figure 2.5 A-D).  Nanopass® MNs were attached to 
a conventional syringe and delivery was achieved by injecting a liquid formulation 
through the needles.  Dermaroller® 500µm consists of two rows of 8 x 500µm 
length stainless steel MNs mounted on a plastic base (Figure 2.5 E-H).  To 
achieve delivery using Dermaroller® solid MNs, deliverable drug was coated onto 
individual needles (see Section 2.2.5) which was then inserted into the skin to 
deliver drug load. 
 
The morphology of both types of MNs were compared against a conventional 
29G insulin injection needle (Figure 2.5 A&E).  Both Nanopass® and 
Dermaroller® MNs had a much more refined structure than a conventional 29G 
needle.  Nanopass® MNs were pyramid shaped with a bore-opening of 51.6µm 
(Figure 2.5 C&D).  Dermaroller® MNs, on the other hand, were a conical shape 
with needle tip diameter of less than 10µm (Figure 2.5 G&H).   
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Figure 2.5 Images of Nanopass 450µm MNs and Dermaroller® MNs. A. Nanopass 
450µm (left) compared with 29G Insulin injection needle (right), B. Magnified view of 
Nanopass MNs, C. SEM image of Nanopass 450µm and D. Needle opening and its size, 
E. Dermaroller® 500µm (left) compared with 29G Insulin injection needle (right), F. 
Magnified view of Dermaroller® MNs, G. SEM image of Dermaroller® 500µm side view 
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Skin delivery depth was demonstrated histologically using H&E stained sections 
of human and mouse skin, as examined using light microscopy.  Anatomical 
differences between human and mouse skin are shown in Figure 2.6.  Following 
blunt dissection, the thickness of the human skin explants was approximately 2-
3mm, with a densely packed epidermal layer measuring 60-100µm (Figure 2.6 
A).  Mouse skin on the other hand is much thinner (Figure 2.6 B).  The total 
thickness of mouse skin is 200-300µm with a very thin layer of epidermis (20-
30µm). Figure 2.7 A shows that 450µm hollow MNs delivered the majority of 
peptide (m31-5TAMRA, shown in red) into the lower dermis in human skin 
explant.  Some peptide was left in the needle track when the needle was 
retrieved, but this only represents a small proportion of the total delivered 
peptide.   When using mouse skin, most peptide (shown in green) was injected 
into the subcutaneous layer as well as the dermal layer.  On the other hand, as 
shown in Figure 2.7 C, fluorescent peptide delivered using 500µm long solid-
coated MNs was left in the epidermis and the uppermost layer of the dermis.  For 
mouse skin, 500µm long solid MNs are able to target most dermal areas (Figure 
2.7 D).  The penetration depth of solid MNs in human skin was measured using 
the OCT imaging system.  Dermaroller® MNs were inserted into human skin 
explants and imaged using OCT in situ.  The insertion depth of 500µm 
Dermaroller® MNs measured in human skin explants was between 300-400µm. 
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Figure 2.6 Human vs. mouse skin structure.  Section was stained with H&E to 
distinguish cellular (blue) and connective tissue (pink).  A. Human breast skin cross 
section.  The thickness of human skin epidermis is between 60-100µm and densely 
packed with cells.  The dermis is mainly constructed of connective tissues with scattered 
cells; B. Mouse flank skin cross section.  The total thickness of mouse skin is between 
200-300µm with a very thin epidermal layer (approximately 20µm).  
 
B.A.
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Figure 2.7 Delivery depth of peptides using hollow MN and solid MN in human and 
mouse skin.  A. Hollow MN injection of fluorescent peptide (red) to human skin explant; 
B. Hollow MN injection of fluorescent peptide (green) to mouse skin; C. Fluorescent 
peptide (red) was coated on 500µm solid MN and delivered to human skin explant; D. 
Fluorescent peptide (red) was delivered to mouse skin using 500µm solid-coated MNs; E. 
In situ OCT image of 500µm solid MNs inserted into human skin explant. 
 
2.4.1.2. Skin disruption using solid MNs of different length 
OCT was used to determine MN disruption to human skin in human volunteers.  
Two solid metal MNs of different length were tested here: 500µm long 
Dermaroller® MNs and 750µm long GeorgiaTech MNs.  Before MN treatment, 
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treatment, pores caused by MN damage can be observed on the surface of the 
skin, and are indicated in the images presented by yellow arrows (Figure 2.8 B, 
D).  There was no obvious difference in the pores created using 750µm long 
needles (Figure 2.8 B) or 500µm long needles (Figure 2.8 D) shown from the 
enface view of the skin.  Cross-sections of the pores revealed the extent of skin 
disruption after MNs were removed.  The damage track by 750µm long needles 
appeared to be deeper and wider compared with the damage created by 500µm 
long needles (Figure 2.8 C, E).   
 
 
Figure 2.8 Skin disruption in human volunteers by solid MNs imaged by OCT.  A. 
Skin surface features before treatment; B. Skin surface features after treatment with 
750µm MNs. C. Cross-section of skin damage following removal of 750µm MNs from the 
skin. D. Skin surface features after treatment with 500µm MNs.  Yellow arrows indicate 
the pore or skin disruption after application of MNs.. E. Cross-section of skin damage 
after 500µm MNs were removed from skin.  Yellow arrows indicate the pore or skin 







  81 
2.4.2. Development of a novel coating formulation 
2.4.2.1. Peptide properties 
Three different peptides were coated onto MNs.  The amino acid sequence and 
properties of the peptides are listed  below: 
Table 2.1 Peptide properties. Peptide properties were generated using an online 
resource (https://www.genscript.com).   





(overall % Of 
hydrophobic and 






















All peptides included in this study are categorised as hydrophobic peptides.  The 
solubility of these peptides in water is in the order WE14>M31>proinsulin B9-23.  
Preliminary studies showed that a previously reported MN coating formulation 
(Gill and Prausnitz, 2007c) was only able to dissolve low concentrations of WE14 
and would therefore be unsuitable for coating MNs with these hydrophobic 
materials.  
 
2.4.2.2. Choice of solvent for coating hydrophobic peptides 
In order to coat a suitable amount of peptide onto MNs without overloading, a 
novel coating formulation was developed.  Firstly, the desirable criteria of this 
formulation were identified to focus research effort: 
• Water based system. 
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• Solvent used to dissolve the hydrophobic peptide should be, at least 
partially, miscible with water. 
• Solvent will evaporate at room temperature and at atmospheric pressure, 
ideally with a similar vapour pressure to water. 
• The coating formulation would not alter peptide bioactivity. 
• The excipients in the coating formulation would not trigger a non-specific 
proinflammatory immune response. 
• The amount of excipients should be minimised. 
• Peptides should be soluble in the formulation at high concentration ≥ 
10mg/ml. 
• Formulation is able to be stored at -80˚C (i.e. has a melting point of > -
80˚C). 
 
In order to dissolve these hydrophobic peptides, the first approach used was 
to protonate water using acetic acid.  Acetic acid has a low melting point, 16-
17˚C, is miscible with water and will evaporate at room temperature.  The pH 
of acetic acid solutions at concentrations of 1.9, 2.2 and 2.6 mol/L is 2.24, 
2.21 and 2.17 respectively.  All acetic acid solutions were able to dissolve 
WE14 resulting in concentrations ranging from 10mg/ml to 25mg/ml.  
Proinsulin B9-23 and m31 peptides were however not soluble enough in high 
or low concentration acetic acid solutions to produce peptide concentrations 
above 10mg/ml. 
 
Alcohols were initially investigated as potential co-solvents as they are very 
commonly used for dissolving hydrophobic compounds and have relatively 
low toxicity.  Within the series of ethanol, propanol, butanol and pentanol, 
only tert-butanol and tert-amyl alcohol have a melting point of greater than 
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80˚C.  Table 2.2 lists some key physical properties of these two alcohols (tert-
butanol and tert-amyl alcohol) compared with water.  Containing one more 
methyl group, tert-amyl alcohol has a lower solubility in water than tert-
butanol.  The presence of a methyl group in these alcohols also alters the 
melting point, boiling point and vapour pressure.  Both alcohols fit the criteria 
listed above which make them suitable candidates for further investigation for 
use in our coating formulation.  Tert-butanol however was not able to dissolve 
proinsulin B9-23 at a high concentration (≥10mg/ml).  Therefore tert-amyl 
alcohol was chosen as the solvent in coating formulations for hydrophobic 
peptides.  The miscibility of tert-amyl alcohol with acetic acid/water mixtures 
was tested.  Tert-amyl alcohol was able to dissolve in 1.7M-3.5M acetic 
acid/water mixtures at a ratio of 1:5v:v without visual observation of phase 
separation.    
 
Table 2.2 Chemicals physical properties.  The physical properties of acetic acid, tert-














Acetic acid 60.05 Miscible 16 to 17 118 to 119 1.5 
Tert-butanol 74.12 Miscible 25 82 to 83 4.1 
Tert-Amyl 
alcohol 
88.15 120 -9 101 to 103 1.6 
H2O 18 - 0 100 2.3 
 
To dissolve the peptide it was crucial to disperse the peptide in a small 
volume of tert-amyl alcohol first, followed by the acetic acid solution. Three 
different concentrations of amyl alcohol and acetic acid solution were used for 
the three peptides listed in Table 2.2.  The optimal combinations of coating 
formulation components for dissolving 1mg of peptide are listed in Table 2.3.   
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Table 2.3 Coating formulation composition for three peptides.  The formulation was 
tested for its ability to dissolve 1mg of each peptide.  Choice of excipients is listed in 
Table 2.4. 
 
2.4.2.3. Choice of formulation excipients  
A range of further excipients were explored to 1) assist the dissolution of the 
peptide loaded onto MNs once in the in vivo environment and 2) stabilize the 
coating mixture (Table 2.4).  As a previous study has shown the safety profile of 
10µg pro-insulin C19-A3 in a Phase I clinical study (Thrower et al., 2009), it was 
decided that 10µg of peptide would be an appropriate dose to coat onto each MN 
array.  Five excipients listed in Table 2.4 were tested individually to improve the 
coating ability (peptide alone was not able to coat the needle with the current 
coating method).  1µg of each excipient was used to provide a low excipient to 
drug ratio, 1:10w:w.  The five excipients, from three main categories were; PVA 
(polyvinyl alcohol) and PEG (Polyethylene glycol), which were used as 
dispersants; Pluronic F68 and F127, which were used as surfactants, and finally 
2HPßCD (2-hydroxypropyl-ß-cyclodextrin), which was used to form an inclusion 




































56.25 12.5 1.25 0.8 
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Table 2.4 Excipients tested as components in the coating formulation to improve 
coating ability.  
Excipients Function Properties 
PVA (MW 2000) Dispersant Hydrogel 
PEG (MW 1450) Dispersant Polymer 
PF127 Nonionic Surfactant Thermogel 







In order to develop the coating formulation, 1mg of proinsulin B9-23-FITC 
was initially dissolved in each of the solvents (as described in Table 2.3) prior 
to adding each additional excipient respectively.  All excipients were able to 
assist peptide coating on MNs, resulting in a more uniform coating without 
overloading, as shown in Figure 2.9 (as a representative example). 
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Figure 2.9 Fluorescent images of coating ability of proinsulin B9-23-FITC in 
formulation with different excipients.  All excipients were able to assist coating of the 
peptide on the surface of the needle.  Without the use of excipients, peptide was unable 
to coat MNs using the current coating method. 
 
2.4.3. Factors that influence skin delivery efficiency 
2.4.3.1. Excipients in the coating formulation 
Coated MNs were then tested for their ability to deliver the coated material into 
human skin explants. Dermaroller® (500µm) MN arrays were coated with 1µg of 
excipient (as listed in Table 2.4) and 10µg of WE14-5TAMRA.  MNs were 
inserted into human skin for 10 minutes.  The amount of peptide remaining on the 
MNs was measured using UV-vis spectroscope (Nanovue™) with delivery 
efficiency inferred by subtraction using Equation 2.2.  Both dispersants (PVA and 
PEG) improved delivery efficiency to skin, resulting in an overall delivery 
efficiency for WE14 peptide of greater than 40%.  2-hydroxypropyl-ß-cyclodextrin 
also assisted dissolution of the peptide from MNs, resulting in an overall delivery 







  87 
into the skin more efficiently than other excipients and showed a significantly 
higher delivery efficiency than both the surfactants,PF68 and PF127.   
 
 
Figure 2.10 Excipient effect on delivery efficiency of WE14-5TAMRA using 500µm 
Dermaroller® MNs.  MNs were coated with 10µg of WE14-5TAMRA and applied to 
human skin explants for 10 minutes before analysing the delivery efficiency.  n=3.  One 
way ANOVA with Tukey’s post test.  *p<0.05.  D= peptide was delivered using 500µm 
long Dermaroller® MNs.   
 
2.4.3.2. The effect of MN surface properties  
In order to further improve the delivery efficiency, another MN device was tested.   
These MNs, supplied by Georgia Institute of Technology, were laser cut in-plane 
from stainless steel to create a row of 5 MNs of 750µm length. These MNs were 
already post treated by electro-polishing (Figure 2.11 B).  Each MN array (5 
needles) was coated with 10µg of WE14-5TAMRA and 1µg of excipient as 
described above, and inserted into human skin explants for 10 minutes.  The 
delivery efficiency was measured using Nanovue™ and inferred by subtraction 
using Equation 2.2.  Interestingly, all MNs were able to deliver over 80% of 
WE14-5TAMRA regardless of excipient effects (Figure 2.12).  As the dispersant 
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in both polished and unpolished MNs this excipient was selected for further 
testing.   
 
Figure 2.11 SEM images of solid MN surface morphology.  A. Dermaroller® MN B. 




Figure 2.12 Delivery efficiency of WE14-5TAMRA using electro-polished MNs.  MNs 
were coated with 10µg of WE14-5TAMRA and applied to human skin explants for 10 
minutes before analysing the delivery efficiency.  One way ANOVA, with Tukey post test.  
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This dramatic change in delivery efficiency from the GeorgiaTech MNs could be 
due to altered MN length or altered MN surface properties, i.e. an effect of 
electro-polishing. As two variables were potentially responsible for this 
discrepancy, it was necessary to isolate the effects of electro-polishing and 
needle length.  Therefore, in order to make a direct comparison, 5x500µm MN 
arrays were manufactured in-house by wire-EDM and electro-polished.  After the 
electro-polishing process was complete, the dimensions of the MNs was shown 
to be reduced by approximately 12.5% in height and 23% in base width (Figure 
2.13).  In addition Dermaroller® MNs were used without further processing and 
following coating with gold using an EMtech sputter coater to modify surface 
properties.   
 
Figure 2.13 MN dimensions before and after electro-polishing.  Stainless steel MN 
arrays (500µm long) were electro-polished and the dimensions of needles before and 
after electro-polishing were measured using ImageJ software.  L=needle length, 
W=needle base width.  n=10. Mean±SD. Tested with two tailed t test. **p<0.01, 
****p<0.0001 
 
Each array of MNs was coated with 10µg of WE14-5TAMRA and 1µg of PVA.  
Delivery efficiency was measured after MNs were inserted into human skin 
explants for 10 minutes (Figure 2.14).  By visual observation alone it was obvious 
that unpolished MNs were able to deliver far less peptide than their electro-
polished equivalent.  This was confirmed quantitatively using UV-vis 
Needle%length%(L)% Needle%base%width%
(W)%
Unpolished% Polished% Unpolished% Polished%
  90 
spectrometry (Figure 2.15) where it was shown that delivery efficiency using 
electro-polished 500µm MNs was significantly greater than unpolished 
equivalents.  The data showed no difference between gold coated and non-
coated Dermaroller® MNs.  Electro-polished MNs of 750µm length were able to 
achieve the highest delivery amongst all types of MNs and were able to deliver 
significantly more WE14-5TAMRA than Dermaroller® MNs.  500µm electro-
polished MNs showed significantly lower delivery efficiency than 750µm long 
MNs (Figure 2.15). 
 
Figure 2.14 Images show MN penetration and WE14-5TAMRA (pink) release into 
human skin explants after 10 minutes application.  MNs with five different surface 
properties were coated with same amount of WE14-5TAMRA (10µg) and applied to the 
human skin explant for 10 minutes.  The penetration images were visualised using a 
stereo microscope and processed with ImageJ software. 
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Figure 2.15 Effect of surface morphology on the delivery efficiency of WE14-
5TAMRA in human skin.  MNs with different surface morphology were coated with 10µg 
of WE14-5TAMRA and applied to human skin explants for 10 minutes before analysing 
the delivery efficiency.  n=3, Mean±SD, One way ANOVA with Tukey post test.  **p<0.01, 
***p<0.001.   
 
2.4.3.3. Delivery efficiency as a function of hydrophobicity of peptide 
Delivery efficiency can also be influenced by the hydrophobicity of the peptide.  
Each set of 30 x 450µm long electro-polished needles was coated with a total of 
10µg of peptide.  Skin delivery efficiency was determined by applying MNs either 
to human skin explants or to the shaved neck area of a mouse for 10 minutes.  
The amount of peptide delivered was measured using a UV-vis spectrometer and 
delivery efficiency was inferred by subtraction (Equation 2.2).  The delivery 
efficiency of the most hydrophilic peptide, WE14, was 80%. This was almost 
double the delivery efficiency of a very insoluble peptide, proinsulin B9-23 (Figure 
2.16).  Similar phenomena were observed when using the mouse skin model 
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Figure 2.16 Effect of peptide hydrophobicity on delivery efficiency in human skin 
explants using electro-polished 500µm MNs.  The same amount (10µg) of hydrophilic 
peptide, WE14, and hydrophobic peptide (proinsulin B9-23) was coated and delivered to 
human skin explants using 3 arrays of 500µm long electro-polished MNs.  Delivery 
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Figure 2.17 Effect of peptide hydrophobicity on delivery efficiency in mouse skin 
using electro-polished 500µm MNs.  The same amount (10µg) of hydrophilic peptide, 
WE14, and hydrophobic peptide (m31) was coated and delivered to shaved mouse neck 
area using 3 arrays of 500µm long electro-polished MNs.  Delivery efficiency was then 
calculated after MN application.  n=3, Mean±SD, Two tailed t test.  ****p<0.0001 
 
2.4.3.4. Effect of skin species on skin delivery 
In order to examine the effect of the skin model used on delivery efficiency, 
WE14-5TAMRA delivery efficiency was then compared in human skin and mouse 
skin (Figure 2.18).  Using 500µm long electro-polished MNs, 80% of the WE14-
TAMRA load can be delivered to human skin explant but only 60% of the load 
can be delivered to mouse skin.   
 
Figure 2.18 The delivery efficiency of WE14-5TAMRA in human and mouse skin 
using electro-polished 500µm long MNs.  n=3. Mean±SD, two tailed t test, ** p<0.01 
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2.4.3.5. Effect of needle numbers on delivery efficiency 
To determine the effect of coating thickness on the delivery of peptide to skin, 
m31-5TAMRA (10µg) was coated onto 5, 15 or 30 electro-polished needles of 
450µm length, i.e. the material was distributed over more MNs to reduce coating 
thickness per individual MN.  As demonstrated in Figure 2.19, the delivery 
efficiency in mouse skin was almost three times higher when the material was 
distributed over 15 needles compared with 5 needles.  When using 30 needles to 
deliver 10µg peptide, the delivery efficiency is approximately 20%, which is only 
5% higher than when using 15 needles.   
  
Figure 2.19 The effect of distributing the coating on different numbers of MNs on 
delivery efficiency of m31-5TAMRA in mouse skin.  Electro-polished MNs with 
different needle number (5, 10 or 30) were coated with 10µg of m31-5TAMRA.  Delivery 
efficiency of m31-5TAMRA was quantified after 10 minutes application in mouse skin.  
n=3, Mean±SD, one way ANOVA with Tukey post test.  *p<0.1, **p<0.01 
 
2.4.4. Design and manufacture of solid-coated MN systems suitable for 
both human and mouse skin models 
As a result of the data presented in the previous results sections, solid MNs were 
designed and manufactured for use in both human and mouse skin. The 
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• ≤ 500µm long 
• Sharp tip 
• Electro-polished 
• At least 30 needles per application 
• Manufacturable in-house   
 
According to these requirements, new MNs were designed with dimensions as 
shown in Figure 2.20.  Each MN array was fashioned using wire-EDM from a 
100µm thick stainless steel sheet, and contained 10 needles spaced 1 mm apart.  
Each needle is 500µm high and 200µm wide at the base.  Five MN arrays were 
linked together using a breakable join during the cutting process to facilitate more 
efficient electro-polishing.  Figure 2.20 C and D illustrate the MN surface 
morphology before and after electro-polishing.  Prior to electro-polishing, the MN 
surface was uneven due to the heat generated during the cutting process (Figure 
2.20 C).  The debris was removed using electro-polishing (Figure 2.20 D) to 
produce a smoother surface finish with a sharpened tip.  Each array of MNs 
contains 10 needles in a row.  For in vivo applications, 3 MN arrays were 
assembled as shown in Figure 2.20 F using an application device, to provide a 
total needle number of 30 per application.  
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Figure 2.20 Design of MNs suitable for both human and mouse studies.  A. Needle 
dimensions before electro-polishing (µm): 500, 200, 100, (L,W,D) L=length, W=width, 
D=depth; B. Dimensions of each MN array before electro-polishing.  On each array, 10 
needles are spaced with 1mm distance from point to point.  Each array had a rounded 
end, the radius of which was 0.5mm.  The hollow central structure enabled three arrays to 
be assembled together using a specially designed MN holder as shown in F.  C. SEM 
image of needle tip before electro-polishing. D. SEM image of needle tip after electro-
polishing. E. Finished single array stainless steel MN (left) compared with a 29G insulin 
injection needle (right). F. Three MN arrays were assembled together using a purpose 
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2.4.5. Validation of new MN designs for peptide coating and delivery 
To test the formulation uniformity and systematic error from pipetting, m31-
5TAMRA (theoretically 10µg/0.4µl) was first air dried in Eppendorfs (200µl) and 
re-dissolved in 100µl 10%v/v acetic acid prior to quantification.  The recovery of 
peptide was 9.76±0.54µg (n=6) (Figure 2.21).  The coating repeatability was then 
measured by coating MNs with m31-TAMRA and washing this coating off using 
100µl 10%v/v acetic acid.  9.37±1.1µg (n=3) m31-5TAMRA was shown to be 
coated onto the MNs (Figure 2.21).  There was no significant difference between 
amount of peptide in the 0.4µl formulation and the amount coated on MNs, 
showing that a minimal amount of peptide was lost during the coating process.  
Delivery efficiency of m31-5TAMRA and WE14-5TAMRA were tested using 
mouse skin.  After a 10 minute application to shaved mouse neck skin, 
7.46±0.47µg m31-5TAMRA remained on the MNs; this means 1.91±0.47µg was 
delivered to mouse (n=10).  This gives the delivery efficiency of m31-5TAMRA of 
20.39±4.96% (Figure 2.22).  Using the same method, delivery efficiency of 
WE14-5TAMRA to mouse skin was 58.21±4.26% (Figure 2.22).  
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Figure 2.21 Coating repeatability of m31-TAMRA using in house designed solid-
coated MNs.  Three arrays of electro-polished 500µm long stainless steel MNs were 
coated with 10µg (theoretical) m31-TAMRA.  Peptide mass coated on MNs was 
compared with mass of peptide within 0.4µl coating formulation.  N≥3, Mean±SD, two 
tailed t test, ns.  
 
   
Figure 2.22 Delivery efficiency range of m31-TAMRA and WE14-TAMRA using in 
house designed MNs.  Three arrays (30 needles) of electro-polished 500µm long 
stainless steel MNs were coated with m31-TAMRA or WE14-5TAMRA.  MN arrays were 
then assembled using a MN holder and applied to shaved mouse neck skin area for 10 
minutes.  The delivery efficiency was calculated after MN application. n≥3, Mean±SD, two 
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2.5. Discussion 
2.5.1. Targeting skin DCs with minimal damage 
In initial targeting studies, two commercially available MNs were tested.  
NanoPass Technologies Ltd market the MicronJet® MN device as a hollow MN 
device for intradermal drug and vaccine delivery. The Dermaroller® MN device 
comprises solid MNs designed for skin puncture, skin repair and/or drug delivery.  
The MicronJet® MN consists of four 450µm long silicon needles, each with a 
bore-opening at the side of the MN tip (Figure 2.5).  The device can connect via a 
Luer taper to a conventional syringe for simple patient injection.  The delivery 
depth of peptides using this device is in the deep dermis in human skin and in the 
subcutaneous layer in mouse skin (Figure 2.7).  This may be because the bore-
opening faces towards the dermis when the MNs are inserted correctly into skin 
and the injection pressure forces the material through the bore and into the 
dermis.  Dermaroller® MNs consist of two rows of eight 500µm long conical 
shaped stainless steel needles (Figure 2.5).  Peptide delivered by Dermaroller® 
MNs remained in the epidermal and upper dermal layers in the human skin 
model and in the epidermis and dermis in mouse skin, rather than in the deep 
subcutaneous layer (Figure 2.7).  The penetration depth of Dermaroller® 500µm 
long MNs in human skin was imaged using OCT.  The penetration depth in 
human skin explants was approximately 300-400µm, which represents 60-80% of 
the total needle length, when applied using moderate manual pressure.  This 
incomplete insertion depth agreed with previous observations (Donnelly et al., 
2010, Coulman et al., 2011).  Factors that contribute to the incomplete 
penetration include, the sharpness of needle tip, needle shape, insertion force 
and the deformation of soft tissues, which is due to the biomechanical properties 
of the skin; elasticity and flexibility (Donnelly et al., 2010, Davis et al., 2004, 
Boonma et al., 2012).  
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The aim of this project is to target delivery to skin DCs that reside in the 
epidermis (LCs) and the upper dermis (dermal DCs).  For this reason solid-
coated MNs were selected for further functional studies.  The degree of skin 
damage caused by solid MNs was investigated for needles of different lengths 
(500µm and 750µm).  En face OCT images suggested no obvious differences in 
skin surface damage between 500µm and 750µm long needles.  Previous 
studies have shown that skin reseals within 2 hours post MN treatment 
regardless of the needle length (Gupta et al., 2011a).  Another study using SEM, 
a higher resolution methodology, to examine the effect of needle length on 
microporation suggested that longer needles were capable of generating larger 
pores (Kalluri et al., 2011).  One concern could be that the physical insult caused 
by MN penetration increases risk of microbiological ingress.  An in vitro 
experiment has been carried out to assess microbial penetration using solid MNs 
and hypodermic needles (Donnelly et al., 2009b).  Fewer microorganisms were 
observed to penetrate through viable epidermis when using MN treatment 
compared against 21G hypodermic needle.  Based on these observations, it has 
been suggested that MNs are less likely than hypodermic needles to cause local 
or systemic infections.  The low risk of infection caused by MN damage is an 
important factor to this project.  This could minimise the risk of the activation of 
the immune system and prevent a proinflammatory response from occurring.  
Therefore, delivery using solid-coated MN could help maintain skin DCs in an un-
activated state and further benefit the generation of Treg and maximise the 
success potential of ASI.   
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2.5.2. Coating formulation for hydrophobic peptides 
For this project three different peptides will be used in further studies: m31, 
WE14 and proinsulin B9-23.  The peptides’ physicochemical properties are 
shown in Table 2.2.  WE14 and m31 were soluble in PBS at a concentration of 
1mg/ml, while proinsulin B9-23 was only able to dissolve in PBS at a 
concentration of less than 0.5mg/ml.  In a previous clinical study into ASI for T1D, 
10µg of C19-A3 peptide delivered by ID injection was well tolerated (Thrower et 
al., 2009).  We therefore considered 10µg to be a realistic target dose to coat 
onto and deliver via solid-coated MNs.  Several coating formulations have been 
developed previously for solid-coated MNs.  A coating formulation developed at 
GeorgiaTech was used to coat peptide, vaccine, BSA and plasmid DNA (Gill and 
Prausnitz, 2007b, Gill and Prausnitz, 2007c, Tas et al., 2012, Kim et al., 2010a, 
Kim et al., 2010b, Ludvigsson et al., 2014, Gill and Prausnitz, 2007a, Valladeau 
et al., 1999).  This aqueous formulation typically contains 1% (w/v) 
carboxymethylcellulose sodium salt, 0.5% (w/v) Lutro F-68 NF and 15% (w/v) 
trehalose in PBS.  If peptide were able to dissolve in this coating formulation at a 
concentration of 1mg/ml, i.e. 0.1% (w/v), then the API to excipient ratio would be 
1:165, i.e. 1650µg of excipients would be co-coated with every 10µg of peptide.  
Excess excipient could overload the needles (data not shown), which could 
influence skin penetration, delivery and bioavailability (Widera et al., 2006, 
Cormier et al., 2004, Al-Qallaf et al., 2009).  Other formulations for coating 
hydrophobic molecules have also been described.  Gill et al. utilised organic 
solvents such as ethanol and acetonitrile to dissolve hydrophobic compounds for 
coating formulation (Gill and Prausnitz, 2007c).  One disadvantage of these two 
solvents is their high volatility.  As a result, it is difficult to control the stock 
concentration, which can then influence the accuracy and repeatability of coating.  
The authors also investigated a coating formulation for hydrophobic molecules 
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using a molten polymer, polyethylene glycol (MW. 1500).  However, the high 
temperature, 45˚C, and low drug content employed (0.01%w/v), would make it 
impractical for this project.  There was, therefore, a requirement in this project to 
develop a MN coating formulation suitable for both hydrophilic and hydrophobic 
peptides.   
 
The desired formulation criteria were defined as: 
• A predominantly water based system, in order to maintain maximum 
peptide activity without denaturation caused by organic solvent alone.  
• Any organic solvent used as a co-solvent should be, at least partially, 
miscible with water, in order to ensure that there is no phase separation.  
Phase separation can cause the peptide to denature at the phase 
interface and could cause uneven peptide concentration (partitioning due 
to phase separation coupled with differential solubility of peptide). 
• Solvent evaporation at room temperature and atmospheric pressure to 
allow for peptide coating under ambient conditions. 
• Solvents with a similar vapourisation rate to water, in order to ensure that 
no phase separation occurs during storage.  This is important to maintain 
homogeneity of the stock coating formulation during the coating process.   
• The coating formulation does not alter peptide bioactivity.  
• The excipients used in the coating formulation does not stimulate a 
proinflammatory immune response.  Unlike vaccine delivery, this project 
aims to induce immune regulation, therefore it is important that the 
excipient itself causes minimal inflammation and minimises any other 
non-specific immune responses. 
• The amount of excipients should be minimised to increase peptide to 
excipient ratio and to further minimise the biological effect of excipients.  
  103 
This approach is to ensure the final read out is determined by the auto-
antigen and delivery route.  This is also to ensure the sharpness of 
needles is not influenced by the coaing.  
• Peptides are soluble in coating formulation at a concentration ≥ 10mg/ml.  
This is a limitation of the coating method described above (Figure 2.2).  
After optimisation, the coating process took 15 minutes for each MN set 
and therefore concentrations lower than this would result in longer coating 
times.  This may further increase the risk of formulation evaporation, 
altering the concentration of stock formulation during the coating process 
and therefore potentially introducing poor reproducibility.   
• The formulation is amenable to frozen storage at -80˚C.  This is mainly to 
reduce the cost and reduce the systematic error during the formulation 
preparation process.  In order to facilitate storage at -80˚C, all liquid 
solvents used in the formulation should have a melting temperature of 
greater than -80˚C.  Ideally, the systematic melting temperature of all 
reagents combined will fall within the range 0˚C to -20˚C.  This could 
ensure that the formulation can be kept on ice during the coating process 
to minimise the error caused by evaporation and to avoid the freeze-thaw 
cycle.   
 
The first approach in developing a formulation to meet these criteria was to 
use a pH modifier to increase peptide polarity and solubility. Acetic acid is a 
weak organic acid that has been widely used to dissolve hydrophobic 
peptides.  The pH of 2M aqueous acetic acid solution is approximately 2. This 
pH change was enough to dissolve WE14, a peptide with less hydrophobic 
groups (43%), at a concentration of 25mg/ml.  For the other two peptides, 
m31, a basic peptide with 60% hydrophobic groups, and proinsulin B9-23, a 
neutral peptide containing 40% hydrophobic groups, increasing ionisation 
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alone was not sufficient to ensure dissolution at the desired concentration.  
An organic solvent was therefore required to increase peptide dissolution. 
 
DMSO (Dimethyl sulfoxide) is a commonly used solvent for dissolving 
hydrophobic peptides due to its low toxicity and good biocompatibility.  DMSO 
is, however, not suitable for the MN coating formulation.  DMSO can form 
suphoxide or disulphide bonds with amino acids, such as cysteine, 
methionine and tryptophan residues (Lipton and Bodwell, 1973).  Both WE14 
and m31 contain methionine and tryptophan, so DMSO should be avoided.  
Secondly it is very difficult to remove DMSO even under reduced pressure 
conditions, i.e. it is difficult to form a dry coating using DMSO under normal 
atmospheric pressure conditions.  In researching more appropriate co-
solvents we investigated the use of alcohols, since they are chemically stable 
and may offer a range of advantageous properties.  The chain length of the 
carbon backbone was limited to below 5.  This was because in compounds 
with carbon backbone chain lengths of greater than 5 (i.e. hexanol upwards), 
the hydrophobic effect of the chain structure becomes greater than the 
hydrophilic influence of the hydroxyl group, which makes the overall molecule 
immiscible with water.  According to the above defined limiting conditions for 
vapour rate at RT and freezing temperature, two alcohols were selected: tert-
butanol and tert-amyl alcohol.  Tert-butanol however, was found to be unable 
to dissolve peptide at the desired concentration, even with the addition of 
acetic acid solution (data not presented).  Tert-amyl alcohol was able to 
dissolve m31 at a concentration of 50mg/ml and proinsulin B9-23 at 25mg/ml.  
However as tert-amyl alcohol is only partially miscible with water, it was 
necessary to test the miscibility of the ternary system: water, acetic acid and 
tert-amyl alcohol.  As shown in Figure 2.23, the ternary system of water, 
acetic acid and tert-amyl alcohol was able to form a uniform mixture when 
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their molar ratios fell beneath the plot curve (Fahim and Al-Muhtaseb, 1996).  
The optimised concentration of each component in the coating formulation to 
provide a miscible formulation is listed in Table 2.3.  These ratios were all 
within the plot curve as shown in Figure 2.23, which demonstrated that the 
coating formulation is a uniform, equilibrated ternary system.     
 
 
Figure 2.23 Equilibrium ternary system of water, acetic acid and tert-amyl alcohol 
at 298K.  Curves of solid line, dash line and dash-dot line were calculated using URTL, 
UNIQUAC and UNIFAC equilibrium models.  Data points were obtained by 
experimentation in the quoted publication (Fahim and Al-Muhtaseb, 1996). 
 
In order to dissolve the peptide in a uniform solution, it was important to add tert-
amyl alcohol, acetic acid solution and PVA/water sequentially.  If the solution was 
premixed the peptide did not dissolve as expected.  This might be because tert-
amyl alcohol disperses the peptide into fine particles rather than larger 
aggregates.  This approach increased the surface energy and contact area of 
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peptide to acetic acid, which charges the free peptide, increasing its solubility in 
water.  PVA behaves as a stabiliser and a viscosity enhancer for the formulation. 
 
Five excipients in three separate categories were tested: surfactant, dispersant 
and inclusion complex (Table 2.4).  For every 10µg peptide, 1µg of excipient was 
co-coated onto each MN array.  This resulting excipient:drug ratio was far lower 
than ratios reported in other studies using hydrophobic compounds (Gill and 
Prausnitz, 2007c).  All excipients were able to assist the most hydrophobic 
peptide, proinsulin B9-23-FITC to coat onto MNs evenly without overloading or 
material flaking (Figure 2.9).   
 
2.5.3. Factors that influence delivery efficiency using solid-coated MNs 
The delivery of the peptide to skin using solid-coated MN can be achieved by two 
interactive processes: removal of peptide from MN surface and peptide re-
dissolution into the skin.  The efficiency of the first process was demonstrated 
earlier in this study to be related to the MN surface morphology.  The efficiency of 
the second process is related to factors such as peptide solubility, the excipient, 
the thickness of the coating and the skin condition (for example, data obtained in 
human skin vs. mouse skin experiments illustrates this).  The combined effect of 
these two processes determines the final delivery dose of coated peptide.   
 
The delivery efficiency of a mildly hydrophobic peptide, WE14, was initially tested 
using Dermaroller® MNs.  The delivery efficiency of coated peptide was tested 
using human skin explants, and mouse skin in vivo.  UV-vis spectroscopy was 
used to quantify the amount of coated peptide delivered, or at least removed from 
the MN during skin insertion.  Using 5-TAMRA as the probe for detection the 
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linear range of peptide-5TAMRA at 559nm is 6.25µg/ml to 400µg/ml when using 
UV-vis spectrometry. 
 
Excipients were co-precipitated with peptides on MNs during the drying process 
to alter surface tension for coating and/or to promote de-coating in situ.  Addition 
of the surfactants, PF68 and PF127, led to the delivery of 30% of the coated 
WE14-5TAMRA.  The inclusion of the dispersants, PEG and PVA, increased the 
WE14-5TAMRA delivery to 40%.  It was shown that the ability of peptide/coating 
formulation with the addition of 2HPßCD to assist MN de-coating was between 
that of surfactants (PF68 and PF127) and dispersants (PEG and PVA).  The 
dispersant PVA showed the highest delivery efficiency among all five ‘de-coating’ 
excipients, possibly because PVA can dissolve more rapidly than other excipients 
and cause a ‘burst release’ of peptide into the skin.  Based on these studies PVA 
(MW2000) was chosen as the final excipient for use in the coating formulation. 
 
Dermaroller® MNs have been mainly used to create microchannels in the skin for 
transdermal delivery of materials that are applied after MNs are removed by 
patch or topical formulation, i.e. the poke/patch approach.  Another solid MN 
array used in our laboratories, supplied by GeorgiaTech, previously achieved 
90% delivery efficiency for the delivery of vitamin B coated onto the MN surface; 
the original loading was 3% w/v (Gill and Prausnitz, 2007a).  Using these MNs 
the delivery efficiency of WE14-5TAMRA increased from approximately 40% with 
Dermaroller® MNs to ≥80% using GeorgiaTech MNs.  This dramatic difference 
was generally independent of excipient effect, which indicated that it was 
probably due to the needle length or needle surface properties.  As shown in 
Figure 2.11, electro-polished GeorgiaTech MNs have a much smoother surface 
compared to Dermaroller® MNs.  To test the impact of surface finish, stainless 
steel MN arrays were manufactured and electro-polished in house.  As a result of 
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the electro-polishing process, MN dimensions were reduced by approximately 
12.5% (Figure 2.13).  In addition Dermaroller® MNs were coated with 20µm thick 
gold using an EMtech sputter coater to modify surface properties.   
 
WE14-5TAMRA peptide was not released from unpolished 500µm length MNs 
after skin insertion.  Electro-polishing MNs of similar length was shown to 
increase the delivery efficiency from 3% to 60%.  We propose that the change of 
surface properties following electro-polishing contributed to this change, by 
removing debris from needle surface and providing a more uniform, smooth 
surface, therefore absorption of the peptide on needle surface was minimised.  
Delivery efficiency using Dermaroller® MNs showed no difference before and 
after gold coating.  The reduction of MN surface roughness acts to minimise the 
absorbance of the coating material to the needle surface, which enables efficient 
delivery of the MN load on insertion/ removal.   
 
Peptide hydrophobicity is another factor, which may influence delivery efficiency.  
Using the human skin model, a less hydrophobic peptide; WE14, was delivered 
more efficiently than a more hydrophobic peptide, proinsulin B9-23  (Figure 2.16).  
This difference has also been observed when using the mouse skin model 
(Figure 2.17).   
 
The skin model and species is also a factor, which has been shown to influence 
delivery efficiency.  As shown in Figure 2.18, when using the same peptide, 
delivery efficiency was shown to be significantly different between human skin 
and mouse skin.  This is probably due to the biomechanical, physical and 
biological differences between human and mouse skin (Ghosh et al., 2000, Bond 
and Barry, 1988, Wong et al., 2011).  The major differences of skin between the 
two species are listed in the Table 2.5 (Wong et al., 2011).  Several experiments 
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have shown interspecies variation on permeation of the skin by drugs between 
mouse and human.  Narcotic analgesics were shown to permeate through 
hairless mouse skin quicker than human epidermis (Roy et al., 1994).  Another 
drug, 5-fluorouracil, was shown to permeate mouse skin ten times quicker than in 
human models in vitro (Sherertz et al., 1990).  Drug properties can also 
differentially influence skin permeation.  In one study, it was demonstrated that 
hydrophobic drugs flux through mouse skin much quicker than in human skin, 
whereas no difference was observed using a hydrophilic drug (Ghosh et al., 
1992).  This study is the first to show differences in MN delivery efficiency caused 
by interspecies variation.  As shown in Figure 2.6, the epidermis is between 60-
100µm thickness in human skin compared to 20µm thickness in mouse skin.  The 
thickness of the human dermis is between 1.6-2.6mm (Laurent et al., 2007) and 
the mouse dermis was measured to be 200-300µm thick Figure 2.6.  The delivery 
depth of peptide using 500µm electro-polished, solid-coated MN was 
approximately 300-400µm in human skin (Figure 2.7), which targets the 
epidermis and the upper layer of the dermis.  This delivery depth targets both the 
epidermal and the dermal layers in mouse skin.  Therefore, mechanical and 
structural differences between species at this delivery depth may determine the 
delivery efficiency of peptide.  The anatomical differences between human skin 
and mouse skin are listed in Table 2.5.  The main factors that could contribute to 
the delivery efficiency differences are: skin thickness, skin stiffness and the 
hydration state of the skin.  Other differences between human and mouse, 
however, may further influence the drug absorption and bioavailability.  
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Table 2.5 Anatomical differences between mouse and human skin (Wong et al., 
2011). 
 Mouse Human 





No rete ridges Rete ridges present 
Apocrine sweat 
glands 
Not present in skin, 
extensive in mammary 
glands 
Present in axilla, inguinal, and 
perianal skin regions 
Biomechanical 
properties 
Thin, compliant, loose 
Thick, relatively stiff, adherent 
to underlying tissues 
Hypodermal 
thickness 
Hair cycle-dependent Less variable 
Subcutaneous 
muscle layer 
Present throughout as 
panniculosus carnosus 
Present only in neck region 
as platysma 
Major method of 
wound healing 
Contraction 
Granulation tissue formation 
and re-epithelialization 
 
Formulation coating thickness has been shown to have an effect on the delivery 
efficiency of coated MNs (Cormier et al., 2004).  The aforementioned publication 
demonstrated that an increased coating thickness was shown to result in reduced 
delivery efficiency when the same amount of desmopressin was delivered.  To 
test this effect, 10µg of m31-TAMRA was coated on 5, 15 or 30 needles and 
delivered to mouse skin.  As shown in Figure 2.19, spreading the peptide over 15 
needles rather than just 5 needles tripled the delivery efficiency.  Delivery 
efficiency was further increased when the formulation was coated over 30 
needles.  With the reduced thickness of the drug coating on each needle, several 
parameters may change accordingly.  Firstly, with reduced coating thickness the 
sharpness of the needle would be better retained.  Secondly, although the skin is 
hydrated, a significant fraction of the water in the skin is associated with tissues 
or held within cells, leaving only the water contained within the extracellular fluid 
as the mobile fraction, thus over a restricted time frame, the water content in skin 
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is effectively limited.  This limitation on available water effectively limits the 
amount of peptide that is able to dissolve, reducing the peptides saturation 
threshold.  Thin coating helps alleviate this problem by distributing the dry drug 
over a larger area, thereby reducing the possibility of creating a drug saturated 
pocket effect.  Furthermore, when drug de-coats from MNs, it diffuses into the 
skin, creating a diffusion gradient.  The concentration of drug is highest near the 
needle, which may achieve local saturation and thereby reduce the rate of 
diffusion. This is one mechanism by which, within a set time frame, more drug 
can be released into the skin from a thin, rather than a thick coating.   
 
2.5.4. Design of solid MNs for minimally invasive delivery of peptide in both 
human and mouse skin models 
This project aims to develop and test solid MNs that can target immune-
processing cells in the epidermis and upper dermis.  Several considerations need 
to be considered when designing MNs for specific indications including needle 
length, needle shape, needle spacing and needle number. 
 
The total mouse skin thickness (epidermis plus dermis) is approximately the 
same as the human epidermal layer alone (including just the stratum corneum 
and viable epidermis), being approximately 60-100µm (Figure 2.6).  In MN 
penetration depth studies, MNs with 500µm long needles have been shown to 
penetrate deep enough to target the human epidermal and upper dermal layer, 
whilst being superficial enough not to cause extensive damage to the dermis. 
Increased MN length can cause extended skin damage and create larger pores 
than MNs with the same shape but of shorter length (Donnelly et al., 2010).  On 
the other hand, needle lengths of less than 300µm have been shown to cause 
inconsistent penetration in human skin (Verbaan et al., 2007).  Dermaroller® 
  112 
MNs of different lengths were tested for their ability to penetrate the skin whilst 
minimizing skin damage.  It was suggested that 500µm long MNs were sufficient 
to increase drug flux through skin.  Transepidermal water loss (TEWL) data 
suggested that skin surface damage caused by 500µm long MN sealed within 1-2 
hours post MN treatment (Zhou et al., 2010, Badran et al., 2009).   
 
The effect of MN geometry on insulin delivery and the resulting blood insulin 
concentration has been determined using a mathematical model (Figure 2.24).  It 
was suggested that “rocket shaped” MNs were able to increase blood insulin 
concentration more efficiently than other shaped needles (Al-Qallaf et al., 2009). 
One limitation of this study is that it assumes there is no boundary effect between 
viable epidermis and dermis, thus the defined partition coefficient between these 
two layers was as one.  Although this simple assumption did not reflect the 
structural differences between these two anatomically distinct layers, it provided 
a link between needle shape and drug diffusion pattern within the skin to a 
certain degree.  It was shown that “wedge shaped” needles distributed more 
insulin in the top layer of the skin than other types of needles.  In this project, we 
would like peptide to remain in the upper layers of skin for as long as possible to 
increase the probability of peptide uptake by skin resident DCs, especially 
epidermal LCs. Therefore, for this project, “wedge shaped” MNs were determined 
to be preferable. 
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Figure 2.24 Distribution of insulin within skin following delivery via MNs.  The 
penetration depth for all MNs was set to 140µm and insulin concentration gradient was 
calculated using a mathematic model in the quoted publication.  As shown in the 
concentration rainbow scale (right), red colour indicates the highest concentration of 
insulin and the dark blue colour indicates the lowest concentration.  Insulin concentration 
distribution is correlated to the shape of the needle with the same length.  D. Rocket 
shaped needle; E. Arrow shaped needle, F Wedge shaped needle (Al-Qallaf et al., 2009). 
 
Another MN modeling study suggested that MN sharpness inversely correlates 
with the amount of force needed to penetrate the skin and therefore correlates 
with the degree of skin deformation before MN penetration occurs.  A sharp 
needle is able to penetrate the skin with less force than a blunt needle. An 
increase in pressure, as would be required to penetrate the skin with blunt 
needles, is likely to result in greater trauma. Therefore skin irritation and damage 
can be minimized by using sharper needles (Boonma et al., 2012).   
 
In this study, MNs were designed to take into account the previous 
considerations.  Each MN array contained 10 needles with 1mm needle center-
center spacing to ensure efficient skin penetration (Figure 2.20 B).  Each needle 
was wedge shaped with dimensions of 500x200x100 µm (H x L x D), providing a 
sharp needle tip (Figure 2.20 A).  These stainless steel MNs were then electro-
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polished to remove surface debris in order to provide a smooth surface, reducing 
the absorption of peptide to the MNs.  Electro-polishing was shown to further 
sharpen the needle reducing the force required for effective skin penetration 
(Figure 2.20 C, D).  For in vivo testing, 3 MN arrays were assembled together 
using a novel MN applicator to provide a total of 30 MNs.   
 
The resulting stainless steel MN product was then tested for in vivo studies.  
Theoretically, 10µg of peptide was coated over 30 needles.  From the calibration 
curve we calculated the actual mass of the peptide available for coating onto 
MNs was 9.8µg (n=6), with no significant within-group differences (Figure 2.21).  
This indicates that the coating formulation remains uniform during storage (at -
80˚C) and during the coating procedure (at 4˚C for 3-4 hours).  The mass of 
peptide recovered from MNs was 9.4µg (96% coating efficiency) (Figure 2.21).  
The small loss of peptide may be due to traces of peptide left on the pipette tip 
after coating.  Two peptides were tested, WE14 and m31.  WE14 
(WSRMDQLAKELTAE) contains 43% hydrophobic residues and m31 
(YVRPLWVRME) contains 60% hydrophobic residues. The delivery efficiency of 
m31-5TAMRA was 20.39±4.96% and the delivery efficiency was 58.21±4.26% for 
WE14-5TAMRA, despite using the same initial coating amount (10µg) and 
insertion time (10 minutes).  The differences in the solubility of the two peptides 
accounted for the difference in both human and mouse skin delivery efficiency.  
This may be because solubility is an important parameter when delivering a dried 
material into a restricted volume aqueous compartment, as discussed in section 
2.5.3.  These results suggested that this design of MN could be used for mouse 
in vivo study and could deliver two peptides (m31 and WE14) for further study.    
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2.6. Conclusions 
In this study, a solid-coated MN system (MN design, bespoke holder and 
formulation) was developed for the delivery of hydrophobic peptides into the skin, 
with the eventual aim of delivering peptide therapeutics to induce tolerance in 
vivo. 
 
A novel coating formulation was developed which was suitable for hydrophobic 
peptides.  This formulation contains tert-amyl alcohol, acetic acid, water and 
PVA.  Results show that, using this formulation, peptides with a range of 
hydrophobicity can be coated onto MNs in a reproducible fashion.   
 
Several parameters have been demonstrated to influence skin delivery efficiency 
using solid-coated MNs.  These include the excipient used, the proportion of 
excipients in the coating formulation, MN surface properties, skin differences 
between species and the hydrophobicity of peptide.  It is also likely that the 
delivered dose from solid-coated MNs can only be expressed as a dose range 
rather than a relative accurate dose, as would be achieved using traditional ID 
injection. For future clinical applications it might be necessary to examine how 
age, sex and skin conditions affect delivery, and to normalise the differences 
caused by any fluctuation of dosage. 
 
Finally, a solid stainless steel MN array was designed for both human skin and 
mouse skin delivery.  Using this system, skin damage can be minimised and skin 
DC targeting can be enhanced.  The in vivo delivery study showed that this 
system was capable of delivering peptides, WE14 and m31 consistently.  
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Chapter 3 Inducing tolerance in vivo using 
solid-coated MN array 
3.1. Introduction 
3.1.1. Animal models for study of T1D 
In addition to disease models such as NOD and BDC2.5 TCR-Tg mouse (see 
1.1.3.), two other animal models were also used in this study, the NOD-SCID 
mouse and the Foxp3-FIR mouse. 
3.1.1.1. NOD-SCID mouse 
The SCID (severe combined immunodeficiency) mouse was reported to lack 
functional T and B lymphocytes due to a mutation in a gene in which codes for 
DNA repair enzymes (Bosma and Carroll, 1991).  In SCID mice, other immune 
cells such as APC and NK cells remain functional.  SCID mice with a NOD 
background are therefore useful for the study of autoimmune diseases, such as 
T1D.  Successful disease transfer to NOD-SCID mice can be achieved using 
either splenocytes from newly diagnosed diabetic NOD mice or BDC2.5 T cells 
(Christianson et al., 1993).  Without other regulation mechanisms as found in 
NOD mice, transferred islet specific effector T cells can be expanded rapidly in 
NOD-SCID mice.  Therefore, this disease model requires less time to show 
insulitis and can develop diabetes rapidly (showing high blood glucose level 
within 7-10 days post transfer) compared to the NOD natural disease progression 
model (12 weeks).  It has also shown a more consistent disease incidence 
compared to the NOD mouse.   
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3.1.1.2. Foxp3-FIR (Foxp3- internal ribosomal entry site-linked monomeric 
red fluorescent protein) mouse 
Foxp3 (forkhead box P3) has been shown to be an important regulatory gene in 
the development of Tregs, such as the CD4+CD25+ population (Hori et al., 2003, 
Fontenot et al., 2003) (details see section 1.4.1.3).  A mouse model was 
established within which Foxp3 locus was knocked in with a bicistronic reporter 
expressing red fluorescent protein (RFP) (Wan and Flavell, 2005).  It has been 
shown that only Foxp3+ cells co-express RFP.  These Foxp3+ RFP+ Tregs have 
been shown to retain their normal regulatory function.  The expression of RFP 
therefore can be used to quantitatively and qualitatively study Foxp3+ Tregs.  
Foxp3-FIR mice backcrossed with either NOD mice or BDC2.5 mice can be 
useful tools to study the function of polyclonal Tregs and monoclonal Tregs.   
 
3.1.2. CD4+ T cell function and proliferation assays 
After being primed by DCs, naïve CD4+ T cells will undergo activation, 
differentiation and proliferation.  CD4+ T cell activation and differentiation are 
described in Section1.4.1.  After differentiation, activated CD4+ T cells proliferate 
in an antigen specific fashion (clonal expansion), secreting growth factor IL2.  
This occurs in the first 1-2 days after CD4+ T cells are primed by DCs (Miller et 
al., 2004).  In the later stage of the proliferation phase, 2-5 days post activation, 
CD4+ T cells proliferate driven by IL2 and release the proinflammatory cytokine 
IFNγ (Mempel et al., 2004).  Proliferation assays provide a consistent and reliable 
readout.  Therefore, T cell proliferation assays are widely accepted as a useful 
measure of CD4+ T cell activity.  
 
The direct way to analyse T cell proliferation is to measure the change of cell 
numbers after activation.  In an in vitro experiment, cells can be labelled with a 
radioactive compound, such as [3H] thymidine, by direct addition to the culture 
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media.  During mitotic cell division, [3H] thymidine, a radioactive nucleoside, is 
incorporated into the nascent DNA that is synthesised.  Therefore the 
radioactivity count is proportional to total proliferated cell number in each culture 
well (Murat et al., 1990, Mosmann, 1983, Gillis et al., 1978).  One draw back of 
this method is that it measures the total cell number rather than a specific cell 
type.  This assay may also have a high background due to the non-specific 
stimulation, such as FCS in the culture media.   
 
A non-radioactive probe also can be used to label the T cell and monitor T cell 
proliferation in vivo, such as carboxyfluorescein diacetate succinimidyl ester 
(CFDA-SE).  CFDA-SE is a fluorescent dye, which is able to passively diffuse 
through the cell membrane and thereby enter the cell.  Within the cell, the ester 
end of CFDA-SE is cleaved by esterase and generates an amine reactive 
compound, carboxyfluorescein succinimidyl ester (CFSE) (Weston and Parish, 
1990).  CFSE is stable within cells and can be used for long term cell trafficking 
in vivo.  When CFSE labelled cells divide, the fluorescent intensity is halved for 
next generation.  Cells that need to be monitored in vivo can be labelled in vitro 
and transferred to the recipients.  The cell division within the in vivo environment 
can be analysed using flow cytometry after cells are isolated from examined 
organ (Quah et al., 2007, Quah and Parish, 2012).  In this way, a specific cell 
type and its sub generations can be analysed for their proliferation in vivo.   
 
Another way to assess the function of CD4+ T cells is by analysing the 
proinflammatory cytokines they release, such as IFNγ.  As described in section 
1.4.1.1, IFNγ is a proinflammatory cytokine released by Th1 effector T cells.  
IFNγ was shown able to promote CD4+ T cell proliferation (Reed et al., 2008).  
Therefore, the IFNγ released by CD4+ T cells is related to the activity of Teffs and 
therefore reflects the degree of inflammation or T cell activation present.  One 
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way to quantify IFNγ is using enzyme-linked immunosorbent assay (ELISA).  
ELISA is an immunoassay, which can detect a specific substance in liquid 
solution by using antigen specific antibodies (Engvall and Perlmann, 1971, Yalow 
and Berson, 1960).  The most widely used technique is a ‘sandwich’ ELISA 
assay, which uses two antibodies.  The first antibody is used to capture the 
antigen on a solid surface.  The biotin conjugated secondary antibody is then 
added to detect the antigen.  An enzyme, horseradish peroxidase (HRP), is then 
linked to the detecting secondary antibody and 3,3’,5,5’-Tetramethylbenzidine 
(TMB) is then added to produce a colour change.  This enzyme reaction can be 
stopped using a strong acid solution, such as 2M H2SO4.  ELISA is therefore 
useful for detecting cytokines, which are released by cells into the culture media 
(Leng et al., 2008).   
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3.2. Objectives 
• To evaluate peptide bio-activity after coating onto solid MNs using the 
aforementioned coating formulation (Table 2.3), which is reflected in the 
change of IFNγ levels as seen in the BDC2.5 T cell in vitro assay. 
• Using an intravital imaging system, to investigate factors that influence 
the clearance of fluorescent probe conjugated peptides from the skin of 
NOD mouse, following delivery by either MNs or ID injection  
• To optimise the CFSE labelled BDC2.5 T cell proliferation assay for 
evaluation of induced tolerance, including: 
Ø Optimise the CFDA-SE labeling protocol to enable effective 
labeling and manitain the viability of labeled CD4+ T cells 
Ø Optimise the CFSE labelled BDC2.5 T cell number which could be 
then used as a readout for induced tolerance 
• To understand how local skin clearance influences the trafficking of 
peptide in a NOD mouse model, showing the change in proliferation 
profile of CFSE labelled BDC2.5 T cells in different lymphatic organs. 
• Evaluate the efficacy of inducing peripheral tolerance in NOD mice using 
m31 and WE14, delivered either by solid-coated MNs or ID injection, 
showing the change in proliferation profile of CFSE labelled BDC2.5 T 
cells 
• Evaluate the efficacy of inducing peripheral tolerance in NOD mice using 
m31 and WE14, delivered either by solid-coated MNs or ID injection, 
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3.3. Methods 
3.3.1. Mice 
NOD, NOD-SCID, BDC-2.5-TCR-Tg.NOD, BDC2.5 TCR-Tg.Foxp3-FIR, Foxp3-
FIR.NOD mice were bred and maintained in a specific pathogen-free 
environment in the Joint Biological Services Unit at Cardiff University, U.K.  All 
experimental procedures were carried out in accordance with guidelines, as 
provided by U.K. Home Office project license regulations and following approval 
by the Ethical Review committee at Cardiff University. 
 
3.3.2. Preparation of a single cell suspension from murine SP (spleen) and 
LNs (lymph nodes) 
Mice were sacrificed in a sealed chamber filled with CO2.  The SP and different 
LNs (table 3.1) were removed, according to the Van den Broeck’s LN anatomy 
(Van den Broeck et al., 2006) and kept in RPMI1640 media on ice before use.  
LNs were placed in a petri dish and cells were released by mechanically 
dissociating LNs using 29G needles.  Cells were then filtered through a 70µm cell 
strainer, to remove tissue residues, and filtrate was then suspended in 1ml 
RPMI1640 media, which were kept on ice prior to use.  The SP was dissociated 
using a glass homogenizer and cells were filtered through a 70µm cell strainer 
into a 50ml falcon tube.  Cells were then pelleted at 400G for 5 minutes, lysed 
with 900µl of de-ionised H2O and immediately neutralized with 100µl of x10 PBS.  
Splenocytes were then filtered for a second time through a 70µm cell strainer and 
suspended in 20ml of RPMI1640 media and then kept on ice prior to use. 
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Table 3.1 Abbreviations for LNs used in experiments. 
Abbreviation Name 
PLN Pancreatic LN 
ALN Axillary LN (accessory) 
CLN Cervical LN 
ParaLN Para-aotic LN 
ILN Inguinal LN 
 
3.3.3. In vitro BDC2.5 T cell proliferation 
Single splenic cell suspensions (Section 3.3.2. ) were prepared from BDC2.5-
mice.  CD4+ T cells were then isolated using a mouse CD4+ T Cell Isolation Kit, 
as described in Section 3.3.9.  Single cell suspensions were also prepared from 
the SP of NOD mice and were irradiated using a gamma irradiator (delivering 
2000rad) to prevent proliferation of T cells but preserve the function of APCs.  
These irradiated splenocytes were then used as APCs.  CD4+ T cells 
(200,000/well) were co-cultured with the irradiated splenocytes (100,000/well) 
and 0.1, 1 or 10 ng/ml of m31 or 10, 50 or 100µg/ml of WE14 in complete media 
(RPMI 1640 media supplemented with 5% FCS, 2mM L-glutamine, 50µM 2-
Mercaptoethanol and 1U/ml penicillin/streptomycin) at 37˚C, using a 96-well 
round bottom plate.  Cells were then labelled with 20µl of 0.05µCi/µl [3H] 
thymidine in RPMI complete medium at days 0,1 and 2.  Cells were harvested 16 
hours after labelling, at each of these time points. Cell proliferation was 
expressed as radioactivity and read as CPM (counts per minute) using a beta 
counter (MicroBeta2, PerkinElmer, UK).  The stimulation index was calculated 
using the following equation: 
Equation 3.1 Equation used to calculate stimulation index (SI) from CPM.  𝑆𝐼 = [𝑐𝑝𝑚   𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑐𝑝𝑚 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 ] 𝑐𝑝𝑚(𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑑) 
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3.3.4. Evaluating the effect of MN coating formulation on m31 bioactivity 
A coating formulation of m31 was prepared according to table 2.3 and MNs were 
coated with 0.4µl of coating formulation as described in 2.3.5.  In order to 
evaluate whether the coating formulation influenced the bioactivity of m31, m31 
peptide or air dried m31-formulation was dissolved to a concentration of 0.2, 2 or 
20 ng/ml in RPMI 1640 media supplemented with 5% FCS, 2mM L-glutamine, 
50µM 2-Mercaptoethanol and 1U/ml penicillin/streptomycin (complete media).  
Splenocytes (300,000/well), which had been obtained from BDC2.5-TCR-
Tg.NOD mice were cultured in 96-well round bottom plates together with 100µl of 
complete media, to which 100µl of m31 solution was added to give a final 
concentration of 0.1, 1 or 10ng/ml respectively.  The plates were incubated at 
37˚C with 5% CO2 for 3 days.  IFNγ concentration in the supernatant was then 
analysed using ELISA. 
 
3.3.5. Cytokine detection of IFNγ using ELISA (enzyme linked enzyme-
linked immunosorbent assay)  
In order to detect IFNγ secreted by T cells, purified Rat Anti-mouse IFNγ antibody 
was diluted 1/500v/v using a coating buffer (carbonate buffer).  Diluted capture 
antibody (50µl) was then added into each well of a F96 CERT Maxisorp plate and 
the plate was then incubated at 4˚C overnight.  The coated plate was then 
washed with washing buffer (1x PBS, 0.05%v/v Tween-20) three times and 
blotted dry on a tissue paper.  The plate was then blocked by adding 100µl of 
blocking buffer (1%w/v BSA and 0.1%v/v tween-20 in PBS) to each well and 
incubated at 37˚C for 1 hour.  The blocking buffer was then discarded; the plate 
was washed three times with washing buffer and subsequently blotted dry.  To 
test the IFNγ level, 50µl of supernatant from cell culture or IFNγ standards using 
diluent (1%w/v BSA in PBS,) was then added to each well and incubated at 
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ambient temperature for 2 hours.  The supernatant was then discarded; the plate 
washed three times and then blotted dry.  The secondary antibody, biotin Rat 
Anti-Mouse IFNγ detection antibody (50µl/well), was then added and the plate 
was incubated at ambient temperature for 1 hour.  The antibody solution was 
then discarded; the plate was washed three times and then blotted dry.  To 
detect secondary antibody, 50µl of streptavidin, horseradish peroxidase (HRP) 
(1/4000v/v in diluent) was then added to each well and the plate was incubated at 
ambient temperature for 30 minutes.  The streptavidin-HRP solution was then 
discarded, the plate was washed three times and then blotted dry.  HRP was 
then reacted with 50µl 3,3,5,5-Tetramethylbenzidine (TMB) substrate solution in 
each well and the plate was incubated at ambient temperature for 5-15 minutes 
until the substrate was fully converted (conversion was indicated by blue colour).  
Once conversion had taken place, the reaction was stopped by adding 50µl of 
stopping agent (2M H2SO4).  Data was then acquired using a Multiwave plate 
reader set at 450nm to obtain the OD (optical density) value. 
 
3.3.6. Intravital imaging of peptide clearance from murine skin. 
Mice were kept under general anaesthetic using isoflurane during all processes 
including shaving, injection, MN treatment and imaging.  To minimise background 
signal, hair was removed from the back of the neck of NOD mice (5-7 weeks old) 
using a Contura Clipper.  For ID injection, 5TAMRA (fluorescent probe) 
conjugated peptides were dissolved in PBS to a final concentration of 40µg/ml for 
m31-5TAMRA and 120µg/ml for WE14-5TAMRA.  Then 2µg of m31 or 6µg of 
WE14 was administered by injecting a 50µl solution intradermally into the shaved 
skin area using a 0.5ml insulin injection syringe (29G x 0.5" x 100unit).  For MN 
treatment, three 5TAMRA conjugated peptide coated MN arrays were assembled 
in a specially designed holder and applied by pressing and holding MNs against 
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the shaved skin area for 10 minutes.  To image the treatment area, the mouse 
was placed onto the observation cabinet and Ex/Em 546nm/579nm pair was 
used to detect the 5-TAMRA-peptide (Figure 3.1).  During the imaging process 
the observation cabinet was kept at ambient temperature.  Mice were imaged 
before treatment then 0, 1, 4 and 24 hours post treatment.  Between each time 
point, the mouse cage was maintained at 26±1˚C, unless otherwise stated.  To 
investigate the effect of pre-treatment of mouse skin with topical application of 
BD cream, 0.1ml of DiproSone®0.05%w/w Cream was applied once per day for 
two days before peptide injection. 
 
White light images were taken before fluorescent images to allow anatomical co- 
localisation.  To minimise the fluorescent background noise from hair, for each 
displayed image the minimum fluorescent intensity of peptide-5-TAMRA was set 
as 50 and maximum intensity was set as 150.  Images were then analysed using 
Carestream MI software.  For each fluorescent image the same area of ROI 
(region of interest) was applied to the data.  Net fluorescent intensity for the ROI 
was calculated by subtracting the net intensity of the skin prior to treatment from 
the observed values obtained from the treated area.  The normalised relative 
intensity (NRI) for each tested mouse was then calculated using equation 3.2. 
 
Equation 3.2 Equation used to calculate normalised relative intensity (NRI). NRI   %max = Net  intensity  at  each  time  pointMaximum  net  intensity  for  each  tested  mouse×100% 
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Figure 3.1 Schematic view of Kodak in vivo imaging system.  The mouse was 
carefully placed in the observation cabinet with the treated area facing downwards.  
White light or fluorescent images were then taken by changing excitation and emission 
filters.  The mouse remained under general anaesthetic to prevent movement for the 
duration of the imaging process.   
 
3.3.7. Optimising CFDA-SE labelling conditions and concentration for 
BDC2.5 T cells using an in vitro assay 
CD4+ T cells were sorted from a population of BDC2.5 TCR-Tg mice splenocytes 
using a MACs CD4+ isolation column, as described in Section 3.3.9.  After 
sorting, cells were suspended at a concentration of 107/ml in RPMI1640 
supplemented with 10%v/v FCS.  Cells were then cultured in 10%v/v FCS/RPMI 
containing 0.1, 1, 3, 10 or 20µM of CFDA-SE for 5 minutes at ambient 
temperature, avoiding exposure to light.  Cells were then washed twice with 
10%v/v FCS/RPMI and pelleted at 400G for 5 minutes.  After washing, CFSE 
labelled CD4+ T cells (500,000/well) were co-cultured with irradiated splenocytes 
(500,000/well) together with 0.01, 0.1, 1 and 10ng/ml m31 in complete media for 
3 days.  After 3 days, cells were harvested, labelled with CD4 antibody (PE-cy7) 
and viability dye and the proliferation profile was then acquired using Flow 
Cytometry (Section 3.3.10. ).  To identify the CFSE labelled cell proliferation 
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profile, CD4+CFSE+ was first gated then the percentage of proliferated population 
was calculated by gating out the first generation, i.e. the percentage of cells with 
diluted CFSE labelling. 
 
3.3.8. Investigating the time and minimum CFSE+BDC2.5 T cell number 
required for in vivo studies. 
To determine the time that adoptively transferred BDC2.5 T cells require to 
proliferate in vivo, NOD mice (female, 6-8 weeks old) were adoptively transferred 
with 107 CFSE labelled BDC2.5 T cells by injection into the tail vein.  Mice were 
sacrificed at 1, 2, 3 and 4 days post transfer and cells from the PLNs were 
isolated (as described in section 3.3.2. ). The proliferation profile of CFSE 
labelled cells were then analysed using flow cytometry (Section 3.3.10. ). 
 
To determine the minimum number of BDC2.5 T cells that were required for 
reliable analysis, NOD mice (female, 6-8 weeks old) were adoptively transferred 
with 10x, 4x, 2x and 1x 106 CFSE labelled BDC2.5 T cells through the tail vein.  
Mice were sacrificed three days post transfer and cells from PLNs were isolated 
(as described in section 3.3.2. ) and the proliferation profile of CFSE labelled 
cells was analysed using flow cytometry (Section 3.3.10. ). 
 
3.3.9. CD4+ T cell isolation using MACs kit 
To obtain a purified population from a single cell suspension as prepared 
according to section 3.3.2. , CD4+ T cells were sorted using CD4+ MACs isolation 
kit (Miltenyi Biotec, UK) in a biosafety class II cabinet according to manufacturers 
instructions.  Briefly, 107 single cells were suspended in 40µl MACs buffer (0.5% 
BSA, 2mM EDTA (Ethylenediaminetera acetic acid disodium salt solution)) and 
10µl biotin-conjugated antibody cocktail solution (antibodies against CD8a, 
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CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105, Anti-MHC-class II, 
Ter-119 and TCRγ/δ. (information obtained from http://www.miltenyibiotec.com)).  
Cells were incubated at 4˚C for 5 minutes.  After incubation, cells were labelled 
with 30µl of MACs buffer and 20µl of anti-biotin magnetic beads per 107 cells.  
Cells were then incubated at 4˚C for another 10 minutes.  One LS column, filled 
with ferromagnetic spheres, was used for every 108 labelled cells and the total 
cell number was less than 2x109.  The column was placed on MACs magnetic 
separators and then washed with 3ml cold MACs buffer.  To isolate CD4+ T cells, 
the cell suspension was then applied on the column and the column was washed 
three times with 3ml MACs buffer.  CD4+ T cells were washed through the 
column and collected in a 50ml falcon tube.  Other (non-CD4+) cells were 
collected by removing the column from the magnetic field and flushing using 5ml 
MACs buffer.  
 
3.3.10. Using Flow cytometry to identify cell phenotypes 
Single cell suspensions were prepared (see section 3.3.2. ) and kept in ice cold 
staining buffer (1% w/v BSA and 0.1% sodium azide in PBS) at a concentration 
of 106/ml and were stained with both a viability dye and the relevant antibodies, 
as listed in Table 3.2, at 4˚C for 30 minutes in the dark.  Cells were then washed 
with 2ml staining buffer (1% w/v BSA and 0.1% sodium azide in PBS), pelleted at 
400G for 5 minutes and suspended in 200µl of staining buffer.  Cells were kept 
on ice in the dark before analysis.  Data were acquired using a CANON II FACs 
machine (BD Biosciences, UK) and analysed using software (FlowJo™). 
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Table 3.2 Antibody panel and dyes for cell staining used to identify CFSE labelled 
CD4+ T cell phenotype by flow cytometry.  
Ab/Dye Fluorophore Dilution v/v 
CD62L APC 1/400 
CD25 Pacific Blue 1/100 
CD4 PE Cy7 1/400 
CD44 Percp cy5.5 1/400 
Vb4 FITC 1/200 
Viability eFluor 780 1/1000 
CFSE CFSE / 
 
3.3.11. Trafficking of m31 in vivo 
NOD mice were injected with 2µg of m31 either by ID injection or by MN 
administration.  In order to examine m31 trafficking in vivo, either immediately or 
7 days after m31 delivery, CFSE labelled BDC2.5 T cells were adoptively 
transferred.  Briefly, splenocytes from BDC2.5-TCR-Tg.NOD mice were 
magnetically sorted using a CD4+ isolation kit (Section 3.3.9. ).  Isolated CD4+ T 
cells were labelled with CFSE (Section 3.3.7. ).  CFSE labelled CD4+ T cells 
(4x106 cells/200µl) were adoptively transferred by intravenous injection, using a 
short 27G needle, to the tail veins of NOD mice (Female, 5-7 weeks old).  Three 
days post transfer, ALNs, ILNs, CLNs, PLNs, SPs, and PaLNs (for abbreviations 
see Table 3.1) were mechanically dissociated and single cell suspensions were 
obtained.  Cell phenotypes and proliferation profiles were then determined by 
flow cytometry (Section 3.3.10. ). 
 
3.3.12. Administration of peptides 
To administer peptides by ID injection, peptides were dissolved in PBS to 
achieve concentrations of 40µg/ml and 120µg/ml for m31 and WE14 respectively.  
Mice were anesthetized using 2% isofluorane through an inhalation mask during 
the injection procedure.  The hair of the neck area was then removed using an 
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electric clipper. 50µl of peptide solution was then injected intradermally to the 
shaved area using a 29G insulin injection needle. 
 
To administer peptides by MNs, 10µg of peptide was coated on 3 arrays of solid 
stainless steel MNs with 30 needles in total (as described in section 2.3.5.  Mice 
were anesthetized and the hair of the neck area was removed using an electric 
clipper.  MNs were applied to the shaved area for 10 minutes (see section 2.3.7.  
Each MN application delivers, on average, 2µg m31 or 6µg WE14 (See Section 
2.4.4). 
 
3.3.13. Inducing tolerance in vivo 
On day 0, NOD mice were anesthetised using 2% isofluorane through an 
inhalation mask and peptide was administered either by ID or solid-coated MN 
array to the shaved neck area as described in section 3.3.12.  This was repeated 
on day 21.  A week after the second peptide administration, 4x106 CFSE labelled 
BDC2.5 T cells were transferred to mice through the tail vein using a 27G short 
needle.  3 days post transfer, mice were sacrificed and single cell suspensions 
were prepared from the ALN, PLN and SP.  The BDC2.5 T cell proliferation 
profile was then analysed using flow cytometry 3.3.10.    
 
3.3.14. Foxp3+BDC2.5 T cells suppressive effect in vivo 
CD4+ T cells were isolated from either BDC2.5-Foxp3-Fir mice or NOD-Foxp3-Fir 
mice (Section 3.3.9.  Then, CD4+Foxp3+ cells were sorted on a FACS AriaIII Cell 
Sorter.  NOD-SCID mice were adoptively transferred with either 200µl saline 
containing 1.5x106 Foxp3+BDC2.5+ T cells or 1.5x106 Foxp3+CD4+ T cells 
intravenously through the tail vein using a 27G (1/4inch) needle.  24 hours after 
the initial transfer, the same mice were co-transferred with 1.5x106/200µl 
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CFSE+BDC2.5+ T cells.  BDC2.5 T cell proliferation was then analysed using a 
Canto II flow cytometer three days after the second cell transfer. 
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3.4. Results  
3.4.1. Characterization of BDC2.5 T cells 
CD4+ T cell sub populations were compared between NOD mice and BDC2.5-
TCR-Tg.NODmice.  Splenocytes were stained with CD4 and Vβ4 antibodies to 
identify BDC2.5 T cells.  Figure 3.2 A and B show that, approximately 85% of 
CD4+ T cells were Vβ4 positive in BDC2.5-TCR-Tg.NOD mice splenocytes 
compared to approximately 10% in NOD mice.  When BDC2.5 T cells were 
stimulated with m31 they proliferated dramatically compared with cells co-
cultured with the WE14 peptide (Figure 3.2 C, D) (Sequence of m31 and WE14 
see Table 2.1).  BDC2.5 T cells were able to respond to 0.1ng/ml m31 after a 
three-day incubation time, the SI of which was 110 on average compared to 
background (background was 443 cpm).  On the other hand, at least 50µg/ml 
WE14 was needed to stimulate BDC2.5 T cells.  The SI of BDC2.5 T cells treated 
with 50µg/ml WE14 over 3 days had a mean value of 3.4, with an average 
background signal of 517cpm.   
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Figure 3.2 Identification of BDC2.5 T cells.  A. Representative flow cytometry plot of 
BDC2.5 T cell population in total CD4+ T cells from NOD mouse and BDC2.5-TCR-
Tg.NOD mouse.  B. A graph to illustrate differences in the percentage of BDC2.5 T cells 
detected in NOD and BDC2.5-TCR-Tg.NOD mouse SPs.  C. Proliferation of BDC2.5 T 
cell to m31 in vitro.  D. Proliferation of BDC2.5 T cell to WE15 in vitro.  n≥3, Mean±SD, 
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3.4.2. Evaluating the effect of MN coating formulation on m31 bioactivity 
M31 was coated on MNs and washed off to test whether the formulation and 
coating process altered the bioactivity of m31.  Stock m31 solution or re-
dissolved coating formulation were cultured with splenocytes of BDC2.5-TCR-Tg 
mice.  The bioactivity of the m31 was reflected by the level of IFNγ detected in 
the supernatant, which was released by BDC2.5 T cells.  The MN coated m31 
showed no significant differences at 10, 1 and 0.1 ng/ml when compared with 
relevant m31 controls.  Trace IFNγ was released by BDC2.5 splenocytes without 
m31 (Figure 3.3).  Cells cultured with blank formulation, i.e. formulation without 
m31, showed no activation over three days and there was no significant 
difference between splenocytes alone and blank control formulation.   
 
Figure 3.3 A graph to illustrate the impact of the MN coating process on the 
bioactivity of the m31 peptide.  Three concentrations of m31 (10, 1 and 0.1ng/ml) were 
added to splenocytes, either before or after dry coating on a MN device. Stimulation of 
the cells by the peptide was determined by measuring IFNγ levels. SP=splenocytes 
alone.  N=3, Mean±SD. Unpaired two tailed t-test; ns p>0.05.  Data were compiled from 
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3.4.3. Clearance of peptide from skin 
In order to investigate the PKs of the peptide in the skin, a Kodak in vivo imaging 
system was used to visualise the clearance of a peptide conjugated with a 
fluorescent probe (5-TAMRA), from murine skin (Figure 3.5).  The bioactivity of 
the conjugated peptide was tested and IFNγ ELISA results indicate that 5-
TAMRA did not alter the bioactivity of m31 (Figure 3.4).  Therefore, probe-
conjugated peptide was considered to be a valid model to predict the skin 
clearance of the therapeutic peptide.   
  
Figure 3.4 A graph to compare the bioactivity of the 1ng m31 peptide, both with 
and without 5-TAMRA conjugation.  Bioactivity was determined by quantifying the IFNγ 
levels in BDC2.5 splenocyte cell culture 3 days after addition of the m31 peptide. SP = 
Splenocytes alone; m31 = Splenocytes cultured with m31 and m31-5TAMRA = 
Splenocytes cultured with m31-5TAMRA. n=3, Mean±SD, two tailed t test, ns, p>0.05. 
 
3.4.3.1. Effect of environmental temperature on m31-5TAMRA peptide 
clearance from mouse skin 
Mice were ID injected with m31-5TAMRA and either kept in a cool environment 
(22±1˚C) or in a warm environment (30±1˚C).  At the lower temperature, the 
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and then quickly declined over the next 4 hours.  Over the next 20 hours the 
clearance rate slowed (Figure 3.6 A).  At a higher temperature (30˚C), there was 
a more rapid decline of fluorescence intensity during the first hour.  After this the 
profile of peptide loss from the skin was comparable to the clearance at lower 
temperature (Figure 3.6 A).  The area under curve (AUC) was calculated (Figure 
3.7 A).  AUC is inversely correlated with the clearance rate, therefore the higher 
the AUC the lower the clearance rate.  At lower temperature, 22±1˚C, the AUC is 
significantly higher than at 30±1˚C.  Based on this finding, it is important to 
control environmental temperature, particularly during the first 4 hours post 
delivery.  The ambient temperature of the clearance experiments was generally 
controlled at 26±1˚C and thus the clearance of the peptide was measured at 
ambient temperature unless stated otherwise. 
 
3.4.3.2. Effect of peptide solubility and administration method on clearance  
To determine whether the inherent aqueous solubility of the peptide would 
influence its clearance rate in skin, two peptides with different solubility were 
used, WE14 and m31.  When administered by ID, the NRI of WE 14-5TAMRA 
dropped sharply within 1 hour compared with m31-TAMRA.  At the 4 hour point, 
WE14-5TAMRA was almost entirely eliminated from the skin, while m31-TAMRA 
was still traceable.  Using MN delivery, both WE14-5TAMRA and m31-TAMRA 
showed similar local kinetics within the first hour.  However, WE14-5TAMRA was 
cleared more quickly from the local area from 1 hour onwards (Figure 3.6 B).   
 
The overall clearance rate from the skin was analysed using AUC.  AUC of both 
peptides, m31-TAMRA and WE14-5TAMRA, was significantly higher for MN 
delivery than for ID delivery (Figure 3.7 B).  The solubility of peptides was also 
shown to play a role in clearance over a 24 hour period.  The MN delivery of 
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m31-5TAMRA showed a significantly higher AUC than the relatively more soluble 
WE14-5TAMRA.  Although the AUC of ID delivery of m31-5TAMRA showed no 
significant difference compared to WE14-5TAMRA, a lower AUC of WE14-
5TAMRA was observed compared to m31-5TAMRA  (Figure 3.7 B).   
 
3.4.3.3. Local effect of pre-treatment of skin with BD cream on m31-
5TAMRA peptide clearance from skin 
In order to precondition skin DCs, a topical steroid (0.05% w/v betamethasone 
dipropionate cream) was applied once every 24 hours for two days before m31-
TAMRA administration.  M31-5TAMRA was either delivered by ID injection or 
using a 10 minute application of a solid-coated MN array.  Fluorescent images 
were taken using the Kodak in vivo imaging system at 0, 1, 4 and 24 hours. 
 
For peptide administered by ID injection, the maximum fluorescent intensity 
occurred immediately after injection (0 hour time point) and is shown as 100% 
(Figure 3.6 C).  At the 1 hour time point, NRI dropped to 80% without pre-
treatment and to approximately 40% with pre-treatment.  Within 4 hours, in both 
mice with and without pre-treatment, both NRIs drop down to near baseline levels 
(Figure 3.6 C).  As shown in Figure 3.6 C, a peptide deposition was clearly 
observed post MN treatment.  The maximum fluorescent intensity of peptide 
administered by MN was measured at 1 hour post delivery (Figure 3.6 C).  The 
trend of NRI is to increase by approximately 30% during the first hour, followed 
by a decline to ~50% of maximum NRI during the following 3 hours.  NRI then 
gradually declined to baseline levels within a 4 to 24 hour period (Figure 3.6 C).  
There was no statistically significant difference in NRI over the time period when 
comparing mice pre-treated with steroid and those without, except the initial NRI 
was slightly higher (60%) with preconditioning than without preconditioning 
(40%).  Topical application of BD cream pre-treatment showed no influence on 
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clearance of peptide delivered either by MNs or ID injection, demonstrated by the 
non-significant difference observed in the total clearance rate of treated and un-
treated groups over a 24 hour period (Figure 3.7 B).   
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Figure 3.5 Representative fluorescent intravital image for analysing peptide-
5TAMRA conjugate clearance from the skin.  Hair from the back neck area of NOD 
mice was removed using a clipper and 5-TAMRA conjugated peptides were administered 
to this area either using ID injection or MNs.  In order to study the clearance of peptide 
from skin, fluorescence intensity was measured at 0, 1, 4, and 24 hours post treatment.  
A. Representative fluorescent image of m31-TAMRA delivered by MN 0hr post delivery.  
The higher magnification image shows the MNs footprint at the 0 hour post delivery time 
point; B. Representative fluorescent images of m31-5TAMRA in skin before treatment, 
and at 0, 1, 4 and 24 hours post treatment.  M31-TAMRA and WE14-5TAMRA were 
administered either by ID injection or MNs, with or without pre-treatment with topical 
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Figure 3.6 Clearance curve of injected peptide-5TAMRA within the skin.  NRI of 
each treated area shown in Figure 3.5 was calculated for each treated mouse.  A. The 
effect of environmental temperature on clearance rate of m31-5TAMRA at 22±1˚C or 
30±1 ˚C; B. Effect of peptide solubility on clearance.  WE14-5TAMRA was compared with 
m31-5TAMRA administered either by ID injection or MNs.  (m31-5TAMRA treatment n=6, 
WE14-5TAMRA treatment n=3); C. Effect of pre-treatment with BD cream on clearance of 
m31-5TAMRA from skin.  Peptide was administered either by ID injection or MNs two 
days after BD cream pre-treatment (n=6).  Mean±SD.  Data were compiled from four 
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Figure 3.7 Graph showing the factors that influence the overall clearance rate of 
peptide from the skin.  A. AUC of graph Figure 3.6 A. showing the effect of 
environmental temperature on clearance.  Two tailed t test. *p<0.05.  B. AUC of graph 
Figure 3.6 B and C, showing the relationship of peptide solubility, delivery method and 
pre-treatment of BD cream on overall clearance rate.  Mean±SD. One way ANOVA with 
Tukey post test.  *p<0.05, ***p<0.001, ****p<0.0001.  AUC=area under curve 
 













































  142 
3.4.4. Optimising the CFSE labelling protocol for monitoring m31 trafficking 
and BDC2.5 T cell proliferation in vivo 
3.4.4.1. MACs sorting purity check 
In order to obtain purified CD4+ T cells from BDC2.5 mice, splenocytes from 
BDC2.5 mice were sorted using a MACs CD4 isolation kit.  Before sorting, 
CD4+CD8- T cells comprised approximately 30% of total splenocytes, of which, 
the majority were B cells and APCs (data not shown).  After sorting, a purified 
CD4+ T cell population was obtained with purity in the range of 85-90% of total 
live cells (Figure 3.8 A).  The majority (90-95%) of these purified CD4+ T cells 
were demonstrated to express the CD4+Vβ4+ phenotype (Figure 3.8 B), which 
identified these cells as BDC2.5 T cells.  Therefore, in this project, purified CD4+ 
T cells from BDC2.5 TCR-Tg mouse’s splenocytes were considered to be pure 
BDC2.5 T cells.   
 
  143 
 
 
Figure 3.8 Purity of CD4+ T cells after using a MACs CD4 isolation kit.  A. 
Representative flow cytometry plot showing the percentage of CD4+ T cell population 
before and after splenocytes were sorted with MACs CD4+ isolation kit.  B. 
Representative flow cytometry plot showing the percentage of CD4+Vβ4+ (BDC2.5) T cell 
subset in whole CD4+ T cell population, after splenocytes were sorted with MACs CD4+ 
isolation kit.   
 
3.4.4.2. Optimizing CFDA-SE labeling conditions and concentration for 
BDC2.5 T cells using an in vitro assay 
After purification, BDC2.5 T cells were labelled using a fluorescent dye (CFDA-
SE), which enabled the proliferation of BDC2.5 T cells to be monitored, either in 
vitro or in vivo.  When cells were stained according to the manufacturer’s 
instructions, i.e. cells were stained in PBS (37˚C) containing 1µM CFDA-SE dye 
for 15 minutes, low cell viability was observed (Figure 3.9 A).  After optimising the 
incubation time (5 minutes) and incubation media (10%v/v FCS/RPMI) according 
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a method by Quah, B.J. et.al, the viability of CD4+ cells after labelling was 
improved to over 90% (Figure 3.9 B) (Quah and Parish, 2012, Quah et al., 2007).  
Cells also showed increasing fluorescent intensity when using increasing 
concentrations of CFDA-SE dye for labelling (Figure 3.9 C).  Both 10µM and 
20µM CFDA-SE were able to label cells sufficiently to differentiate them from the 
unstained control, providing separation of the sub-populations for proliferation 
analysis.  After CFSE labelling, BDC2.5 T cells were stimulated with m31 and 
were allowed to proliferate over a three-day incubation period.  A concentration of 
20µM CFDA-SE produced a sub-generation of BDC2.5 T cells with sufficient 
resolution from the untreated sample (Figure 3.9 D).  Therefore for in vivo 
proliferation experiments, 20µM of CFDA-SE was used to stain every 107/ml 
CD4+ T cells.  
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Figure 3.9 Optimisation of CFDA-SE labelling protocol to monitor m31 trafficking 
and BDC2.5 T cell proliferation in vivo.  The toxicity of CFDA-SE dye was determined 
by testing the viability of BDC2.5 T cells after labelling.  Representative flow cytometry 
plot showing the percentage of viable BDC2.5+CD4+ cells after labelling using either A. 
according to manufacture’s protocol or B. optimised protocol.  A serial concentration of 
CFDA-SE dye (0.1µM-20µM) was tested to determine sufficient staining.  C. Fluorescent 
intensity of labelled BDC2.5 T cells using different concentrations of CFDA-SE dye were 
shown in histogram overlay.  Both 10µM and 20µM were able to stain cells sufficiently 
without exceeding the detection limit of the flow cytometer used.  D. Histogram overlay 
showing the generation peaks of BDC2.5 T cells labelled either with 10µM or 20µM 
CFDA-SE after co-culture with APCs and 10ng/ml m31 for 3 days.  
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3.4.4.3. Optimizing the proliferation time required for transferred 
CFSE+BDC2.5 T cells in vivo 
In order to investigate the time that T cells required to proliferate in vivo, 10x106 
CFSE labelled CD4+ (BDC2.5) T cells were transferred to female NOD mice (5-7 
weeks old).  After 1, 2, 3 and 4 days, cell proliferation in the PLNs was assessed.  
Endogenous antigen of BDC2.5 T cells is located in the pancreas and presented 
to T cells in the PLN, therefore the proliferation of transferred BDC2.5 T cells in 
the PLN represent the degree of the endogenous activation.  Mice without cell 
transfer had no CFSE+ labelled cells (Figure 3.10 A).  One day after cell transfer, 
CFSE+ cells were found in the PLN, but no clear cell division was observed.  At 
least 4 generations of CFSE+ CD4+ T cells were detected in the PLN on day 2.  
On day 3, six generations were observed in the PLN and by the sixth generation 
the signal from CFSE stained cells was only slightly greater than that in 
unstained cells (Figure 3.10 B).  On day 4 the detection limit was reached, which 
means the last two subgenerations of CFSE+CD4+ T cells could not be 
distinguished from the background unstained population (Figure 3.10 B).  
Therefore for these experiments, mice were only examined up to 3 days post 
CFSE transfer. 
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Figure 3.10 Representative flow cytometry plot showing the time course of 
CD4+CFSE+ T cells in vivo proliferation in PLN. A. Negative control mouse without 
CD4+CFSE+ cell transfer.  B. CD4+CFSE+ proliferation profile in the PLN, 1, 2, 3 and 4 
days post transfers.   
 
3.4.4.4. Titrating the minimum number of CFSE labeled BDC2.5 T cells 
required for in vivo tolerance study 
The minimum number of CFSE labelled CD4+ T cells, which were required to 
generate a reliable signal was also tested.  10x, 4x, 2x or 1x106 CFSE labelled 
BDC2.5 T cells were adoptively transferred to NOD mice and endogenous 
proliferation in the PLN was analysed.  Three days post transfer, CFSE labelled 
BDC2.5 T cells were gated as shown in Figure 3.11 A.  It was possible to 
distinguish transferred CFSE-labelled BDC2.5 T cells from the endogenous CD4+ 
T cell population for each of the groups.  The low initial cell numbers, 1 x106 and 
2 x106, were unable to generate distinct subgenerations.  When the transferred 
cell number was increased to 4 x106 and 10 x106, distinguished subgenerations 
could be observed.  Transfer of 4 x106 cells resulted in, on average, 0.9% CD4+ T 
cells in the PLN that were CFSE labelled, with a total recorded cell number of 
between 4000 and 5000 (Figure 3.11 B and C.).  This provided enough cells in 
each generation to allow for adequate proliferation studies. 
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Figure 3.11 Titration CFSE labelled cells in vivo.  A. Representative flow cytometry 
plot of CD4+ cells in PLN.  Gated population showed the percentage of CFSE+CD4+ cell 
three days after the NOD mouse was transferred with 10x, 4x, 2x or 1x106 CFSE+BDC2.5 
T cell;  B. CD4+CFSE+ as a percentage of total CD4+ T cells in PLN;  C. Absolute 
CD4+CFSE+ cell number in PLN three days post transfer.  n=3. Mean±SD.  M=106 
 
3.4.5. Tracking m31 in vivo using CFSE labelled BDC2.5 T cells 
Female NOD mice (6-8 weeks old) were treated with 2µg of m31; delivered either 
by ID injection or by solid-coated MNs, and mice were immediately adoptively 
transferred with CFSE labelled BDC2.5 T cells.  Peptide distribution after delivery 
was determined by determining the proliferation of BDC2.5 T cell populations in 
different LNs and the SP.  Without any exogenous antigen, BDC2.5 T cells only 
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proliferated in the PLN, where endogenous antigen was presented.  No cell 
division was observed in other LNs or the SP (Figure 3.12).  In the peripheral 
lymphoid organs, 3-4% CFSE+CD4+ T cells were demonstrated to have 
proliferated, which was considered to be a non-specific proliferation response.  
For mice treated with 2µg of m31 (by either ID injection or MNs), proliferation of 
BDC2.5 T cells was not only observed in the PLN but also in the LNs that drained 
the treatment site; the skin of the neck, i.e. the ALN.  There were no activated 
BDC2.5 T cells observed in other LNs, even in the ILN; another skin draining LN 
situated in the hind limb (Figure 3.12).  Greater proliferation was also observed 
when m31 was administered by solid-coated MN array rather than by ID injection 
at both 3 and 10 days post injection (Figure 3.13 C).  T cells also showed a more 
consistent proliferation profile between experiments for MN administration rather 
than ID administration.  Both 3 days and 10 days post ID injection of m31, the 
proliferation profile of CFSE+CD4+ BDC2.5 T cells in the PLN was not significantly 
altered (Figure 3.13 D).  No enhanced stimulation of transferred CFSE+CD4+ 
BDC2.5 T cell was observed in the PLN when m31 was administered using solid-
coated MNs when compared with ID injection (Figure 3.13 D).  
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Figure 3.12 Representative flow cytometry plots of CD4+CFSE+ BDC2.5 T cell 
proliferation profiles in different LNs and the SP.  NOD mice were treated with 2µg of 
m31 to the shaved neck area using either ID injection or solid-coated MN arrays. CFSE 
labelled BDC2.5 T cells (4x106) were then immediately transferred through the tail vein.  
Three days post-transfer, the proliferation profile of BDC2.5 T cells was analysed using 
Flow cytometry.  The gate shows the divided population of transferred BDC2.5 T cells.   
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Figure 3.13 Tracking the distribution of m31 in vivo using CFSE labelled BDC2.5 T 
cells.  A. and B. trafficking protocol at 3 or 10 days post m31 administration.  BDC2.5 T 
cell proliferation profile in the ALN (C.) or the PLN (D.) was analysed 3 or 10 days post 
m31 administration.  n≥3. Mean±SD.  One way ANOVA with Tukey post test, *p<0.05, 
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3.4.6. Inducing peripheral tolerance in vivo 
3.4.6.1. Expanding antigen specific Tregs in the BDC2.5 TCR-Tg.Foxp3-FIR 
mouse  
BDC2.5 TCR-Tg.Foxp3-FIR mice were used to determine the effect of 
administration of antigen WE14 (an endogenous antigen), in vivo.  WE14, a weak 
stimulant of BDC2.5 T cells (section 3.4.1. was used to induce tolerance instead 
of a strong stimulant, m31, which is lethal for monoclonal Tg mouse, i.e. BDC2.5 
TCR-Tg mice.  BDC2.5 TCR-Tg.Foxp3-FIR mice were injected with 6µg of WE14 
and 7 days later the phenotype of the CD4+ cells was analysed (Figure 3.14 A).  
The CD4+Foxp3+ was thought to be a Treg marker as has been described in 
many publications.  No significant difference was observed in CD4+Foxp3+ Treg 
populations in the PLN, ALN or SP before or after WE14 treatment.  The 
subpopulations of CD4+Foxp3+ Tregs, such as CD4+Foxp3+CD25+ and 
CD4+Foxp3+CD62L+, were increased significantly in the PLNs of the WE14 
treated group compared with controls (Figure 3.14 B).  However, these two CD4+ 
T cell subsets comprise a small percentage of the total CD4+ T cell population, 
approximately 1.5% in the untreated group and 3% in the WE14 treated group.  
No difference was observed in the Treg population in the ALN or SP.   
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Figure 3.14 Expanded antigen specific Treg cell population in BDC2.5 TCR-
Tg.Foxp3-FIR mouse following a single dose of WE14 delivered by ID injection.  A. 
Protocol of expanding Treg in vivo in BDC2.5 TCR-Tg.Foxp3-FIR.  B. CD4+ Treg 
phenotype before and after WE14 treatment in PLN, ALN and the SP.  n=3. Mean±SD.  
Two tailed t test, * p<0.05, **p<0.01 
 
3.4.6.2. CD4+Foxp3+ BDC2.5 T cells suppress the immune response in vivo 
As demonstrated previously, WE14 was able to expand the CD4+ T cell 
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was to determine whether these BDC2.5 T cells with a Treg phenotype possess 
regulatory function, showing prevention of transferred naïve BDC2.5 T cells from 
becoming effector T cells in NOD-SCID mouse.  Secondly, we are interested in 
whether this inhibitory effect is TCR specific.  In order to investigate the stated 
question, NOD-SCID mice were adoptively transferred with BDC2.5 T cells or co-
transferred with CD4+Foxp3+ Tregs from Foxp3-FIR.NOD mice or BDC2.5 TCR-
Tg.Foxp3-FIR mice.  No change of proliferation profile of the transferred BDC2.5 
T cells in NOD-SCID mice was observed when co-transferred with polyclonal 
CD4+Foxp3+ Tregs, compared to NOD-SCID mice without co-transferred with 
polyclonal Tregs.  However, mice that were co-transferred with BDC2.5 Foxp3+ 
Tregs, which shared the same TCR with Teffs (BDC2.5 T cells) showed a clear 
inhibition of proliferation in vivo (Figure 3.15 A).  There were no obvious 
phenotype changes in total BDC2.5 T cell population in all three groups.  
Interestingly, CFSE labelled BDC2.5 T cells showed some shift in their 
phenotypes (Figure 3.15. C), with an increased expression of CD62L and 
decreased expression of CD44.  There was also some change in the expression 
of CD25, however these changes were less clearly demonstrated.   
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Figure 3.15 BDC2.5 Foxp3+ Tregs suppress the antigen specific immune response 
in vivo.  NOD-SCID mice were adoptively transferred with either 1.5x106 Foxp3+BDC2.5+ 
T cells or 1.5x106 Foxp3+CD4+ T cells intravenously.  Twenty-four hours after the initial 
transfer, the same mice were co-transferred with 1.5x106 CFSE+BDC2.5+ T cells.  
BDC2.5 T cell proliferation in PLN was then analysed using a Canto II flow cytometer 
three days after the second cell transfer.  A. Histogram overlay of CFSE labelled BDC2.5 
T cell proliferation profile.  Cells were isolated from the PLN of NOD-SCID mice co-
transferred with CFSE+ BDC2.5 T cells and Foxp3+ BDC2.5 Tregs.  The expression of 
CD62L, CD25, and CD44 was analysed for either all BDC2.5 T cells (B) or CFSE labelled 
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3.4.6.3. Peripheral tolerance could be induced in NOD mice by using WE14 
delivered by solid-coated MNs, showing a dose sparing effect compared to 
ID injection.   
As demonstrated above, antigen specific Tregs were shown to have a 
suppressive effect on antigen specific Teffs in vivo, showing a reduction of 
transferred Teff proliferation.  This provided a tool for understanding whether 
using an ASI approach to induce tolerance can be applicable in a more 
comprehensive T1D disease model, NOD mice.  It was also important to 
understand whether a single antigen (rather than an antigen cocktail) could 
induce tolerance.  Therefore, the aim of this section was to investigate whether 
tolerance can be induced using peptide coated MNs or ID injection in female 
NOD mice by analysing the proliferation profile of transferred BDC2.5 T cells in 
the PLN. 
 
NOD mice (Female, 4-5 weeks old) were treated on two occasions with either 
m31 or WE14, with a three-week interval between treatments.  A week after the 
second treatment, CFSE labelled BDC2.5 T cells were adoptively transferred 
through the tail vein to determine the proliferation profile (Figure 3.16 A).  There 
was no significant reduction in BDC2.5 T cell proliferation in the PLN when using 
m31 antigen treatment compared with the untreated group (Figure 3.16 B).  
When using a 6µg dose of WE14, both solid-coated MNs and ID injection 
treatment groups showed a reduction in proliferation in the PLN, although only 
the solid-coated MN treated group showed a statistically significant difference to 
the control group.  In general, 51.3% CD4+CFSE+ cells proliferated in the PLN of 
NOD mice without any treatment.  After treatment with WE14, the 6µg ID 
injection showed a 9% reduction in proliferation while the solid-coated MN array 
treated group showed a 15% reduction.  Increasing the WE14 dose further 
reduced BDC2.5 T cell proliferation.  The proliferation of transferred cells was 
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reduced by 28.53% when the dose delivered by ID injection was increased from 
6 µg to 50µg (Figure 3.16 C).  
 
Phenotypic changes were also examined in order to further support the 
proliferation data.  There was no difference observed in the level of CD25+ 
expression within either intrinsic CD4+ T cells or transferred CD4+CFSE+ T cell 
populations (data not shown).  In consideration of the previous observation, the 
CD62L+CD44- subpopulation (naïve T cells) was analysed for all CD4+CFSE+ 
cells (Figure 3.16 D).  Before transfer, on average, 51.5% CFSE+CD4+ BDC2.5 T 
cells were shown as CD62L+CD44-.  After transfer to NOD mice, without any 
treatment, only 22.8% of transferred CFSE+CD4+ BDC2.5 T cells retained their 
CD62L+CD44- naïve phenotype.  A higher percentage of CFSE+CD4+ BDC2.5 T 
cells were shown as CD62L+CD44- (29.5%) when NOD mice were treated with 
two rounds of 6µg WE14 using solid-coated MNs (Figure 3.16 E).  Using the 
same dose, WE14 administered by ID injection showed no significant change in 
BDC2.5 T cell phenotype (23.4%), when compared to the control.  By increasing 
the dose to 50µg (ID), WE14 was shown to be able to preserve a significant 
proportion of naïve BDC2.5 T cells (35.5%) compared to control and low dose 
(6µg) groups.   
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Figure 3.16 Peripheral tolerance was shown to be induced in NOD mice by using 
WE14 delivered by solid-coated MNs, showing a dose sparing effect compared to 
ID injection.  A. Protocol for inducing tolerance in NOD mouse using m31 or WE14.  
Young female NOD mice were treated with two rounds of peptides and induced tolerance 
was reflected as a change in the proliferation profile of transferred CFSE+BDC2.5+ T 
cells. B. Proliferation profile of CD4+CFSE+ BDC2.5 T cells in the PLN was analysed in 
mice treated with 2µg of m31 either delivered by ID injection or MNs.  C.  Proliferation 
profile of CD4+CFSE+ cells in PLN was analysed in mice treated with 6 or 50µg of WE14 
either delivered by ID injection or MNs.  D. Gating strategy for CD62L+CD44- population 
in CD4+CFSE+ BDC2.5 T cells.  E. Phenotypic changes of CD4+CFSE+ BDC2.5 T cells 
after transfer to NOD mice with or without WE14 treatment.  n≥4. Mean±SD.  One way 
ANOVA with Tukey post test, *p<0.05, ***p<0.001, ****p<0.0001.  Data were compiled 
from five separate experiments. Control=NOD mice without injection of peptides; 
m31+MN=NOD mice treated with m31 by solid-coated MNs; m31+ID=NOD mice treated 
with m31 by ID injection; W+MN=NOD mice treated with WE14 by solid-coated MNs; 
W+ID 6µg= NOD mice treated with 6µg of WE14 by ID injection; W+ID 50µg= NOD mice 
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3.5. Discussion 
3.5.1. Characterization of the BDC2.5-TCR-Tg mouse 
It was reported that the TCR of BDC2.5 T cells is composed of Vα1 and Vβ4 
subunits (Haskins et al., 1989).  A lack of a Vα1 antibody means that the 
CD4+Vβ4+ BDC2.5 T cell phenotypic feature was compromised in this project.  
Approximately 85% of CD4+ T cells from BDC2.5-TCR-Tg mice were shown to be 
Vβ4+, while in NOD mice only 10% were shown to be Vβ4+.  These CD4+Vβ4+ 
cells from BDC2.5 TCR-Tg mice were able to react with m31 in the presence of 
irradiated APC.  M31 has been reported to be a strong stimulus for BDC2.5 T 
cells (Dai et al., 2005).  The high reactivity of BDC2.5 T cells to m31 confirmed 
that the BDC2.5 T cells from mice which were bred in-house, were functional and 
were comparable with those in the published data.  Another peptide, WE14 which 
has a lower affinity for BDC2.5 TCR has also been tested.  At least 50µg/ml of 
WE14 was needed to promote the proliferation of BDC2.5 T cells in vitro.  
Therefore, because of the higher potency of m31, it was chosen as an indicator 
peptide to test for BDC2.5 T cell activity and peptide trafficking in vivo 
experiments.  Both peptides were tested in the NOD mice for their ability to 
induce tolerance in following experiments.   
 
3.5.2. Evaluating the effect of coating formulation on m31 bioactivity 
IFNγ is a pro-inflammatory cytokine mainly secreted by Th1 and cytotoxic T cells 
or NK (natural killer) cells when they are activated by antigens, mitogens, or 
alloantigens (Schroder et al., 2004).  M31 bioactivity was therefore quantified by 
culturing BDC2.5 T cells in the presence of m31 and quantifying IFNγ in the 
culture supernatant using ELISA.  This was used to assess the bioactivity of m31 
in a solid-coated MN coating formulation.  There was no significant difference 
between coating formulation and the m31 PBS controls, as shown in Figure 3.3.  
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This indicates that the m31 did not lose its bioactivity during the formulation, 
preparation, storage or coating processes.  Blank formulation, i.e. PVA2000 
alone, did not trigger any non-specific proinflammatory immune response.  
PVA2000 is known to be a useful excipient for in vivo and in vitro medical 
applications due to its documented stability, biocompatibility and low toxicity 
(Alexandre et al., 2014).  Low IFNγ levels therefore indicated that PVA did not 
cause a significant inflammatory response when it is used in a solid-coated MN 
formulation.  Therefore, we would expect PVA 2000 to have a negligible effect in 
terms of its ability to trigger an inflammatory immune response in the in vivo 
experiments.  This provides a safe foundation for solid-coated MN for inducing 
tolerance in the following experiments. 
 
3.5.3. Pharmacokinetics of peptide administered by solid-coated MNs or ID 
injection 
3.5.3.1. Factors that influence the in vivo clearance of peptides from mouse 
skin 
One of the objectives of this project was to target skin DCs using different 
administration methods.  It was thought that the longer the peptide remains in the 
skin the more likely it is that peptide can be taken up by skin DCs, especially LCs 
which have a slow migration rate and low regeneration rate ((Kissenpfennig et 
al., 2005, Rattanapak et al., 2014)).  Therefore, it is necessary to understand the 
factors that influence the clearance of peptide from the local skin environment.   
 
Body temperature was shown to be a factor which could influence local clearance 
of the peptide (Neelam, 2012).  M31 was shown to be cleared from the skin more 
quickly when mice were kept at 30˚C rather than at 22˚C during a 24-hour 
monitoring period (Figure 3.6 A, Figure 3.7 A).  This could be because an 
increase in temperature can increase the blood flow in the microcirculation of the 
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skin, which in turn increases the diffusion and distribution rate of compounds 
from the skin to the circulatory system (Neelam, 2012, Trabaris et al., 2012).  In 
order to maintain experimental stability, mice were therefore kept at 22±1˚C in 
subsequent experiments. 
 
Solubility of the drug itself and the administration route used were other factors 
which influence the clearance of peptides from the skin.  The fluorescent signal of 
the peptide with higher solubility (WE14-5TAMRA) had declined more quickly 
than the lower solubility peptide (m31- 5TAMRA) four hours post administration 
by ID injection (Figure 3.6 B), however, no significant change in the AUC was 
observed (Figure 3.7 B).  This may be because when using ID injection, WE14-
5TAMRA and m31-5TAMRA were already in solution, which results in the effect 
caused by solubility difference being eliminated.  Therefore, the rate of peptide 
diffusion from the skin to systemic circulation was the main contributor to the skin 
clearance rate.  On the other hand, peptides delivered by solid-coated MN 
showed a different clearance profile.  There are two factors, which may contribute 
to the skin clearance of peptides when using solid-coated MNs: dissolution rate 
and diffusion rate.  Both rates were correlated with the solubility of peptide.  
Therefore, peptide with low solubility would remain in the skin longer over a 24-
hour monitoring period than a more soluble peptide, which is reflected in 
significant differences on AUC, which inversely correlates with the overall 
clearance rate. 
 
One of the striking observations was that the administration method was shown 
to be a major contributory factor to the rate of skin clearance.  Compared with a 
matching dosage administered by ID injection, peptides, either m31-5TAMRA or 
WE14-5TAMRA, delivered using solid-coated MNs cleared from skin significantly 
more slowly than the same peptide delivered via ID injection (Figure 3.7 B).  As 
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discussed above, the skin clearance rate of peptide administered by MN was 
determined by dissolution rate and diffusion rate.  On the other hand, clearance 
following ID delivery was mainly determined by diffusion.  When m31-5TAMRA or 
WE14-5TAMRA were delivered by solid-coated MNs, peptide concentration 
reached saturation in the local area of tissue due to the limited solubility of 
peptide in a restricted skin area.  Therefore, any excess delivered peptide would 
remain in the solid state, thus acting as a reservoir and prolonging delivery.  The 
rise of RNI one hour after solid-coated MN delivery further supports the 
hypothesis that peptide was delivered to the skin in the solid state.  The 
excitation and emission pair of 5-TAMRA is different in solid state and in aqueous 
phase.  The detector pair in the Kodak in vivo imaging system was set at 
553nm/576nm, which does not image the solid-fraction of delivered peptide-
5TAMRA.  Another potential explanation for the rise of NRI is that the relatively 
densely packed probe (solid state) could have a self-quenching effect (Christie et 
al., 2009, Kuzmanich et al., 2011).  Solid-state m31-TAMRA or WE14-TAMRA 
dissolves within the skin compartment due to tissue hydration, which results in a 
rise of RNI one hour after solid-coated MN treatment.  The pocket deposition 
effect of solid-coated MNs therefore provides a prolonged release profile of 
peptide compared with ID injection.  This results in slower skin clearance of 
peptide (Figure 3.7 B).  The slowed release of peptide within skin enables skin 
DCs expose to the peptide for longer.  This prolonged exposure time further 
enhanced the chance of the skin DCs uptake peptide/autoantigen (as discussed 
in section 3.5.3.2. ).  
 
In order to precondition the skin, a topical application of BD cream was used.  
GCs are a group of common immunosuppressive and anti-inflammatory drugs.  
Local treatment with GCs can influence the maturation of DCs and thereby 
induce Tregs (Kerzerho et al., 2012, Stary et al., 2011b, Koopman et al., 2001, 
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Pan et al., 2001a).  The mechanism by which GCs induce Tregs is related to its 
dosage, local/systemic metabolism, and cell signalling.  Short-term topical 
application of GC treatment is well tolerated, however long term treatment may 
cause a loss of Langerhans cells in the epidermis (Furue and Katz, 1989a, 
Belsito et al., 1982a, Ashworth et al., 1988, Grabbe et al., 1995).  Within a short 
treatment window (24 hours) topical application of BD cream was shown to down 
regulate expression of HLA DR on human epidermal cells (Section 4.4.1.1. ).  BD 
cream was also shown to increase the secretion of IL10 in mouse epidermal cells 
(Section 4.4.1.3. ).   
 
In the first hour post treatment, a rapid decline of NRI was observed when mice 
were pre-treated with topical BD cream followed by ID injection of m31-5TAMRA 
(Figure 3.6 C).  Increased liquid flux space created by ID injection together with 
the hydration effect created by the BD cream may have caused the increased 
rate of skin clearance.  In order to minimise the hydration effect, dry peptide was 
delivered using coated MNs.  With BD cream pre-treatment, a higher NRI is 
observed initially, which may be due to an increased rate of dissolution in the 
hydrated skin.  This hydration effect caused by BD cream did not show a 
significant influence on the clearance of peptide over time when administered by 
solid-coated MNs.  Although short term pre-treatment of BD cream showed some 
effect on clearance curve at individual time points, the hydration effect, did not 
show a significant effect on the overall skin clearance of peptide, which suggests 
that skin hydration, caused by the BD cream, was not the main factor in 
determining the rate of skin clearance of peptide (Figure 3.7 B).  This finding 
provided the additional support for the use of BD cream in combined therapy with 
solid-coated MN for ASI.   
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3.5.3.2. Trafficking of the m31 peptide in vivo 
As discussed in Section 3.5.4.2, solid-coated MN delivery was shown to prolong 
the retention of peptides within the skin.  Therefore, it is important to understand 
how this prolonged effect influences local antigen presentation within the skin 
and whether this could result in different peptide trafficking.   
 
In NOD mice, BDC2.5 T cells recognise antigens from the islet of Langerhans 
and therefore proliferate in the pancreas draining LNs, PLNs.  When a strong 
stimulus such as m31 was introduced through the skin, BDC2.5 T cells also 
proliferated in the ALN, therefore confirming the exogenous nature of this 
antigen.  One interesting observation was that BDC2.5 T cells proliferated more 
strongly when using MNs as a delivery method as compared to ID injection.  This 
raised two questions:  1. Why, when using the same dose of peptide, did MN 
administration induce a greater proportion of antigen specific T cells to proliferate 
than ID administration?  2. How long does the peptide remain in the skin when 
using the two different methods of administration?  The possible explanations are 
discussed next.   
 
After delivery, peptides were trafficked to all secondary lymphoid organs within a 
few hours following ID injection in an in vitro study (data not shown).  However, 
our in vivo study showed that BDC2.5 T cells only proliferated in the local skin 
draining LNs.  In order to prime T cells in LNs, the antigen must first be taken up 
by DCs, which then migrate to the lymph nodes through the lymphatic vessels 
(Randolph et al., 2005).  The observed presence of peptide in the local skin 
draining LNs may be explained by the migration of the peptide carrying DCs from 
skin to LNs.  These DCs then present the peptide, rather than un-associated 
peptide trafficking, to T cells in LNs.   
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One potential explanation for increased proliferation in MN treated mice is that 
the MNs can target skin DCs more efficiently than ID injection, thereby inducing 
relatively higher levels of proliferation for the same dose of delivered peptide.  
When using the mouse skin model, solid-coated MN delivery can target both LCs 
in the epidermal layer and DCs in the dermal layer, as described previously 
(Section 2.4.1.2. ).  ID injection was by comparison more likely to deliver peptide 
to the deep dermal layer or even subcutaneously.  Skin DCs can therefore be 
targeted more efficiently by using MN delivery and were thus exposed to more 
m31 peptide per dose when the peptide was delivered by MN.  One study 
revealed that skin DCs are able to take up peptide between 40 and 360 minutes 
post treatment (Rattanapak et al., 2014).  Skin DCs have also been observed in 
the draining LNs just 24 hours after the skin was painted with Rhodamine B 
(Randolph et al., 2005).  These studies suggest that the kinetics of skin DC 
activity (uptake and migration) could contribute to our observed differences in the 
method of peptide delivery.  Previous skin clearance data suggests that most 
peptide is cleared from the skin within 4 hours post ID injection, which limits the 
time available for antigen uptake.  However skin DCs were exposed to m31 for a 
prolonged time when using the solid-coated MN delivery method, thus increasing 
the opportunity for antigen uptake and enabling more DCs to encounter the 
peptide.  Epidermal LCs have different kinetics compared to dermal DCs.  LCs 
showed a delayed migration compared with dermal DCs under inflammatory 
conditions (Kissenpfennig et al., 2005).  This may imply that using a MN to 
induce tolerance is particularly beneficial when targeting tolerogenic epidermal 
LCs, due to the prolonged release profile.   
 
An extended in vivo tracking study was also undertaken to provide further 
understanding of the benefit of using solid-coated MNs in skin targeted delivery.  
A proliferation profile of BDC2.5 T cells in the ALN was observed 10 days post 
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m31 delivery (Figure 3.13 D).  A kinetic result has shown that antigen bearing 
LCs remained in the epidermis for 10 days after sensitization with Rhodamine B 
(van Wilsem et al., 1994).  Therefore, the persistent response observed in our 
studies could be due to residual trace m31 in the skin and/or m31 bearing DCs 
that remain in the skin. In both 3 and 10-day trafficking studies, solid-coated MN 
delivery showed a more consistent response than ID injection between 
treatments.  This can be explained by more targeted and persistent skin DC 
delivery when using MN rather than using ID injection.   This prolonged exposure 
time may not only enhance the uptake, but may also reduce the trauma caused 
by repeated dosing, which reduces the chance of generating an inflammatory 
signal and therefore further benefits ASI approach. 
 
3.5.4. Optimise CFSE labelling protocol for the analysis of cell proliferation  
CFDA-SE is a well-documented cell tracing dye.  After diffusion into the cell, 
CFDA-SE is cleaved by esterase enzymes and becomes CFSE, an amine 
reactive product.  CFSE binds to lysine residues and has been used to analyse 
cell division by tracking the dilution of CFSE fluorescent intensity (Quah and 
Parish, 2012).  CFSE, however, can be toxic to cells and may inhibit cell 
proliferation (Quah et al., 2007, Quah and Parish, 2012).  The aforementioned 
article states that the degree of toxicity may differ for different cell types, 
therefore it was necessary to optimise the labelling protocol for BDC2.5 T cells.   
 
In order to obtain good resolution of division peaks, 20µM CFDA-SE was used for 
107 cells /ml.  This is much higher than the manufacturers suggested 
concentration of 5µM, and could therefore result in an increased risk of toxicity.  
10%v/v FCS was used to buffer the toxicity of CFSE during the labelling process 
and results showed that using optimised conditions, BDC2.5 T cells were still 
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functional and proliferated after labelling.  Transferred BDC2.5 T cells showed 
proliferation for between 5-6 generations over three days in vivo.  Transferred cell 
numbers for in vivo study were also titrated (Figure 3.11).   
 
Tregs constitute a small proportion of the total T cell population in NOD mice 
(approximately 5% in circulation) (Kukreja et al., 2002, Girvin et al., 2000).  In 
experiments that have attempted to show the suppressive effect of Tregs, the 
Treg:Teff ratio was set as high as 1:1.  This was thought due to the low frequency 
of antigen specific Tregs in the polyclonal NOD mouse.  It has also been shown 
that a reduced Treg:Teff ratio (<1:10) is appropriate when using a monoclonal 
BDC2.5-TCR-Tg mouse (Tang et al., 2004).  In this project, it was shown that 
Foxp3+CD4+ T cells (nTreg) from a NOD mouse (polyclonal T cells) were not able 
to suppress proliferation of BDC2.5 T cells in SCID mice, but suppression was 
observed when using Foxp3+CD4+ BDC2.5 T cells (Figure 3.15).   
 
The hypothesis for this project was that it would be possible to induce/expand 
peripheral antigen specific Tregs to generate peripheral tolerance using an 
autoantigen.  However, expanding Tregs in vivo has proved to be difficult due to 
their anergic nature (Walker, 2004).  As the antigen specific Tregs are anergic 
and low in frequency, the tolerance readout needs to be optimised in order to 
generate meaningful results.  In this study iTreg induced tolerance is indicated by 
reducing the proliferation of antigen specific Teffs.  CFSE labelled BDC2.5 T cells 
were used as responder cells to demonstrate the effect of the induced Treg 
population.  However, due to the strongly diabetogenic nature of BDC2.5 T cells, 
it was necessary to titrate the transferred BDC2.5 cell number in order to enable 
the induced Tregs to generate a meaningful result.   
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A lower limitation was imposed by the need to provide a large enough initial 
(transferred) cell population to ensure resolution of cell division in subsequent 
generations.  Results demonstrated that CFSE labelled BDC2.5 T cells could 
produce a clear proliferation profile, which was easily resolved for 5 to 6 
generations in the PLNs of NOD mice transferred with 4x106 BDC2.5 cells.  
Therefore, the proliferation of transferred 4x106 BDC2.5 cells in the PLN of 
untreated NOD mice was calculated to provide a base line as an intrinsic 
response of BDC2.5 T cells to endogenous antigen from pancreas.   If peptide 
delivered by MNs or ID injection induce antigen specific Tregs, these Tregs will 
home back to the site where the inflammation initiated, i.e. the pancreas, and its 
draining LN, PLN (Chow et al., 2015)  The induced antigen specific peripheral 
tolerance could then be reflected as a reduced proliferation in PLN compare to 
the base line proliferation in untreated NOD mice as showed in following section.   
 
3.5.5. Peripheral tolerance could be induced in NOD mice by using WE14 
delivered by solid-coated MNs, showing a dose-sparing effect1 compared to 
ID injection.   
The m31 peptide has a strong affinity with MHCII and BDC2.5 TCR.  BDC2.5 T 
cells pulsed with m31 in vitro can accelerate diabetes when introduced into NOD 
and SCID mice (Christianson et al., 1993).  When m31 was injected into a 
BDC2.5-TCR-Tg mouse, it stimulated a fatal immune response.  This could be 
due to the monoclonal diabetogenic T cells response in the BDC2.5-TCR-Tg 
mouse and the lack of other tolerogenic mechanisms.  On the other hand, WE14 
is a weak epitope of BDC2.5-TCR, and therefore this did not cause any adverse 
                                                
1 The term Dose-sparing effect herein refers to an improved therapeutic effect using a 
comparison dose.  In this case solid-coated MN was able to improve induced peripheral 
tolerance compared to ID injection using the same dose, 6µg WE14, resulting in reduced 
BDC2.5 T cell proliferation in NOD mice.  
  169 
effects to the BDC2.5-TCR-Tg mice.  After treatment with WE14, two CD4 
subpopulations, CD4+CD25+Foxp3+ and CD4+CD62L+Foxp3+, were increased 
compared to the untreated group.  CD4+CD25+Foxp3+ T cells are Tregs that can 
either be generated naturally or can be induced in the periphery.  They can 
suppress antigen specific Teffs in a cell-cell contact fashion (Chatenoud, 2011, 
Feuerer et al., 2009).  These Foxp3+CD4+CD25+ BDC2.5 T cells were shown to 
prevent the progression of T1D in NOD mice (Jaeckel et al., 2005).  Absence of 
CD4+CD25+Foxp3+ Treg accelerates T1D in NOD mice, and recovery of antigen 
specific CD4+CD25+Foxp3+ Treg could restore the balance (Brode et al., 2006).  
CD62L (L-selectin) is an adhesion molecule which is expressed on Leukocytes 
and regulates lymphocyte homing to secondary lymphoid organs (Bevilacqua et 
al., 1991).  A low frequency of CD62L+ Tregs is associated with T1D in both 
mouse models and human patients (Ryba et al., 2011, Kaminitz et al., 2014).  
Here, we have shown that WE14 was able to induce these antigen specific Tregs 
in the TCR-Tg mouse.  This ability to induce both types of Tregs in BDC2.5-TCR-
Tg mouse in vivo, indicates that WE14 could potentially be used as a therapeutic 
antigen for inducing tolerance.  
 
To prove that CD4+Foxp3+ BDC2.5 Tregs are functional, SCID mice were co-
transferred with CD4+Foxp3+ BDC2.5 Tregs and CFSE labelled BDC2.5 T cells.  
Subpopulations of CD62L+ or CD25+ of CD4+Foxp3+ cells were not sorted due to 
the low frequency of these two populations.  In SCID mice, reduced proliferation 
was observed when using a 1:1 ratio of antigen specific CD4+Foxp3+ Treg to Teff 
rather than using polyclonal Tregs.  This finding agreed with previous 
publications in regard to the role of antigen specific Tregs in suppressing Teffs.  
In vitro expanded BDC2.5 Tregs could suppress Teffs in a ratio as low as 1:9 in a 
NOD.RAG-/- transfer experiment,resulting in controlled blood glucose level of 
below 250mg/dL over a 105 day monitoring period (Tang et al., 2004).  It has 
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also been reported that antigen specific Tregs were more effective than 
polyclonal Tregs in inducing tolerance to prevent the progression of T1D in CD28-
/- NOD mice (Masteller et al., 2005).  These publications together with the 
findings of this study suggest that if the proliferation of transferred BDC2.5 T cells 
were suppressed in NOD recipients, the Treg/tolerance induced is antigen 
specific. 
 
Having demonstrated that it was possible to generate Tregs using WE14 in a 
monoclonal background, it was then important to demonstrate that WE14 could 
be administered intradermally to generate antigen specific Tregs in vivo in a 
polyclonal background.  The use of WE14 to induce tolerance in vivo has 
previously been reported.  In one investigation, splenocytes and cells from the 
PLN were taken from NOD mice, which had previously been injected 
intraperitoneally with either 50 or 100µg of WE14 and incomplete Freund’s 
adjuvant.  These cells showed a suppressive effect on inflammatory response in 
both CD4+ and CD8+ T cells in vitro (Haskins et al., 2012).  They also showed 
that splenocytes from WE14-treated NOD mice can delay disease progression in 
SCID mice.  Tolerance induced by WE14 can influence/reduce the recruitment 
and expansion of BDC2.5 T cells in the PLN, which was reflected in the rate of 
BDC2.5 proliferation in the PLN.  Using skin targeted delivery by solid-coated 
MNs, a much lower dose of WE14 could be used (6µg on average) to achieve a 
similar outcome, due to the improved targeting of skin DCs.  In our experiments 
significant suppression of BDC2.5 proliferation was observed when NOD mice 
were treated with WE14 solid-coated MNs.  A reduced proliferation profile was 
also observed when using ID injection, but it was not as efficient as solid-coated 
MN administration.  This could be due to the prolonged release of peptide in skin 
when using solid-coated MNs delivery, which can target skin DCs more efficiently 
than ID injection, as discussed in Section 3.5.3.  This targeted and prolonged 
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delivery using solid-coated MNs provides a dose sparing effect in inducing 
tolerance when compared to ID injection.  This is the first report on the dose 
sparing effect of solid-coated MN used to inducing tolerance.  Other reports have 
previously demonstrated that MNs provide a dose sparing effect for vaccination 
applications (Kenney et al., 2004, Van Damme et al., 2009). 
 
Apart from administration route, WE14 dosage was another factor that influenced 
the activation of transferred BDC2.5 T cells.  Using ID injection, high dose (50µg) 
WE14 showed 16% greater reduction of proliferation than a low dose (6µg).  
Transferred cells also experienced a phenotypic shift, which was shown to be 
paired with their proliferation ability.  When cells were recruited to the PLN, they 
lose L-selectin, resulting in half of transferred cells losing their naïve 
(CD62L+CD44-) state and becoming activated.  Where tolerance was induced 
using WE14, more transferred T cells remained in their naïve state.  As one of 
the functions of Tregs is to prevent the activation of naïve T cells through 
tolerogenic DCs (section 1.4.1.2), the preserved naïve T cell population further 
suggests that tolerance was induced using WE14. 
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3.6. Conclusion 
Experiments in this chapter demonstrate that the MN coating formulation used 
does not alter peptide activity during the formulation preparation, coating and 
decoating processes.  The excipient used in the formulation, specifically 
PVA2000, did not cause any non-specific inflammatory immune response, in the 
amounts that it was used. 
 
Several factors influence the skin local pharmacokinetics of the delivered peptide, 
such as the environmental temperature, delivery method, hydration effect and 
hydrophobicity of the peptide.  Increased environmental temperature increased 
the skin clearance rate of m31-5TAMRA which could be due to the increased 
microcirculation.  It was shown that the administration route was the main factor 
that controls the peptide skin clearance rate.  Peptide delivered by MNs using a 
solid-coated formulation remained in the skin significantly longer than a peptide 
solution delivered using ID injection.  Another important contribution to the skin 
clearance of peptide is the solubility of peptides.  Preconditioning of the skin 
using a BD cream was not shown to have any significant influence on the local 
kinetics.  The clearance differences observed between delivery routes were then 
further tested to examine their effect on local antigen presentation and on 
inducing tolerance. 
 
A prolonged release was reflected in an increased proliferation profile for BDC2.5 
T cells in the draining LN at both 3 and 10 days post solid-coated MN treatment.  
MN administration of a solid-coated peptide formulation can therefore target skin 
DCs more effectively than ID injection of a peptide solution, thereby allowing for 
lower dosages to be used to induce tolerogenic effects, which can in turn reduce 
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the risk of inducing an undesirable proinflammatory immune response or causing 
systemic effects.   
 
Using a low potency epitope; WE14, two types of Tregs, CD4+CD25+Foxp3+ and 
CD4+CD62L+Foxp3+ were shown to be induced in vivo in BDC2.5 TCR-Tg mice.  
These CD4+Foxp3+ BDC2.5 T cells were shown to suppress BDC2.5 T cell 
proliferation in the NOD-SCID mouse.  It is therefore logical to use WE14 to 
induce peripheral tolerance.  This is the first demonstration that intradermal 
delivery of WE14 using solid-coated MNs and ID injection can induce peripheral 
tolerance in a NOD mouse, resulting in a reduced proliferation profile of BDC2.5 
T cells and preservation of CD4+CD62L+CD44+ Naïve T cell populations  
Although both solid-coated MNs and ID injection can promote peripheral 
tolerance, results clearly demonstrated that MN administration was more 
reproducible and effective than ID injection.  Furthermore, this induced antigen 
specific tolerance was dose responsive, showing a reduced proliferation when 
using higher dose, 50µg.  
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Chapter 4 Effect of short term topical 
Betamethasone on ASI 
4.1. Introduction 
4.1.1. Topical glucocorticoid and its local effect on immune cells 
Glucocorticoids (GCs) are a class of small lipophilic compounds, which have 
medical use as steroid hormones.  They are commonly used as anti-inflammatory 
or immunosuppressant drugs for the treatment of diseases such as asthma, 
rheumatoid arthritis, and inflammatory bowel disease.  GCs exert their anti-
inflammatory effect through binding with GC receptors within cells, which in turn 
regulate pro-inflammatory gene transcription (Danielsen et al., 1987, Barnes, 
1998, Rhen and Cidlowski, 2005, Coutinho and Chapman, 2011).   
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Figure 4.1 Basic mechanisms of action for GCs on immune cells.  The GC receptor 
is widely expressed on cells such as DCs, T cells, B cells, NK cells, neutrophils, 
macrophages and fibroblasts.  By binding to their receptors, GCs can suppress the 
immune response by inducing apoptosis either directly or indirectly, down regulating 
inflammatory cytokines, up regulating regulatory cytokines, and preventing proliferation 
either directly or indirectly (Gary, 2013). 
 
4.1.1.1. Effect on DCs 
GCs can suppress immune responses by changing the phenotype and 
functionality of DCs, which are mediatory cells, which create an important bridge 
between innate and adaptive immune systems.  Maturation of DCs can be 
suppressed by GCs both in vitro and in vivo.  In mouse studies, DCs, which have 
been treated with a GC, remain in an immature state when encountering an 
antigen and consequently show an impaired ability to stimulate T cells (Piemonti 
et al., 1999b, Moser et al., 1995).  After co-culturing with GCs (betamethasone or 
dexamethasone), monocyte-derived human DCs showed an impaired stimulation 
of T cells, which was dose related (Kalthoff et al., 2003).  Human DCs derived 
from cord blood showed a reduced expression of HLA DR and co-stimulators 
(CD86, CD83, and CD40) when co-cultured with GCs (Larange et al., 2012).  
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GCs also showed an inhibitory effect on antigen presentation of DCs through the 
MHCII pathway (Pan et al., 2001b).  For epidermal LCs, GCs have the ability to 
promote production of tolerogenic cytokines and can induce Tregs in vitro (Stary 
et al., 2011a).  Cytokine production was shown to be regulated by GCs by 
reducing pro-inflammatory cytokines, and promoting IL10 secretion (Almawi et 
al., 1996, Piemonti et al., 1999b).  The combination of these mechanisms might 
contribute to inducing tolerogenic DCs (tol-DC) using GCs.  
 
4.1.1.2. Betamethasone 
Betamethasone is a potent synthetic GC that has been widely used as anti-
inflammatory and immunosuppressive drug (Table 1.2).  Its dipropionate form 
(betamethasone dipropionate, BD), which has poor water solubility but high skin 
penetration, has been used as a topical treatment for diseases such as allergic 
rhinitis, psoriasis, tinea pedis and dermatitis (Edwards, 1995, Menter et al., 2009, 
Smith et al., 1992, Lebrun-Vignes et al., 2000).  For systemic treatment, a more 
soluble form is used, such as betamethasone disodium phosphate (BSP).   
 
Our hypothesis for this section of the thesis is that topical betamethasone would 
precondition the skin to induce tol-DCs and thus enhance peptide specific 
immunotherapy. 
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Table 4.1 Potency and pharmacodynamics of betamethasone compared with other 
GCs.  Betamethasone is a very potent and long acting GC with a biological half-life of 



















Cortisone 25 0.8 0.8 0.5 8-12 
Cortisol 20 1 1 1.5-2 8-12 
Intermediate-Acting 
Methylprednisol
one 4 5 0.5 >3.5 18-36 
Prednisolone 5 4 0.6 2.1-3.5 18-36 
Prednisone 5 4 0.6 3.4-3.8 18-36 
Triamcinolone 4 5 0 2->5 18-36 
Long-Acting 
Dexamethasone 0.75 20-30 0 3-4.5 36-54 
Betamethasone 0.6 20-30 0 3-5 36-54 
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4.2. Objectives 
The aim of this chapter was to determine whether short-term topical BD 
treatment could condition skin DCs and create a tolerogenic environment, which 
would enhance the effect of ASI.  The specific objectives of this chapter were set 
as follows: 
• To investigate the effect of short term (two day) topical BD cream 
treatment on mouse epidermal cells, by analysing the change in IL10 
levels in culture media. 
• To investigate the effect of a single dose of topical BD cream vs a single 
application of betamethasone disodium phosphate (BSP) coated MNs on 
human epidermal cells  The effect of this treatment was analysed by: 
a. Characterising epidermal DC phenotype with or without BD cream 
treatment by flow cytometry. 
b. Examining whether BD treatment affects the proliferation of MLR. 
c. Analysing the secretion of IL10 in MLR by BD and non-BD treated 
epdermal cells. 
• To examine the effect of short term topical BD cream treatment on 
induction of tolDCs by analysing BDC2.5 T cell proliferation in skin 
draining LN (ALN) after m31 delivered either by MN or ID injection 
• Examining the local and systemic effects of short term BD cream 
treatment on T cells and DCs in the lymphoid organs of NOD mouse by 
examining changes in the T cell and DC populations and phenotypes. 
• Exploring the effect of short term topical BD cream on ASI in vivo using a 
BDC2.5 proliferation tolerance assay. 
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4.3. Methods 
4.3.1. Preparation of human epidermal cells 
All human skin samples were obtained from female patients undergoing 
mastectomy or breast reduction surgery with informed patient consent and local 
ethical committee approval.   
 
Subcutaneous fat and most of the dermal layer was removed using a pair of 
surgical scissors leaving a thin layer of upper dermis and epidermis.  The 
epidermal piece was then cut into thin strips and cultured in an enzyme cocktail 
(RPMI 1640 supplemented with 1mg/ml collagenase D, 20U/ml DNase I and 
2.5mg/ml Dispase II) at 37˚C for 30-45 minutes.  The epidermis was then peeled 
away from the upper dermis using a pair of fine forceps.  Residual enzymes were 
neutralised by floating the piece of epidermis in 2mM EDTA/PBS solution.  In 
order to obtain a single epidermal cell suspension, the epidermis pieces were 
incubated in 5 ml 0.25% trypsin (0.02% EDTA) at 37˚C for 35 minutes.  After 
incubation, epidermal cells were released from the epidermal pieces by agitating 
using a 1 ml pipette.  Trypsin was then neutralised by adding 5 ml of 1mg/ml 
soybean trypsin inhibitor solution.  Cells were pelleted at 400G for 10 minutes 
and suspended in 0.025% DNase, 10%v/v FCS in PBS, then incubated at 37˚C 
for 1hr.  Epidermal cells were filtered through a 70µm cell strainer into a 50ml 
falcon tube.  Cells were pelleted at 400G for 5 minutes and washed twice with 
RPMI 1640 supplemented with 10%v/v FCS.  For subsequent use, cells were 
centrifuged at 400G for 5 minutes and the supernatant was discarded. 
 
4.3.2. Human peripheral blood mononuclear cell (PBMC) preparation 
All human blood samples were obtained from healthy blood donors under 
informed donor consent and local ethical committee approval.   
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Peripheral blood (20ml) from a healthy donor was taken and placed into a 50 ml 
falcon tube prefilled with 500 units of heparin.  The heparin was then mixed 
thoroughly with the blood by gently swirling.  The blood was then mixed with 25 
ml RPMI 1640 media supplemented with 1%v/v L-glutamine and 1%v/v 
Antibiotic-Antimycotic (100 units/mL of penicillin, 100 µg/mL of streptomycin, and 
0.25 µg/mL of Fungizone® Antimycotic, Lifetechnologies, UK), which was pre-
warmed in a 37˚C water bath.  Ficoll solution (10ml) was added to an empty 50 
ml universal sample tube.  The blood/media mixture was added drop wise to the 
Ficoll solution without disturbing the interface between the Ficoll solution and the 
blood/media mixture.  Red blood cells and mononuclear cells were then 
separated by centrifuging the universal tube at 400G on a 40-minute cycle, 
followed by progressive deceleration. The top layer containing plasma and white 
cells was removed using a Pasteur pipette and placed in an empty universal 
tube.  The white cells were then suspended in 10 ml RPMI 1640 media 
supplemented with 1%v/v L-glutamine and 1%v/v Antibiotic-Antimycotic (100 
units/mL of penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL of Fungizone® 
Antimycotic) and pelleted at 400G for 10 minutes, followed by progressive 
deceleration.  White cells were washed with 10 ml RPMI 1640 media 
supplemented with 1%v/v L-glutamine and 1%v/v Antibiotic-Antimycotic and 
pelleted at 400G for 10 minutes followed by progressive deceleration.  Cells were 
then suspended in complete media (RPMI 1640 media supplemented with 
10%v/v human AB serum, 1%v/v L-glutamine and 1%v/v Antibiotic-Antimycotic 
(100 units/mL of penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL of 
Fungizone® Antimycotic) for further use. 
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4.3.3. Intradermal Betamethasone delivery using a topical cream or solid-
coated MNs 
To test the effect of topical application of BD cream, 0.1 ml of cream was applied 
onto a full thickness human skin explant, which was stretched to 2x1cm2 on a 
cork board covered with tinfoil.  The cream was manually massaged into the skin 
surface using the fingertip for 10 minutes to assist drug permeation.   
 
For MN delivery, 1mg of BSP was first dissolved in 200µl 5mg/ml PVA200 
solution and used as a coating formulation (50mg/ml BSP and 5mg/ml PVA).  To 
coat MNs, 0.4µl of BSP coating formulation was coated onto three arrays of 
stainless steel MNs (see chapter 2).  To test BSP coated MNs, MNs coated with 
BSP were inserted into human skin explants for 5 minutes, or shaved mouse skin 
for 10 minutes.  MNs were then removed to analyse delivery efficiency. 
 
4.3.4. Ex vivo human skin explant culture 
A treated or untreated area of full thickness human skin explant was excised 
using an 8mm biopsy punch.  Each skin biopsy was inserted in a Millicell Cell 
Culture Insert 12mm (base membrane was removed), with the epidermis facing 
up, exposed to the air, and the dermis facing down touching the liquid culture 
media.  The inserts were then placed in a 24 well culture plate filled with 1ml of 
complete media (RPMI 1640 media supplemented with 10%v/v human AB 
serum, 1%v/v L-glutamine and 1%v/v Antibiotic-Antimycotic (100 units/mL of 
penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL of Fungizone® 
Antimycotic)) and cultured at 37˚C with 5% CO2 for the required period. 
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4.3.5. Quantification of BSP using HPLC (high pressure liquid 
chomography) 
BSP was quantified using an Agilent HP1200 UV reverse phase HPLC machine.  
The column used was an ODS C18 Gemini 5µm.  HPLC running parameters 
were set as below: 
Mobile phase A: Acetonitrile 
Mobile phase B: 0.1%v/v phosphoric acid in DI water 
Running time: 30min 
Sample injection volume: 20µl 
Detector wave length: 234nm 
Post time: 5min 
Gradient was shown in Table 4.2. 
Table 4.2 HPLC mobile phase gradient for detecting BSP.  A=Acetonitrile, B=0.1%v/v 
phosphoric acid in DI water 
Time/min A v/v% B v/v% 
0 30 70 
25 50 50 
26 30 70 
30 30 70 
 
4.3.6. Preparation of mouse epidermal cells 
Mice were sacrificed using a sealed CO2 chamber.  Hair was removed from the 
treated skin area using a pair of curved forceps by pulling against the hair growth 
direction.  Skin was then excised using an 8mm biopsy punch and subcutaneous 
fat was removed using a scalpel.  Skin pieces were floated on 5ml of RPMI 1640 
medium containing 2.14unit/ml dispase II and 0.25%w/v trypsin in a 50mm petri 
dish at 37˚C for 1 hour.  After incubation, enzymes were washed off by rinsing 
the skin in 5%v/v FCS/PBS.  The epidermis was then separated from the dermis 
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using a pair of fine curved forceps.  The epidermal piece was then transferred to 
500µl of complete media (RPMI 1640 supplemented with 5%v/v FCS, 1%v/v L-
glutamine and 1%v/v Antibiotic-Antimycotic).  Epidermal cells were then released 
by pipetting up and down using a 1 ml pipette until the culture media turned 
cloudy.  The remaining portion of the epidermis was then carefully removed from 
the cell suspension.   
 
4.3.7. Imaging mouse LCs in an epidermal sheet 
Isolated mouse epidermal sheet was prepared as described in section 4.3.6.  The 
epidermal sheet was then fixed in acetone at -20˚C for 15 minutes.  In order to 
reduce non-specific staining, fixed epidermal sheets were incubated in a blocking 
agent; 5% w/v BSA/PBS and anti-CD16/32 mAb, for 1 h at ambient temperature.  
The epidermal sheet was then rinsed in fresh PBS three times to remove the 
blocking agent.  To stain LCs, the epidermal sheet was incubated with CD207-PE 
mAb in 1%BSA in the dark at ambient room temperature for 1 hour.  The 
epidermal sheet was then washed with PBS to remove excess antibody.   
 
For imaging, the epidermal sheet was mounted on a glass slide using Dako 
fluorescence mounting media and covered with a glass coverslip.  The slide was 
then sealed with nail polish after the mounting media was set.  Fluorescent 
images were captured using a Leica DM IRB Fluorescence Microscope and 
processed using ImageJ software. 
 
4.3.8. Evaluating the effect of betamethasone on the phenotype of human 
epidermal DCs  
Human skin explants that had been treated with BD cream or BSP coated MNs 
were cultured ex vivo for 24 hours after treatment.  Epidermal cells were then 
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isolated, stained with antibodies as listed in Table 4.3, and data were acquired 
using a CantoII Flow Cytometer.  Mean fluorescent intensity (MFI) of 
CD1a+Langerin+ epidermal cells was analysed using FlowJo. 
Table 4.3 Antibody list for examining the effect of betamethasone on the phenotype 
of human epidermal cells.   
Ab Fluorophore Dilution v/v 
HLA DR Percp Cy5.5 1/200 
Langerin PE 1/200 
CD1a Pacific Blue 1/100 
Viability eFluor 780 1/1000 
 
4.3.9. Evaluating the effect of betamethasone on human epidermal cells 
using the Mixed Lymphocyte Reaction (MLR) assay 
In order to examine the effect of betamethasone on human epidermal DCs, 
human skin explants were first treated with either BD cream or BSP coated MNs 
as described in 4.3.3.  Treated skin epidermal cells were then prepared as 
described in 4.3.1.  In each well of a 96 round bottom plate, approximately 
50,000 epidermal cells were seeded with 200,000 PBMCs in RPMI 1640 
supplemented with 1%v/v L-glutamine, 1%v/v Antibiotic-Antimycotic and 10%v/v 
human AB serum.  Cells were incubated at 37˚C, with 5% CO2 for 30 hours.  
100µl supernatant was then taken from each well and replaced with 100µl of 
fresh complete media.   
 
4.3.10. Assessing the effect of topical BD cream on murine epidermal cells  
Mouse epidermal cells were prepared as described in 4.3.6.  BDC2.5 T cells 
were prepared as described in 3.3.9.  Epidermal cells from each 8mm biopsy 
punch were co-cultured with 200,000 BDC2.5 T cells in the presence of 1ng/ml 
m31 in each well of the 96 round bottomed plate at 37˚C with 5% CO2 for 3 days.  
After incubation, IL10 levels in the supernatant were analysed using ELISA 
(introduced in section 3.1.2. ).  
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4.3.11. Titrating topical BD cream for in vivo study 
DiproSone®0.05% w/w Cream was diluted 1/10, and 1/50 times in Diprobase 
Cream using geometric dilution.  Geometric dilution was used to ensure the 
betamethasone was mixed uniformly in the Diprobase cream.  Undiluted and 
diluted 0.1ml creams were applied to the shaved neck area of NOD mice once 
per day for two days.  After treatment, single cell suspensions were prepared 
from the SP, ALN and PLN for analysis of changes to the CD4+ T cell phenotype.  
Cells were then stained with antibodies (see table Table 4.4), and data was 
acquired using a CANTOII flow cytometer and data was analysed using FlowJo 
software. 
Table 4.4 Antibody list to analyse the effect of BD cream on the phenotype of local 
and systemic CD4+ T cells.   
Ab Fluorophore Dilution v/v 
CD62L PE 1/400 
CD69 PB 1/100 
CD4 PE Cy7 1/400 
CD44 Percp cy5.5 1/400 
GITR Alex Fluor 488 1/100 
Viability eFluor 780 1/1000 
 
4.3.12. Topical BD effect on local antigen presentation 
The neck area of NOD mice were shaved using an electric clipper and were 
treated with 0.1ml topical BD cream once per day for two consecutive days.  
Twenty-four hours after the second cream treatment, mice were adoptively 
transferred with 4 X 106 CFSE labeled BDC2.5 T cells through the tail vein and 
2µg m31 by intradermal injection.  Three days post injection, cells from the ALN 
and PLN were isolated and the cell proliferation profile from each organ was 
acquired using a CANTO II flow cytometer and analyzed using FlowJo software. 
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4.3.13. Determining the dose of BD cream 
Aliquots of 0.1ml BD cream were measured onto a piece of grease proof paper, 
using a 1 ml syringe and weighed to determine the mass of 0.1ml BD cream.  
This allowed the mass of betamethasone in each 0.1 ml 0.05% w/w BD cream to 
be calculated.   
 
4.3.14. Topical BD effect on inducing tolerance in vivo 
NOD mice (Female, 4-5 weeks old) were treated with 0.1ml BD cream or 1/50 BD 
cream once a day for 2 days, then, 24 hours after the second treatment, mice 
were injected with peptide by either ID injections or via coated MNs at the site of 
topical steroid preconditioning.  After 3 weeks, mice were treated again with BD 
cream for 2 days followed by peptide treatments using ID injection or MNs.  A 
week after the second treatment, mice were transferred with 4x106 CFSE labelled 
BDC2.5 T cells through the tail vein.  Mice were then sacrificed 3 days post cell 
transfer and the cell proliferation profile was analysed using a CantoII Flow 
Cytometer and FlowJo software.   
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4.4. Results 
4.4.1. Effect of topical steroid on epidermal cells in both human and mouse 
skin models 
4.4.1.1. Quantification of BSP using HPLC 
As discussed in Chapter 3, the hydration effect from BD cream treatment could 
change the rate of clearance of peptide delivered to the skin.  MNs were used to 
deliver BSP to minimise the hydration effect of topical steroid delivery.  Any BSP 
left on MNs after skin delivery was recovered and quantified using HPLC.  As 
demonstrated in Figure 4.2 A, water-soluble BSP can be quantified using HPLC 
with a linear calibration range from 3.9µg/ml to 1000µg/ml.  BSP (20µg) was 
coated on solid MNs and onto average (17.83±0.9)µg (88.71% delivery 
efficiency) was delivered to human skin and (10.6±3.9)µg (52.7% delivery 
efficiency) was delivered to mouse skin (Figure 4.2 B).  The delivered dose of 
BSP was more consistent in human skin than in mouse skin.   
 
Figure 4.2 HPLC quantification of BSP dose delivered to human or mouse skin 
using solid-coated MN.  A. Calibration range for BSP as quantified by HPLC (93.9µg/ml 
to 1000µg/ml).  B. BSP delivery efficiency using solid-coated MNs to human skin explants 
or mouse skin in vivo.  20µg BSP was coated on solid MNs and delivered to either human 
or mouse skin, the delivery efficiency was reverse-quantified using HPLC.  n=3, unpaired 
t test, * p<0.05, Mean±SD.   
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4.4.1.2. Effect of steroid on human epidermal cells 
Topical application of betamethasone changed the expression of HLA DR on 
CD1a+Langerin+ epidermal DCs (Figure 4.3).  As shown in Figure 4.3 A, 
CD1a+Langerin+ DCs accounted for approximately 2% of total epidermal cells.  
The effect of betamethasone on these DCs was measured by analysing the 
expression of HLA DR, a human MHCII cell surface receptor whose expression 
correlates with the level of stimulation (Fainaru et al., 2012, Matsuo et al., 2004, 
Berger et al., 2009, Chung et al., 2013).  The absolute MFI of HLA DR 
expression on CD1a+Langerin+ is illustrated in Figure 4.3 B.  Experiments that 
used the same skin donor were linked with a solid line.  The baseline MFI for 
untreated skin samples varied between each donor, from 5999 to 61141, which is 
slightly greater than a 10-fold difference.  Compared with the relevant controls, 
four out of seven of the BD cream-treated group showed a reduction in HLA DR 
expression, whilst one showed a small increase and the other two showed no 
change.  The effect of MN-coated BSP on HLA DR was similar to BD cream, with 
five samples showing a decline in comparison with the relevant control sample.  
There was no obvious trend between BD cream and BSP-coated MN groups, 
with three skin samples showing more reduction when using BD cream 
compared with BSP-coated MNs.  Three skin samples showed the opposite trend 
and one showed no difference between the two treatments.  With blank MN 
treatment, three skin samples showed an increased stimulation response and 
two showed no difference compared with control.  To provide an overall 
understanding of how betamethasone affected HLA-DR expression, the MFI of 
the experimental the group was normalised against its relative control (Figure 4.3 
C).  Both BD cream and BSP-coated MN-treated skin showed a significant 
reduction in HLA DR expression compared to untreated skin.  Blank MN 
treatment alone showed no notable trend but there was a large standard 
deviation between specimens.  This indicated that betamethasone can 
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normalised/conditioned the LCs to a state in which they expressed reduced HLA 
DR, i.e. an immature phenotype.   
 
Epidermal DC function was also tested after BD treatment (Figure 4.3 D&E).  By 
mixing epidermal cells with unmatched allogenic PBMCs, a non-specific 
lymphocyte reaction was triggered.  Five negative controls were set as follows: 
epidermal cells alone, PBMCs alone, epidermal cells with blank MN treatment, 
epidermal cells with BSP-coated MN treatment and epidermal cells with BD 
cream treatment.  The functionality of the PBMCs used in the MLR was 
confirmed by response to Phytohaemagglutinin (PHA) as positive control.  In the 
proliferation assay, both BD cream and BSP coated MN treated skin epidermal 
cells produced a small reduction in proliferation compared with untreated 
epidermal cells.  However, this was not reflected by a change in the IL10 level 
measured in the supernatant (Figure 4.3 D&E).   
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Figure 4.3 Effect of betamethasone on human epidermal DCs.  A. Representative 
flow cytometry plot of CD1a+Langerin+ DCs in the human epidermal cell population.  
B&C, phenotypic change of LCs from skin explant cultured for 24 hours (data compiled 
from five separate experiments).  B. Absolute MFI of HLA DR expressed on 
CD1a+Langerin+ cells.  Experiments involving the same skin donor were linked using a 
solid line.  C. Normalised MFI of betamethasone treated skin compared to untreated skin, 
n≥6. Mean±SD One way ANOVA, Wilcoxon matched pair test, *p<0.05.  D&E MLR of 
epidermal cells and PBMCs.  Skin explant was treated with betamethasone (cream or 
MN) and cultured for 24 hours.  Epidermal cells were then isolated and co-cultured with 
PBMCs.  IL10 level in supernatant was analysed using ELISA 54 hours post co-culture.  
Cells were pulsed with 3H-Thymidine and proliferation was analysed 18 hours later.  D. 
Radioactivity counts of MLR between epidermal cells and PBMCs, CPM (counts per 
minute).  E. IL10 level in MLR supernatant, n=3, Mean±SD.  
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4.4.1.3. Effect of topical steroid on mouse epidermal cells 
Because the mouse epidermis is very thin (around 20µm, see Chapter 1), the 
epidermis separation protocol (adapted from human epidermis separation) was 
validated to ensure LCs were not lost during the separation process.  As 
demonstrated in Figure 4.4 A&B, LCs remained in the epidermis after enzyme 
digestion and separation from the dermis.  On average, 48.73±3.72 µg of BD was 
applied topically to shaved mouse skin (Figure 4.4 C).  After 2 days treatment 
with topical steroid, mouse epidermal cells showed higher capacity for releasing 
IL10 in vitro than untreated skin (Figure 4.4 D).  
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Figure 4.4 The effect of short-term topical BD cream on mouse epidermal cells.  
A&B Immunofluorescence images of CD207 antibody stained mouse epidermis.  A. x10, 
scale bar=100µm, B. x45, scale bar=10µm.  C. Average mass of BD applied to mice by 
measuring 0.1ml 0.05%w/v BD cream n=5, Mean±SD.  D. IL10 level in the culture media.  
NOD mice were treated with 0.1ml BD cream once/day for two days.  Twenty four hours 
after the second treatment, epidermal cells were isolated and co-cultured with 200,000 
BDC2.5 T cells in the presence of 1ng/ml m31.  The tolerogenic effect of BD cream on 
epidermal cells was measured as IL10 level in culture media, which was analysed using 
ELISA.  C&D were compiled from two separate experiments.  n=4, Mean±SD, unpaired t 
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4.4.2. Titration of topical BD cream for in vivo study 
4.4.2.1. Short term effect of topical steroid on local and systemic antigen 
presentation 
BD cream (0.05% w/w) was tested in vivo for its local or systemic suppressive 
effects.  BD cream was applied once per day for two days followed by m31 
treatment and BDC2.5 T cell adoptive transfer as seen in Figure 4.5 A.  Effects of 
BD cream on the transferred BDC2.5 T cell proliferation in the ALN or PLN are 
presented in Figure 4.5 B. and C.  BD cream did not cause any non-specific 
stimulation in the local draining lymph node, the ALN.  It also did not have any 
significant effect on BDC2.5 T cell proliferation in the ALN.  Interestingly, 
proliferation of BDC2.5 T cells was suppressed in the PLN in mice treated with 
BD cream (Figure 4.5 C.).  BDC2.5 T cells in mice pre-treated with BD cream 
showed a significant reduction in proliferation compared to the untreated group.  
BD cream also impacted on BDC2.5 T cell proliferation in the PLN from mice 
treated with m31.  The result in Figure 4.5 C suggested that topical BD cream 
alone suppressed the immune response in the PLN.  The CD4+ T cell population 
was analysed to check whether the suppression was due to induced tol-DCs or 
systemic suppression.  It became apparent that full dose BD cream alone could 
cause the depletion of CD4+ in both ALN and PLN (Figure 4.5 D.&E.).  This effect 
lasted for four days post BD cream treatment.  In order to minimise the systemic 
effect of BD cream, a reduced dose of betamethasone was required. 
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Figure 4.5 Effect of 0.05%w/w BD cream on local and systemic antigen 
presentation, reflected by a change to the proliferation profile of transferred 
BDC2.5 T cells.  A. Protocol for testing the effect of BD cream in vivo.  BD cream was 
applied two days before peptide treatment, followed with CFSE labelled BDC2.5 T cell 
adoptive transfer.  Cell proliferation in the ALN and PLN were analysed using FACs.  
B.&C. Proliferation profile of BDC2.5 T cells in the ALN or PLN 3 days post peptide 
treatment.  The proliferation profile was presented as percentage of CFSE+CD4+ apart 
from first generation to total CFSE+CD4+ cells.  D.&E. Percentage of CD4+ T cells in ALN 
or PLN 3 days after peptide treatment.  Unpaired t test, **p<0.01.  For all experiments, 
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4.4.2.2. Effect of BD cream on cells in LNs 
As mentioned in the section 4.4.2.1, full dose topical BD showed depletion effect 
on both CD4+ T cells and CD11c+ DCs.  In order to confirm this finding, a 
separate experiment was undertaken to examine the effect of BD cream on these 
two cell types without the three-day interval used in section 4.4.2.1 to enable 
CFSE+ BDC2.5 T cell to proliferate.  In order to do this, NOD mice were treated 
with BD cream for two days, and 24 hours post the second treatment, cells from 
the ALN and PLN were analysed using flow cytometry.   
 
The result demonstrated that the effect of BD cream on T lymphocytes was 
focused on the CD4+ population rather than CD8+ cells.  A significant reduction of 
CD4+ T cells was observed after BD treatment, while there was no change in the 
CD8+ T cell percentage (Figure 4.6).  CD11c was used to identify DCs.  BD 
cream did not have any effect on DC population in the skin draining LN, the ALN.  
However, in the PLN, the DC population was reduced by applying BD cream.  
This indicated that systemic suppression may be caused by the topical BD.  As 
the intention was to use BD to educate local skin DCs rather than cause systemic 
suppression, a reduced dose of BD cream was required.  
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Figure 4.6 Effect of BD cream on T cell and DC population in the ALN and PLN.  Cell 
isolated from ALN and PLN were stained with CD4, CD8 and CD11c to distinguish T cells 
and DCs.  FACs gating strategies are shown on the left.  CD4+ and CD8+ population were 
gated from total live cells and CD11c+ population was gated from CD4-CD8- population.  
Mean±SD. t test, *p<0.05, **p<0.01, ***p<0.001. 
 
4.4.2.3. Titration of topical steroid for murine study 
Section 4.4.2.2 confirmed that topical BD does have a depletion effect on CD4+ T 
cells and CD11c+ DCs.   A titration experiment was then undertaken to determine 
the BD dosage, which would elicit minimal systemic effect.  BD cream (0.05% 
w/w) was diluted to 0.005% w/w and 0.001% w/w using geometric dilution with 
Diprobase cream.  Diprobase cream alone without BD, was applied as a control.  
Cells from the ALN, PLN and SP were analysed to determine the effect of topical 
BD on CD4+ T cells.  As seen in Figure 4.7 cream alone did not have any effect 
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caused a reduced CD4+ T cell in both ALN and PLN (section 4.4.2.2.  By 
reducing the dose of BD, the CD4+ T cell depletion was significantly reduced.  
Interestingly, there was no significant change in the number of CD4+ T cells in the 
SP with or without treatment using a BD cream.   
 
BD cream also affected cell phenotypes in the LNs and SP (Figure 4.8).  The 
summary of these changes is listed in Table 4.5.  In general BD reduced the total 
CD4+ population in both ALN and PLN but not in the SP.  CD4+ T cell 
subpopulations were also analysed.  CD4+CD44+ can be recognised as a marker 
for memory/activated T cells (Henao-Tamayo et al., 2010, Pepper and Jenkins, 
2011).  CD69 is another marker for activated T cells.  GITR can also be up-
regulated on CD4+CD25+ Treg cells and was found to be expressed on the 
surface of effector T cells (Zhang et al., 2013a, Ronchetti et al., 2004, Shevach 
and Stephens, 2006).  CD62L expression is related to T cell homing and 
activation.  T cells shed CD62L when homing to the lymph nodes (Klinger et al., 
2009).  It has been demonstrated that CD62Llo and CCR7- CD4 T cells exhibit an 
effector memory cell function (Bingaman et al., 2005).  In the ALN, CD44+, GITR+ 
and CD69+ subpopulations were increased after BD cream application, while no 
obvious changes were seen in the CD62L population.  A similar trend was 
observed in the PLN; however, no changes were found in the CD44+ population 
but CD62L- was significantly increased.  In the SP, BD cream had almost the 
opposite effect to CD4+ T cells compared with the ALN and PLN.  CD44+, GITR+ 
and CD62L- populations all showed a reduction in the SP.  As in the ALN and 
PLN, the CD69+ subpopulation was increased in the SP.  Interestingly, CD62L+ 
population was increased after BD cream treatment, with obvious changes in the 
other two lymphoid organs (ALN and PLN).   
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DC were also analysed following titration of the BD cream dose.  BD cream did 
not influence CD11c+ DCs in the ALN at different BD doses.  In the PLN, CD11c+ 
DCs decreased when using full dose BD and recovered to control levels when 
the BD was diluted 50 times.  In both cases, vehicle alone did not have any effect 
on DC numbers.  
 
With the titration of BD cream from 0.05% w/w to 0.005% w/w and 0.001% w/w, 
the systemic effects of BD cream on both CD4+ T cells and DCs was reduced.  A 
50 times dilution had no effect on the CD4+ T cell and CD11c+ cell population 
when compared with the untreated and cream-only groups.  Therefore for later 
experiments 1/50 diluted BD cream was used.  
 
 
Figure 4.7 BD effect on CD4+ T cell population.  NOD mice were pre-treated with 
either full dose BD or diluted (1/10, 1/50) BD for two days and percentage of CD4+ T cells 
as a percentage of total cell population were analysed by flow cytometry. N≥3.  
Mean±SD.  Data were compiled from two separate experiments.  One Way ANOVA with 
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Figure 4.8 Effect of short term topical BD on CD4+ T cell phenotypes.  NOD mice 
were pre-treated with either full dose BD or diluted (1/10, 1/50) BD for two days and CD4+ 
T cell phenotypes were analysed by flow cytometry. N≥3.  Data were compiled from two 
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Figure 4.9 Effect of BD on CD11c+ DCs population in ALN and PLN.  NOD mice were 
pre-treated with either full dose BD or diluted (1/10, 1/50) BD for two days and CD11c+ T 
cell population were analysed by flow cytometry.  Data were compiled from two separate 
experiments.  N≥3.  Mean±SD.  One Way ANOVA with Tukey post test.  *p<0.05, 
**p<0.01, ***p<0.001. 
 
Table 4.5 Effect of topical betamethasone on CD4+ T cell subpopulation in ALN, 
PLN and SP.  Summary of BD effect on CD4+ populations as demonstrated in Figure 
4.8.  Topical BD showed different influence on the same CD4+ T cell population in 
different lymphoid organs.  Downwards arrow: BD reduced its population significantly 
(p<0.05); upwards arrow: BD increased its population significantly; horizontal line: BD 
showed no effect; horizontal line with downwards arrow: BD showed a small change on 
its population, but not significantly.   
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4.4.3. Effect of short term topical BD on inducing antigen specific tolerance 
in vivo 
Short term pretreatment with topical BD was then tested for its effect in inducing 
tolerance with or without ASI.  Both BD cream (0.05% w/w) and 1/50 diluted BD 
cream (0.001% w/w) were used to induce tolerance as illustrated in Figure 4.10 
A.  When using BD cream for pre-treatment, no reduction of proliferation was 
observed when compared with the control group.  However, a small increase was 
seen in the proliferation profile of mice that were treated with BD, with or without 
m31 (Figure 4.10 B).  In order to eliminate the systemic effect of BD cream, 1/50 
diluted BD was used to promote pre-conditioning of skin DCs into tol-DCs.  When 
using potent m31 as an antigen, no sign of tolerance was observed with m31 
alone.  Diluted BD cream (1/50) pre-treatment together with m31 did not show 
any benefit with respect to inducing tolerance (Figure 4.10 C).  The endogenous 
antigen, WE14, was then used to investigate whether the effect of topical BD in 
enhancing WE14 induced peptide-specific tolerance.  However, despite the 
demonstrated efficacy of WE14 in inducing tolerance, 1/50 BD cream reversed 
proliferation back to control levels (Figure 4.10 E).  One interesting observation 
was that 1/50 BD cream alone-down regulated BDC2.5 T cell proliferation 
significantly when compared to full dose BD cream (Figure 4.10 D).   
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Figure 4.10 Effect of topical BD pre-treatment on inducing antigen specific 
tolerance in vivo.  Both BD cream and 1/50 BD cream were tested.  WE14 and m31 
were used as an antigen for inducing tolerance and BDC2.5 T cell proliferation profile 
was used as an indicator of induced tolerance.  A. Tolerance protocol with two days pre-
treatment with BD cream.  B. BDC2.5 T cell proliferation profile in PLN of mice that were 
treated with BD cream and m31.  C. BDC2.5 T cell proliferation profile in PLN with mice 
that were treated with 1/50 BD cream and m31.  D. Comparison of 1/50 diluted BD cream 
and full dose BD cream on BDC2.5 T cell proliferation (re-analysed data from Figure 
B&E).  E. BDC2.5 T cell proliferation profile in PLN with mice that treated with 1/50 BD 
cream and WE14. n≥3.  Data were compiled from three separate experiments,  
Mean±SD.  One way ANOVA with Tukey post test, *p<0.05, **p<0.01.  Control= without 
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4.5. Discussion 
4.5.1. Effect of BD cream on epidermal cells 
As demonstrated in Chapter 3, the local clearance rate of a peptide could be 
altered if the skin is hydrated with a topical formulation.  Therefore, this study was 
designed to test the use of BSP-coated MNs to minimise this effect.  The 
aqueous solubility of BD is very low, even when using an optimised formulation 
as described in Chapter 2.  The phosphate salt form of betamethasone, BSP, 
was used to coat MNs.  BSP is a water-soluble compound can be delivered using 
solid-coated MNs.  On average, 18µg of BSP was delivered into human skin and 
11µg into mouse skin using the same MN delivery system.  This provides further 
evidence that the skin model can influence delivery efficiency when using a solid-
coated MN system, as discussed in Chapter 2.  We also demonstrated that HLA 
DR expression on human skin Langerin+CD1a+ DCs (LCs) were down-regulated 
by topical BD cream compared to untreated skin from the same donor.  BSP-
coated MNs showed a similar effect on HLA DR expression compared with BD 
cream.  Blank MNs alone had a variable influence on HLA DR.  This variation 
was reduced after MNs were coated with BSP (Figure 4.3).  This suggested that 
BSP could regulate skin DCs even if they were activated.  A similar finding 
regarding down-regulation of HLA DR expression on human skin DCs has also 
been reported elsewhere (Piemonti et al., 1999b).  Indeed, it has been shown 
that GCs can regulate the maturation process of human DCs by inhibiting co-
stimulator (CD83 and CD86), HLA DR expression and secretion of cytokines 
such as IFNγ (Larange et al., 2012).   
 
Mouse skin epidermal cells isolated from skin treated with 0.1ml BD cream were 
able to induce more IL10 with BDC2.5 T cells than untreated skin (Figure 4.4).  
IL10 is a cytokine, which can be released by both DCs and T cells.  It functions 
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as an immune regulator, which can down regulate Th1 cytokines and co-
stimulators (Ng et al., 2013, Ouyang et al., 2011, Saraiva and O'Garra, 2010).  It 
has been shown that an inflammatory response can be suppressed by IL10 and 
lack of IL10 can aggravate development of autoimmune diseases (Hata et al., 
2004).  Therefore, the up regulation of IL10 can be viewed as an indicator of the 
promotion of immune tolerance.  GCs have been shown to prevent the 
maturation of DCs and alter the DC activation pathway, resulting in generation of 
a tol-DC, which secretes IL10 (Rea et al., 2000).  A genomic study also has been 
shown that expression of IFNγ-regulated genes in human keratinocytes were 
suppressed by GCs 24 hour post application (Stojadinovic et al., 2007).  These 
findings support the hypothesis that GC treatment could result in a more 
tolerogenic skin environment.  However, in a human epidermal cell function 
experiment, no obvious change in IL10 level was observed from a MLR 
compared to untreated skin (Figure 4.3).  Interestingly, epidermal cells from the 
same patient were shown able to suppress the proliferation of MLR.  The low 
response demonstrated may have been related to the age of the skin donor 
(Agrawal et al., 2008, Sprecher et al., 1990).  Lower HLA DR expression was 
found on DCs when the skin donor age was greater than 60.  As there is have 
limited controls over certain-parameters in human skin explant experiments, such 
as age and ethnic background of donors, it would be necessary to have a larger 
sample size than was used in this study in order to be able to draw a meaningful 
conclusion. 
 
4.5.2. Titration of topical steroid for murine study 
Mouse skin is approximately 10 times thinner than human skin and therefore less 
BD is retained in mouse skin than human skin when using the same dose.  It has 
been shown that once BD was absorbed through skin, this absorption into the 
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system may be sufficient to cause systemic suppression.  A reduction of CD4+ T 
lymphocytes and CD11c+ DCs in the PLN was observed after a 2-day BD cream 
treatment regime.  This cell depletion had a beneficial effect on BDC2.5 T cell 
proliferation in vivo three days after the second BD treatment.  This may be 
because BD is a potent GC with a biological half-life of between 36 and 54 hours 
(Gary, 2013).  By systemic injection, GC together with proinsulin B9-23 can 
induce antigen specific Tregs in vivo and prolong survival rate of NOD mice 
(Zhang et al., 2013a).  In this project, however, we intend to utilise GCs to induce 
tol-DCs rather than causing a systemic depletion of T cells or DCs.  A titration 
study was carried out to minimise the systemic effect whilst retaining the local 
therapeutic effect over skin DCs.   
 
In this study, BD had a depletion effect on CD4+ T cells that migrated to LNs, 
ALN and PLN, but not on cells that in the SP.  This may be because T cells, 
which migrated to LNs were in an activated state and they are more sensitive to 
the GC than when they are in a naïve state in the SP (Wu et al., 2013).  GCs 
have been shown to cause apoptosis or functional changes to the lymphocytes 
(Herold et al., 2006, Wu et al., 2013).  Apart from depletion of all CD4+ T cells, 
topical BD also showed an effect on CD4+ T cell subtypes.  In LNs, 
phenotypically, a higher proportion of memory T cell subtypes was found after BD 
treatment.  This could be due to GC induced apoptosis of the activated T cells 
and sparing of the effector/memory T cells (Wu et al., 2013, Tischner et al., 2011, 
Jamieson and Yamamoto, 2000).  Thus the relative fraction of memory CD4+ T 
cell subsets comprised a higher proportion of the BD treated group than the 
control group.  Conversely, Tregs can be induced in the EAE (Experimental 
autoimmune encephalomyelitis) mouse model when using GCs (Chen et al., 
2006).  It was also suggested that CD4+CD62L+ central memory T cells are able 
to convert to Foxp3+ T cells, which show suppressive function as iTregs (Zhang 
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et al., 2013b). This could explain the increased subpopulation of CD4+CD62Lhi in 
the SP.  Nevertheless, systemic toxicity by over dosing with BD must be avoided 
in our experiments.  After titration, 1/50w/w diluted BD cream showed no 
systemic adverse effects on either CD4+ T cells or CD11c+ DCs.   
 
4.5.3. Effect of topical BD cream on inducing antigen specific tolerance in 
vivo 
The primary approach was to use undiluted (0.05% w/w) BD cream together with 
m31 to induce tolerance.  GCs have already been shown to have an 
immunoregulatory effect in the treatment of autoimmune disease in murine 
models (Chen et al., 2006, Zhang et al., 2013a).  The question was whether 
topical BD treatment could enhance tolerance.  However, no reduction in 
proliferation was observed in the BD treated groups.  As described above, when 
using undiluted BD cream as a tolerogenic enhancer, activated T cell depletion 
would occur.  It has been shown that after BD was cleared from the system, a 
non-specific T cell proliferation will occur because of cell homeostatic state after 
depletion (Ge et al., 2002).  This could be the main reason that undiluted BD 
cream may not be suitable for induct tolerance using the current protocol.   
 
The second approach was to use 1/50w/w diluted BD cream together with a high 
affinity antigen (m31) and a low affinity antigen (WE14) to induce tolerance in 
vivo.  However, no suppression of proliferation was observed.  This could be due 
to several factors.  Although it has been shown that topical corticosteroids 
influence the maturation of skin DCs in vivo, GCs could have an adverse effect 
on the local skin immune system.  It was reported that GCs down regulated the 
expression of MHCII and co-stimulators in the 2 days following topical GC 
treatments; meanwhile, it can promote apoptosis of LCs in vivo (Hoetzenecker et 
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al., 2004, Meingassner et al., 2003).  LC depletion was also reported in an early 
murine skin study (Furue and Katz, 1989b).  A study of topical BD also 
demonstrated a significant depletion of LCs in guinea pig skin (Belsito et al., 
1982b).  GCs also inhibit migration of DCs from skin to draining LNs after 
sensitization (Cumberbatch et al., 1999).  In this project, the approach was to 
induce tolerance by targeting skin DCs with an autoantigen in a minimally 
invasive manner.  If GCs did induce LC apoptosis and inhibit DC migration, this 
would then prevent the induction of Tregs in the draining LNs.  An in vivo study in 
primates also suggested that topical GC treatment resulted in an increased 
mature DC population in the skin draining LNs (Koopman et al., 2001).  When 
these matured DCs in draining LNs captured free-floating injected peptide, an 
immune response could be stimulated.  Although some data suggests that GCs 
can cause an increased capacity for DCs endocytosis, an impaired antigen 
presentation and stimulation of T cells was also observed (Piemonti et al., 1999a, 
Pan et al., 2001b).  Therefore, even if diluted BD cream with reduced potency 
was not sufficient to deplete DCs and antigen-carrying DC migrated to LNs, DCs 
may not be able to cross talk with T cells to induce antigen-specific Treg.  
Furthermore, T cells can be depolarised by GCs and reduce the interaction 
between APCs (Muller et al., 2013).  The aforementioned experiment was not 
shown to enhance antigen specific Tregs.  However, it is possible that under 
other circumstances the GCs could have a different effect.  As demonstrated in 
this study, diluted GC alone had a minor non-antigen specific suppressive effect 
on BDC2.5 T cell proliferation.   
 
Fundamental differences between species may have had an effect on the 
outcome of antigen immunotherapy, i.e. the unsuccessful prevention of BDC2.5 T 
cell proliferation in a murine study may not translate to the same effect (or lack 
thereof) in human studies.  Factors such as the thickness of the stratum corneum 
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and different metabolism of BD, which has been demonstrated by another group 
to vary in different types of human skin cells, could influence the 
pharmacokinetics of BD and be further reflected as a change in 
pharmacodynamics (Gysler et al., 1999).   
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4.6. Conclusion 
The results presented show that topical BD treatment can alter the phenotype of 
human LCs in the epidermis to a less mature phenotype, showing reduced HLA 
DR expression.  Using BSP-coated MNs, a similar reduction of HLA DR 
expression on LCs was also observed.  This suggested that it is possible to use 
solid-coated MNs to deliver betamethasone, targeting skin DCs.  Human 
epidermal cells extracted from skin pre-treated with BD were able to regulate 
PBMC proliferation, however the level of IL10 secretion in the MLR was not 
shown to be influenced when using human epidermal cells, which may due to the 
small sample group size.  In the murine study, topical BD was shown to be able 
to alter the IL10 level secreted by epidermal cells.  These data suggested topical 
BD could potentially alter the maturation process of DCs and promote Tol-DCs.   
 
When an undiluted (0.05% w/w) BD cream was used in murine studies, systemic 
toxicity was observed.  This toxicity was reflected by CD4+ T cell depletion in both 
ALN and PLN and CD11c+ DC depletion in the PLN.  A change to the CD4+ T cell 
subtypes also suggested that BD went into the systemic circulation after 
absorption through the skin.  The aim of this project was to induce antigen-
specific tolerance by skin vaccination rather than induce systemic suppression.  
Therefore, it was deemed necessary to titrate 0.05% w/w BD cream to minimise 
the systemic suppressive effect of BD.  Using CD4+ T cell population and a 
change of CD4+ T cell phenotype as an indicator, it was shown that 1/50 dilution  
(0.001% w/w) minimised the systemic effects of BD.   
 
As shown in Chapter 3, tolerance can be induced in NOD mice when using an 
endogenous antigen, WE14.  However, BD pre-treatment impaired the effect of 
inducing tolerance in vivo using WE14.  This could potentially be due to a number 
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of individual or combined reasons summarised from other publications, including: 
1. LC/DCs were depleted from skin by BD; 2. Following BD pre-treatment, skin 
DCs, which migrated to draining LNs showed an intermediate maturation; 3. GCs 
have a negative impact on DC antigen uptake and presentation to T cells.  These 
hypotheses still need to be further tested in future studies, which are not included 
in this project.  GCs have complex immunomodulatory mechanisms.  Even 
though GCs have been shown to induce tolerance (Tregs and Tol-DCs in vitro 
and in some in vivo models), the non-specific immunosuppressive effect of GCs 
may cause side effects when used in this manner.  
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Chapter 5 General discussion 
5.1. Brief overview  
The aim of this thesis was to investigate whether peripheral tolerance can be 
induced using autoantigen delivered by MNs or ID injection.  Further investigation 
was undertaken to determine whether short term pre-treatment with topical BD 
cream could enhance ASI-induced tolerance.  Three main elements were 
involved in this project: developing an effective MN system, inducing peripheral 
tolerance using autoantigen and assessing the impact of pre-treatment with 
betamethasone on ASI. 
 
5.2. Significance, limitations and future work 
5.2.1. MN design and coating formulation 
Solid-coated MNs have been shown to be an effective delivery system with which 
to target skin DCs, especially LCs located in the epidermis in both human skin 
and mouse skin models, when compared to hollow MNs (section 2.4.1. ).  One 
problem with using solid-coated MNs however, is the difficulty encountered in 
coating hydrophobic materials onto the MN surface and ensuring their efficient 
release upon skin insertion.  A novel coating formulation was designed and 
tested to enable the effective delivery of hydrophobic peptides using a coated MN 
system.  This formulation maximised delivery efficiency whilst using minimal 
additive ingredients.  Of the excipients tested during this project low molecular 
weight PVA was shown to assist the delivery when used at a low (1:10) w:w ratio 
to peptide.  This ratio is much lower than other reported coating formulations 
(1:165 excipient:drug) (Gill and Prausnitz, 2007c).  A benefit of using a low 
amount of coating excipient is the ability to coat the desired amount of peptide 
without overloading the needles excessively with material, which may adversely 
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influence MN skin puncture performance by reducing the effective needle 
sharpness.  No immune response (non-specific) was observed when using a 
PVA-only formulation in an in vitro T cell response assay, which ensured minimal 
trauma to the skin when using MN delivery, which in turn should encourage the 
immune system to respond by inducing tolerance rather than causing activation.  
Using a combination of a water-miscible alcohol (2M2B) with adjusted pH (using 
acetic acid), it was demonstrated that peptides with a broad spectrum of 
hydrophobicity could be dissolved and used to coat MNs.  It has been estimated 
that approximately 40% of approved drugs are hydrophobic (Basavaraj and 
Betageri, 2014).  The novel coating formulation developed in this project enabled 
a simple preparation process for both hydrophobic and hydrophilic peptides 
without using harsh solvents or exposing sensitive reagents to high temperatures 
(Gill and Prausnitz, 2007c).  This approach could potentially, therefore, enable a 
wide range of therapeutic drugs to be delivered into the skin using a solid-coated 
MN system.  Regarding the delivered dose, by lowering the excipient ratio, the 
amount of hydrophobic material coated onto the MNs is potentially increased 
without overloading the MNs and affecting skin puncture.  A previous solid-
coated study has shown that a peptide (salmon calcitonin) lost its bioactivity 
during the formulation preparation process, showing a low bioavailobility in vivo 
(Tas et al., 2012).  Other MN studies on coated peptides have been undertaken 
(Zhu et al., 2014) (Mohammed et al., 2014), but no stability validation data is 
available in the published literature.  In this study, we have demonstrated that it is 
possible to preserve peptide bioactivity during the dissolving, storage and coating 
processes involved in producing a peptide/drug formulation for solid-coated MN 
delivery.  This provides two important pieces of information for future work: 1) the 
coating formulation outlined above ensured that no undesirable immune 
response was triggered due to the presence of denatured peptide; 2) this 
formulation could potentially be used to deliver other peptides using solid-coated 
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MNs.  To provide optimal characteristics for clinical use, it will be important to 
characterise the storage stability of solid-coated formulation and to compare this 
with an equivalent peptide solution.  This will help to provide information, which 
could help improve the shelf life of coated peptides and reduce cold chain costs.   
  
Other factors known to influence peptide delivery efficiency include skin thickness 
and hydration state. Therefore, there are differences in delivery efficiency 
between model species.  The optimised formulation on its own was unable to 
deliver the desired dose of hydrophobic peptide to mouse skin, due to the low 
water content and the thin structure of mouse skin compared to human skin 
(Wong et al., 2011).  Differences in skin hydration will not be the only 
considerations when selecting appropriate biological models to test MN 
performance. For example, it has been demonstrated that the mechanical 
properties are different between mouse and human skin and it has been 
suggested that murine skin may not be a useful biomechanical model for human 
skin (Groves et al., 2013).  This project has demonstrated for the first time the 
significant implications of using different skin models when testing the delivery 
efficiency of solid-coated MNs.  Differences between models mean that it may be 
necessary to test MNs using an appropriate human skin model, in addition to the 
murine in vivo model, before transitioning to clinical trials. 
 
This project has demonstrated that removing surface debris and cleaning the 
surface of stainless steel MNs by electro-polishing can significantly benefit 
delivery efficiency, especially for hydrophobic peptides such as proinsulin B9-23.  
The delivery efficiency of peptide can also be increased by increasing the 
number of needles per MN array, without increasing the amount of peptide 
coated on MNs.  We believe that this is due to the increased dispersion of the 
hydrophobic material over a greater surface area, thus exposing the peptide to 
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sufficient moisture within the skin compartments to facilitate dissolution (Chapter 
2).   This approach could however be limited by size of the application area which 
requires treatment by the MNs and the optimum MN density on the array to allow 
sufficient skin penetration (Yan et al., 2010).  It is suggested that future work 
should be conducted to test the combination of these three parameters (density, 
area and coating thickness) to assist in optimising the dosage for MN coated 
therapeutic drugs.   
 
In order to target skin DCs, especially LCs effectively, MN shape and length were 
also considered.  The needle shape design used was a wedge shape, which is 
thought to be able to release the model drug in the upper layer of the skin (Al-
Qallaf et al., 2009).  This MN design therefore increases the potential to release 
more substance into the epidermal layer and therefore maximise its facility to 
target tolerogenic LCs.  A needle length of 500µm (before electro-polishing) was 
chosen for both human and murine studies.  This is because previous 
publications suggested that skin sealed 35% faster when using short (500µm) 
rather than long (750µm) needles (Gupta et al., 2011a).  It was suggested that 
use of 400µm long MNs will effectively penetrate skin without causing 
significantly increased skin irritation (Bal et al., 2008).  This needle length was 
selected to provide for efficient puncture of both human and murine skin without 
causing significant trauma.  Although the anatomy differences between species 
was taken into consideration during the MN design process, we finally considered 
that the most appropriate approach would be to use the same length for both 
human and murine studies for reasons including:  The needle length would be 
too short to coat using the current coating method, if the needle length were 
scaled down for murine study according to the skin thickness.  It is also difficult to 
manufacture a scaled down needle but keep the needle dimensions in the same 
proportion.  Thirdly, because this project could lead to a clinical study, use of the 
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same needle length for murine and human studies may help to ensure more 
efficient translation from pre-clinical to clinical study.  
 
As a result of these studies on device/formulation optimisation, the solid-coated 
MN system thereafter used in murine studies comprised three arrays of electro-
polished MNs with 10x450µm long needles per array.  By combining an 
optimised coating formulation with electro-polished MN arrays, we were able to 
achieve a delivery dose of 6µg (WE14) and 2µg (m31) to live mice in vivo.  One 
drawback of the solid-coated MN approach is that it is difficult to dose precisely 
due to variations in skin morphology between individuals or the hydration status 
of the skin.  We were, however, able to control the standard error for dosing to 
within a narrow range (Chapter 2). To better understand the dynamics of the 
delivery process and establish the likely clinical variation when using coated 
MNs, it will be important to test MN delivery against a range of measurable skin 
parameters, such as sex and age of donors, hydration status (as measured by 
TEWL) and body site skin was taken from.  This could provide useful information 
for future clinical studies and help to establish meaningful guidelines for dosage 
and usage. 
 
5.2.2. Inducing tolerance in vivo using solid-coated MNs 
The local skin clearance of peptide following delivery was analysed using the 
Kodak in vivo imaging system.  Clearance following ID injection of a TAMRA-
labelled peptide was observed to be altered when the skin had been pre-treated 
with a topical BD cream, presumably as a result of the topical treatment 
occluding the skin and increasing tissue hydration.  This hydration effect showed 
minimal effect on clearance when solid-coated MNs were used instead of ID 
injection.  In fact, solid-coated MN delivery resulted in an increased retention of 
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the peptide m31 in skin compared to ID injection, both with and without topical 
corticosteroid pre-treatment.  Clearance of peptide from the skin can be altered 
by factors such as temperature and peptide solubility (Nakayama et al., 1999, 
Higaki et al., 2002, Neelam, 2012, Trabaris et al., 2012).  Indeed, in our study 
peptide m31 was cleared more rapidly from the skin at high temperature than in a 
controlled cool environment.  The intensity of signal arising from the more 
hydrophilic peptide (WE14) was shown to decline more rapidly than in the low 
solubility peptide (m31) when administered either by ID injection or MNs.  The 
prolonged retention of peptide in the skin when using MNs may be due to a solid 
depot of the peptide being deposited at the delivery site with subsequent slow 
dissolution in the locally restricted water content of the skin.  These data 
suggested that during a 24-hour monitoring period, peptides remained in skin 
longer when delivered by MN than ID injection.  One drawback of this 
measurement is that the detection level is limited by the sensitivity of the Kodak 
in vivo imaging system.  Factors such as autofluorescence, light scattering within 
the tissue and noise from the detector are all known to influence the final result 
(Leblond et al., 2010).  The Kodak in vivo imaging system was, therefore, only 
used to gain an understanding of the factors that can influence the clearance of 
the peptide from skin.  A cellular tracking experiment, as discussed below, was 
also undertaken to help understand the peptide trafficking route; and determine 
whether peptide trafficked through a cellular route (i.e. uptake by skin DCs with 
subsequent trafficking to lymphoid organ) or through systemic circulation. 
 
In order to investigate whether peptide delivery using coated MNs translated to a 
functional advantage, we conducted in vivo studies in a murine model where 
BDC2.5 T cells were transferred intravenously to non-obese diabetic (NOD) 
mice.  Compared with intradermal injection, coated MNs appeared to more 
effectively target skin dendritic cells as a higher BDC2.5 T cell proliferation profile 
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was observed in the draining lymph node (ALN) in MN treated skin, than in skin 
treated with the same dose of peptide via. ID injection.  In mice, BDC2.5 
proliferation was observed 10 days post MN delivery but no proliferation was 
observed at this time following intradermal injection.  These data further confirm 
the results from the clearance study in that MN delivery can target skin DCs more 
effectively than ID injection and that solid peptide delivered by MNs is retained in 
the skin for longer than peptide in solution delivered by ID injection.  These 
kinetic differences could translate to differences in inducing tolerance in vivo and 
indicate that solid-coated MN delivery could be an effective intradermal delivery 
method for targeting skin DCs and minimising any undesirable systemic 
influences.  If this were the case MN administration could potentially be useful for 
therapies such as ASI, vaccination and skin cancer therapy (Koutsonanos et al., 
2012, Quan et al., 2013, Zaric et al., 2013, Mohammed et al., 2014). 
 
BDC2.5 T cells from TCR-transgenic mice can recognise endogenous antigen in 
the pancreas of NOD mice (Haskins et al., 1988, Haskins et al., 1989).  Induced 
tolerance can therefore be reflected in a change in the proliferation profile of 
BDC2.5 T cells in the PLN of recipient NOD mice.  When using the high potency 
peptide m31 to immunise NOD mice, no suppression of BDC2.5 T cell 
proliferation was observed using either ID or MN delivery.  This may be because 
m31 has high affinity with TCR of BDC2.5 T cells, and it activates T cells (Delong 
et al., 2013).  Another explanation may be related to the solubility of m31.  
Relatively low solubility m31 may remain partially solid in the depot within the 
skin after delivery.  DCs in skin could then be activated by this solid form peptide, 
becoming mature and activating T cells in subsequent processes.  When using a 
hydrophilic peptide; WE14, a reduced BDC2.5 T cell proliferation profile was 
observed.  WE14 is an endogenous antigen, which has been shown to be 
effective in delaying T1D disease progression (Haskins et al., 2012).  Here, we 
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were able to demonstrate for the first time, that delivery by solid-coated MNs 
could enhance the tolerogenic effect of WE14 compared to ID injection; resulting 
in fewer proliferated BDC2.5 T cells in the PLN.  Factors such as minimised 
trauma, DC targeted delivery and a relatively slow release profile, suggested that 
MN delivery could have advantages in inducing tolerance when compared to ID 
injection.  Tolerance was also reflected in the changing phenotype of transferred 
BDC2.5 T cells.  A greater proportion of antigen specific BDC2.5 T cells 
remained in a naïve state (CD62L+CD44-) when NOD mice were treated with 
MNs than when using ID with the same dose of WE14.  No change was observed 
in the total CD62L+CD44- population indicating that antigen-specific tolerance 
was induced using the solid-coated MN/WE14 system.  Encouragingly, 
increasing the ID dose of WE14 from 6µg to 50µg enhanced the tolerance effect, 
demonstrating that antigen immunotherapy is dose responsive and could be 
further improved.  It must be noted that the age of mice was a key factor in the 
effectiveness of this therapy in inducing tolerance.  In the tolerance protocol NOD 
mice were treated with peptide at 4-5 weeks of age.  When mice of older than 5 
weeks were used, the experiment showed inconsistent results.  NOD mice 
develop insulitis at approximately 3 weeks old and develop onset diabetes at the 
age of 12 weeks (Leiter et al., 1987, Atkinson and Leiter, 1999, Leiter, 2001, 
Solomon and Sarvetnick, 2004).  The Tregs induced using WE14 may not be of 
sufficient quantity to suppress the growing population of effector T cells as the 
disease progresses.  This is not to say that tolerance cannot be induced at later 
stages of disease progression, rather, this could be due to a limitation of the 
proliferation readout.  When NOD mice were greater than 5 weeks old, the 
proliferation of Teffs could be enhanced by the increased level of endogenous 
antigen released and the increased level of proinflammatory signals due to the 
increased degree of insulitis.  The induced antigen specific Tregs represent a 
small proportion of the total T cell population, therefore, the tolerogenic effect 
  219 
could be undermined when Teff proliferation is above the detectable threshold of 
induced tolerance.  In another experiment, it has been suggested that young 
mice vaccinated with recombinant DNA encoded insulin peptide lead to earlier 
onset of T1D, which contradicts results obtained in this project (Weaver et al., 
2001).  Although proliferation data suggests that tolerance was induced, it is still 
uncertain whether peptide treatment could alter natural disease progression.  
Therefore, future experiments need to be undertaken using female NOD mice 
treated with WE14 peptide delivered by ID injection or MN to monitor the whether 
this treatment can prevent or delay the progression of T1D.  The tolerance 
protocol can also be optimised.  A recent study has suggested that dose 
escalation was more effective in inducing IL10-secreting Tregs than a single high 
dose injection (Burton et al., 2014).  It is also important to understand the 
tolerance mechanisms that iTregs exploit after ASI.  As introduced in section 
1.4.1.2, iTregs could induce Teff apoptosis, reduce Teff proliferation or cause 
indirect suppression through DCs (Vignali et al., 2008, Schmetterer et al., 2012).  
Based on current proliferation results, it is still uncertain which mechanism or 
combination of mechanisms any iTregs may use to exert their effect.  One study 
demonstrated that BDC2.5-TCR-Tg mice could be protected from developing 
diabetes by injection of a soluble peptide, which was thought to be due to the 
apoptosis of activated Teffs (Judkowski et al., 2004).  Full understanding of ASI 
mechanisms is essential to determine the treatment stage, dose and duration 
and the selection of appropriate combination therapies.  In this project, we 
explored the use of betamethasone pre-treatment as a combined therapy with 
ASI. 
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5.2.3. Effect of short term topical BD on ASI 
To investigate the effect of steroid on enhancing tolerance, we used topical 
betamethasone to educate skin DCs into a tolerogenic state.  As discussed 
previously, the hydration effect caused by topical steroid application can 
influence the clearance of delivered peptide.  Betamethasone coated MNs were 
tested against topical betamethasone application on human skin explants.  HLA 
DR expression on human LCs was reduced when skin was treated with topical 
BD and BSP coated MNs.  Proliferation of MLR was slightly reduced with 
betamethasone treated human skin epidermal cells; this however did not 
correlate with the level of anti-inflammatory cytokine IL10.  Mouse skin epidermal 
cells, on the other hand, showed an increased level of IL10 when co-cultured with 
BDC2.5 T cells.  Although it was demonstrated that topical BD could potentially 
down regulate the maturation of skin DCs, we found that the dose required to 
demonstrate this effect in the murine study caused some systemic toxicity 
(Piemonti et al., 1999b) (Shibata et al., 2009).  This toxicity was reflected in the 
depletion of CD4+ T cells and CD11C+ DCs in LNs.  Interestingly, betamethasone 
has been shown to have different effects on CD4+ T cells in different lymphoid 
organs.  Betamethasone can spare the memory/effector T cells and naïve T cells 
in LNs and in the SP, but induces apoptosis in activated T cells; therefore, the 
subpopulation of CD4+ T cells was changed due to treatment with 
betamethasone (Wu et al., 2013, Tischner et al., 2011, Jamieson and Yamamoto, 
2000).  We found that when topical betamethasone was diluted to 0.001% w/w, 
systemic toxicity was minimised.  NOD mice were therefore pre-treated with a 
reduced dose of topical betamethasone followed by peptide (m31 or WE14) 
treatment, but no enhanced tolerance was observed.  This could be due to non-
specific immunosuppressive effects and the complex mechanisms of 
glucocorticoids on both DCs and T cells (Furue and Katz, 1989b, Moser et al., 
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1995, Koopman et al., 2001, Hoetzenecker et al., 2004, Rozkova et al., 2006, 
Herold et al., 2006).  Increased BDC2.5 T cell proliferation was observed when 
using undiluted BD cream, which may due to the T cell re-reaching its 
homeostatic state after depletion.  A 1/50 diluted cream also showed no effect on 
enhancing tolerance.  One possible explanation for this is that betamethasone 
may deplete DCs and/or prevent DCs migrating from the skin (Hoetzenecker et 
al., 2004, Meingassner et al., 2003).  This would have the effect of reducing 
effective DCs presentation of peptide and consequent interaction with T cells in 
LNs.  In a primate study, DCs were also found in their matured state after skin 
was treated with a topical steroid (Koopman et al., 2001).  These matured DCs 
were likely to trigger an immune response rather than to induce a tolerogenic 
immune response.  The anti-inflammatory effect of betamethasone remains 
undisputed.  As previously stated 1/50 diluted BD cream alone could reduce the 
proliferation of BDC2.5 T cells, showing that the dose we were using was able to 
suppress immune response in vivo.  Betamethasone acts through its receptor in 
cells, which is expressed in a wide variety of cells (Danielsen et al., 1987, 
Barnes, 1998, Rhen and Cidlowski, 2005, Coutinho and Chapman, 2011).  
Therefore, it is very difficult to target one specific cell type using betamethasone.  
This non-specific targeting may cause complex cross talk between lymphocytes 
and non-lymphocytes.  It is therefore very difficult to precisely predict the true 
effect of betamethasone on ASI.    
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5.3. Concluding remarks 
In conclusion in this project the following was achieved: 
1. A novel, universal solid MN coating formulation system was developed for 
materials with a wide range of hydrophobicity.  This formulation system 
contains three co-solvents, water, 2-methyl-2-butanol and acetic acid, and 
one excipient, PVA2000.  No loss of bioactivity was detected when 
peptides were formulated using this coating solution.   
2. Solid stainless steel MNs were optimised for skin-targeted delivery to skin 
DCs.  MNs with needle lengths of 500µm were chosen for effective skin 
delivery in both human and mouse skin.  Electropolishing was performed 
to reduce the surface roughness from MN surface and hence enhance the 
delivery efficiency of hydrophobic peptides.  The optimised MN device 
contained three arrays of MNs, 30 MNs in total, and was shown to be able 
to effectively deliver 2µg m31 and 6µg WE14 to mouse skin. 
3. The clearance of peptides delivered to skin was shown to be influenced 
by environmental temperature, skin hydration, peptide hydrophobicity and 
delivery route.  A key determining factor for clearance of peptide from skin 
is the delivery route;  peptide delivered by solid-coated MNs remained in 
skin longer than ID injection.  This prolonged effect was not influenced by 
the hydration state of the skin. 
4. It was demonstrated for the first time that tolerance can be induced in 
NOD mice in vivo using an endogenous antigen administered either by ID 
or solid-coated MNs.  Although reduced proliferation of transferred 
BDC2.5 T cells in NOD PLN was observed in both groups, the solid-
coated MN treated group showed a dose sparing effect comparing with ID 
injection group.  Therefore, the degree of induced tolerance was 
enhanced by using solid-coated MNs compared with ID injection when 
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delivering the same dose.  The induced tolerance also showed a dose 
responsive effect, showing more BDC2.5 T cells were prevented from 
proliferation when using a high dose of WE14 (50µg). 
5. Both topical and betamethasone coated MNs had an effect on skin DCs.  
A high dose of betamethasone induced apoptosis of T cells and 
upregulated T cell activation markers.  Reduced proliferation of 
transferred BDC2.5 T cells in the PLN was observed when using diluted 
BD.  However, tolerance induced using WE14 was not enhanced when 
combined with short term pre-treatment of topical corticosteroid. 
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